<?xml version="1.0" encoding="UTF-8"?>
<VIOLIN>
	<pathogen pathogen_id="pathogen26">
		<pathogen_name>Human Immunodeficiency Virus</pathogen_name>
		<taxon_id>12721</taxon_id>
		<pathogenesis refs="reference236">The 3 major routes of HIV transmission are sexual intercourse, contaminated needles, and transmission from an infected mother to her baby at birth, or through breast milk. HIV primarily infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages, and dendritic cells. This decreases CD4+ T cells through direct viral killing of infected cells, increased rates of apoptosis in infected cells, and killing of infected CD4+ T cells by CD8 cytotoxic lymphocytes that recognize infected cells. When CD4+ T cell numbers decline below a critical level, cell-mediated immunity (CMI) is lost, and the body becomes progressively more susceptible to opportunistic infections (Chan et al., 1997).</pathogenesis>
		<disease_name>Acquired Immunodeficiency Syndrome (AIDS)</disease_name>
		<protective_immunity refs="reference236 reference237 reference238 reference239">HIV can infect a variety of immune cells such as CD4+ T cells, macrophages, and microglial cells. HIV-1 entry to macrophages and T cells is mediated through interaction of the virion envelope glycoproteins (gp120) with the CD4 molecule on target cells and also with chemokine coreceptors. Macrophages play a key role in several critical aspects of HIV infection. They appear to be the first cells infected by HIV and perhaps the source of HIV production when CD4+ cells become depleted in the patient. T-tropic isolates, or syncitia-inducing (SI) strains replicate in primary CD4+ T cells as well as in macrophages. Dual-tropic HIV-1 strains are thought to be transitional strains of the HIV-1 virus. HIV can also infect a subtype of myeloid dendritic cells, which probably constitute a reservoir that maintains infection when CD4+ T cell numbers have declined to extremely low levels (Chan et al., 1997)(Coakley et al., 2005)(Deng et al., 1996)(Knight et al., 1990).</protective_immunity>
		<host_range refs="reference224">AIDS has killed more than 25 million people since it was first recognized in 1981. Globally, ~40 million people currently live with HIV. Sub-Saharan Africa remains by far the worst-affected region. More than 64% of all people living with HIV are in sub-Saharan Africa, as are more than three quarters of all women living with HIV. Two-thirds of HIV/AIDS infections in Asia occur in India, with an estimated 6 million infections, surpassing South Africa's 5.5 million infections, making India the country with the highest number of HIV infections in the world (Palella et al., 1998).</host_range>
		<introduction refs="reference224 reference225">Human immunodeficiency virus (HIV) is the retrovirus that causes acquired immunodeficiency syndrome (AIDS). Within bodily fluids, HIV is present as both free virus particles and as virus within infected immune cells. So far, AIDS has killed more than 25 million people since it was first recognized in 1981, making it one of the most destructive pandemics in recorded history. Antiretroviral treatment reduces both the mortality and the morbidity of HIV infection, but routine access to antiretroviral medication is not available in all countries. Most HIV-infected individuals develop AIDS and die; however, about 10% remains healthy for many years, with no noticeable symptoms. Treatment with anti-retrovirals increases the life expectancy of people infected with HIV (Palella et al., 1998) (Buchbinder et al., 1994).</introduction>
	</pathogen>

	<host host_id="host55">
		<common_name>Baboon</common_name>
		<scientific_name>Papio cynocephalus</scientific_name>
		<taxon_id>9556</taxon_id>
    </host>
	<host host_id="host43">
		<common_name>Bank vole</common_name>
		<scientific_name>Clethrionomys glareolus</scientific_name>
		<taxon_id>447135</taxon_id>
    </host>
	<host host_id="host31">
		<common_name>Bear</common_name>
		<scientific_name>Ursus americanus</scientific_name>
		<taxon_id>9643</taxon_id>
    </host>
	<host host_id="host51">
		<common_name>Birds</common_name>
		<scientific_name>Passeroidea</scientific_name>
		<taxon_id>175121</taxon_id>
    </host>
	<host host_id="host35">
		<common_name>Brown Trout</common_name>
		<scientific_name>Salmo trutta</scientific_name>
		<taxon_id>8032</taxon_id>
    </host>
	<host host_id="host30">
		<common_name>Buffalo</common_name>
		<scientific_name>Bison bison</scientific_name>
		<taxon_id>9901</taxon_id>
    </host>
	<host host_id="host53">
		<common_name>Carnivores</common_name>
		<scientific_name>Vulpes</scientific_name>
		<taxon_id>9625</taxon_id>
    </host>
	<host host_id="host37">
		<common_name>Cat</common_name>
		<scientific_name>Felis catus</scientific_name>
		<taxon_id>9685</taxon_id>
    </host>
	<host host_id="host52">
		<common_name>Catfishes</common_name>
		<scientific_name>Siluriformes</scientific_name>
		<taxon_id>7995</taxon_id>
    </host>
	<host host_id="host12">
		<common_name>Cattle</common_name>
		<scientific_name>Bos taurus</scientific_name>
		<taxon_id>9913</taxon_id>
    </host>
	<host host_id="host8">
		<common_name>Chicken</common_name>
		<scientific_name>Gallus gallus</scientific_name>
		<taxon_id>9031</taxon_id>
    </host>
	<host host_id="host42">
		<common_name>Chimpanzee</common_name>
		<scientific_name>Pan troglodytes</scientific_name>
		<taxon_id>9598</taxon_id>
    </host>
	<host host_id="host26">
		<common_name>chinchillas</common_name>
		<scientific_name>Chinchillidae</scientific_name>
		<taxon_id>10150</taxon_id>
    </host>
	<host host_id="host24">
		<common_name>Copper Pheasant</common_name>
		<scientific_name>Syrmaticus soemmerringii</scientific_name>
		<taxon_id>9067</taxon_id>
    </host>
	<host host_id="host29">
		<common_name>Deer</common_name>
		<scientific_name>Cervus elaphus</scientific_name>
		<taxon_id>9860</taxon_id>
    </host>
	<host host_id="host32">
		<common_name>Deer mouse</common_name>
		<scientific_name>Peromyscus maniculatus</scientific_name>
		<taxon_id>10042</taxon_id>
    </host>
	<host host_id="host36">
		<common_name>Dog</common_name>
		<scientific_name>Canis familiaris</scientific_name>
		<taxon_id>9615</taxon_id>
    </host>
	<host host_id="host9">
		<common_name>Ducks</common_name>
		<scientific_name>Anas</scientific_name>
		<taxon_id>8835</taxon_id>
    </host>
	<host host_id="host19">
		<common_name>Ferret</common_name>
		<scientific_name>Mustela putorius furo</scientific_name>
		<taxon_id>9669</taxon_id>
    </host>
	<host host_id="host48">
		<common_name>Fish</common_name>
		<scientific_name>Hyperotreti</scientific_name>
		<taxon_id>117565</taxon_id>
    </host>
	<host host_id="host41">
		<common_name>Gerbil</common_name>
		<scientific_name>Gerbillina</scientific_name>
		<taxon_id>10045</taxon_id>
    </host>
	<host host_id="host13">
		<common_name>Goat</common_name>
		<scientific_name>Capra hircus</scientific_name>
		<taxon_id>9925</taxon_id>
    </host>
	<host host_id="host47">
		<common_name>Gray wolf</common_name>
		<scientific_name>Canis lupus</scientific_name>
		<taxon_id>9612</taxon_id>
    </host>
	<host host_id="host7">
		<common_name>Guinea pig</common_name>
		<scientific_name>Cavia porcellus</scientific_name>
		<taxon_id>10141</taxon_id>
    </host>
	<host host_id="host16">
		<common_name>Hamster</common_name>
		<scientific_name>Mesocricetus auratus</scientific_name>
		<taxon_id>10036</taxon_id>
    </host>
	<host host_id="host18">
		<common_name>Horse</common_name>
		<scientific_name>Equus caballus</scientific_name>
		<taxon_id>9796</taxon_id>
    </host>
	<host host_id="host2">
		<common_name>Human</common_name>
		<scientific_name>Homo sapiens</scientific_name>
		<taxon_id>9606</taxon_id>
    </host>
	<host host_id="host39">
		<common_name>Macaque</common_name>
		<scientific_name>Macaca fascicularis</scientific_name>
		<taxon_id>9541</taxon_id>
    </host>
	<host host_id="host40">
		<common_name>Mongolian Gerbil</common_name>
		<scientific_name>Meriones unguiculatus</scientific_name>
		<taxon_id>10047</taxon_id>
    </host>
	<host host_id="host5">
		<common_name>Monkey</common_name>
		<scientific_name>Platyrrhini</scientific_name>
		<taxon_id>9479</taxon_id>
    </host>
	<host host_id="host3">
		<common_name>Mouse</common_name>
		<scientific_name>Mus musculus</scientific_name>
		<taxon_id>10090</taxon_id>
    </host>
	<host host_id="host59">
		<common_name>None</common_name>
		<scientific_name>None</scientific_name>
		<taxon_id></taxon_id>
    </host>
	<host host_id="host50">
		<common_name>Parrot</common_name>
		<scientific_name>Psittacidae</scientific_name>
		<taxon_id>9224</taxon_id>
    </host>
	<host host_id="host15">
		<common_name>Pig</common_name>
		<scientific_name>Sus scrofa</scientific_name>
		<taxon_id>9823</taxon_id>
    </host>
	<host host_id="host6">
		<common_name>Rabbit</common_name>
		<scientific_name>Oryctolagus cuniculus</scientific_name>
		<taxon_id>9986</taxon_id>
    </host>
	<host host_id="host45">
		<common_name>Rainbow trout</common_name>
		<scientific_name>Oncorhynchus mykiss</scientific_name>
		<taxon_id>8022</taxon_id>
    </host>
	<host host_id="host4">
		<common_name>Rat</common_name>
		<scientific_name>Rattus</scientific_name>
		<taxon_id>10114</taxon_id>
    </host>
	<host host_id="host34">
		<common_name>Raven</common_name>
		<scientific_name>Corvus corax</scientific_name>
		<taxon_id>56781</taxon_id>
    </host>
	<host host_id="host54">
		<common_name>sei whale</common_name>
		<scientific_name>Balaenoptera borealis</scientific_name>
		<taxon_id>9768</taxon_id>
    </host>
	<host host_id="host17">
		<common_name>Sheep</common_name>
		<scientific_name>Ovis aries</scientific_name>
		<taxon_id>9940</taxon_id>
    </host>
	<host host_id="host28">
		<common_name>Squirrel</common_name>
		<scientific_name>Spermophilus richardsonii</scientific_name>
		<taxon_id>37591</taxon_id>
    </host>
	<host host_id="host44">
		<common_name>Tree shrew</common_name>
		<scientific_name>Tupaiidae</scientific_name>
		<taxon_id>9393</taxon_id>
    </host>
	<host host_id="host49">
		<common_name>Trouts, salmons &amp; chars</common_name>
		<scientific_name>Salmoninae</scientific_name>
		<taxon_id>504568</taxon_id>
    </host>
	<host host_id="host38">
		<common_name>Turkey</common_name>
		<scientific_name>Meleagris gallopavo</scientific_name>
		<taxon_id>9103</taxon_id>
    </host>
	<host host_id="host33">
		<common_name>Vole</common_name>
		<scientific_name>Microtus ochrogaster</scientific_name>
		<taxon_id>79684</taxon_id>
    </host>
	<host host_id="host27">
		<common_name>Water buffalo</common_name>
		<scientific_name>Bubalus bubalis</scientific_name>
		<taxon_id>391902</taxon_id>
    </host>
	<vaccine vaccine_id="vaccine444">
		<vaccine_name>Adenoviral vector Ad5 expressing SIV gag protein</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000788</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector>Adenoviral vector (Ad5)</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference263">The adenoviral vector was based on a serotype 5 adenovirus that is incompetent to replicate with deletion of the E1 and E3 viral genes, and was propagated subsequently in E1-expressing 293 cells. Recombinant adenovirus expressing the codon-optimized SIV gag gene was then prepared. The recombinant adenovirus (Ad5-SIVgag) was grown in large quantities by multiple rounds of amplification in 293 cells. The virus was purified by caesium chloride gradient centrifugation (Shiver et al., 2002).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="reference263">SIVmac239 gag protein (Shiver et al., 2002)</antigen>

		<gene_engineering gene_engineering_id="gene_engineering239" gene_id="gene98">
			<type>Recombinant vector construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response494" host_id="host5">
			<immune_response refs="reference263">In general, all of the monkeys developed p11CM-specific cellular immune responses after the initial immunization series. The p11CM (residues 181–189) is an immunodominant SIV gag epitope that is presented by the Mamu-A*01 MHC protein and is capable of binding T-cell receptors in the model monkeys. Administration of the third dose of the Ad5 vector resulted in an additional increase of p11CM-specific CD8+ T cells at the time of virus challenge. After the booster inoculation, these animals exhibited peak levels of p11CM-specific CD8+ T cells (Shiver et al., 2002).</immune_response>
			<host_strain refs="">rhesus monkey (Macaca mulatta)</host_strain>
			<vaccination_protocol refs="reference263">In this study, 21 rhesus monkeys were divided into 6 groups, including an unimmunized control cohort. Each of the test vectors expressed the identical SIVmac239 gag gene that had been codon optimized for expression in mammalian cells. In the first study, the two viral vector vaccines were administered, followed by a booster dose; preparations of DNA plasmid vector vaccine were delivered thrice, followed by a booster (Shiver et al., 2002).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference263">Each of the animals in both control groups exhibited acute CD4+ T-cell lymphopenia and peak viral loads of viral RNA copies at about 3 weeks after challenge. With the exception of one animal, all of the control monkeys experienced dramatic loss of CD4+ T cells. During the acute phase of the infection, most monkeys immunized with either the DNA or MVA vectors exhibit an acute CD4+ T-cell lymphopenia. By about 70 d after challenge, many of the immunized monkeys exhibit some evidence of a positive immunization benefit, as manifested by control of viremia and recovery of CD4+ T-cell counts. However, the animals immunized with Ad5 vector exhibited the most pronounced attenuation of the infection with a pathogenic HIV–SIV hybrid virus (SHIV) (Shiver et al., 2002).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference263">At 12 weeks after the final immunization, all monkeys were challenged i.v. with the pathogenic HIV–SIV hybrid virus (SHIV) 89.6P16. The challenge of the control and immunized animals within the context of each of the two independent studies occurred concurrently (Shiver et al., 2002).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine4212">
		<vaccine_name>ALVAC-HIV-2</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004727</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3249">A live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1714" gene_id="gene1720">
			<type>Recombinant vector construction</type>
			<description refs="reference3249">Live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1715" gene_id="gene1717">
			<type>Recombinant vector construction</type>
			<description refs="reference3249">Live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1774" host_id="host5">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference3249">Five monkeys were immunized either three times with ALVAC HIV-2 alone or twice with ALVAC HIV-2 and once with purified native HIV-2 gp125 (Walther-Jallow et al., 2001).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3249">After challenge with SIVsm, three of five monkeys were completely protected against SIVsm infection. Vaccination with an ALVAC HIV-2 vaccine followed by exposure to live HIV-2 could induce cross-protection against mucosal infection with SIVsm and seemed to be more efficient than immunization with a live HIV-2 vaccine only (Walther-Jallow et al., 2001).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference3249">The monkeys were then challenged with HIV-2 given intravenously and finally with pathogenic SIVsm given intrarectally (Walther-Jallow et al., 2001).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine4223">
		<vaccine_name>ALVAC-HIV-2- env/gag/pol</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004737</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3249">A live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1706" gene_id="gene1240">
			<type>Recombinant vector construction</type>
			<description refs="reference3249">Live attenuated human immunodeficiency virus type 2 (HIV-2) vaccine alone versus boosting with live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1707" gene_id="gene1717">
			<type>Recombinant vector construction</type>
			<description refs="reference3249">Live attenuated human immunodeficiency virus type 2 (HIV-2) vaccine alone versus boosting with live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1770" host_id="host5">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference3249">Six monkeys were first inoculated intravenously with live HIV-2(SBL-6669) (Walther-Jallow et al., 2001).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3249">Vaccination with an ALVAC HIV-2 vaccine followed by exposure to live HIV-2 could induce cross-protection against mucosal infection with SIVsm and seemed to be more efficient than immunization with a live HIV-2 vaccine only (Walther-Jallow et al., 2001).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference3249">7 to 10 months after vaccination, the monkeys were challenged intrarectally with 10 MID(50) of cell-free simian immunodeficiency virus (SIV) strain SIVsm (Walther-Jallow et al., 2001).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine4110">
		<vaccine_name>ALVAC-SIV/gp120</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004638</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4204">
		<vaccine_name>CVB4/p24(73(3))</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004719</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3243">A live coxsackievirus B4 recombinant, CVB4/p24(73(3)), that expresses seventy-three amino acids of the gag p24 sequence (HXB2) (Gu et al., 2010).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response1769" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference3243">Immunization was by intraperitoneal (IP) injection or by oral gavage. Mice were immunized with either CVB4/p24(733) or the parental CVB4. PBS-treated mice served as controls (Gu et al., 2010).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3243">Results showed that oral immunization with CVB4/p24(73(3)) induced gag p24-specific immune responses in vector-immune mice (Gu et al., 2010).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference3243">Mice immunized with the avirulent CVB4 variant are protected when subsequently challenged with a virulent variant (Gu et al., 2010).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine154">
		<vaccine_name>DNA and poxvirus priming-boosting SHIV vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000825</vo_id>
		<type>DNA vaccine</type>
		<status></status>
		<vector>pV1R plasmid and recombinant fowlpox virus</vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference322">An HIV vaccine should elicit a cytotoxic T lymphocyte (CTL) response, but the characteristics of effective vaccine-induced CTL response remain unclear. The SHIV/rhesus monkey model has been used to in the course of assessing the relative immunogenicity of vaccine regimens that include a cytokine-augmented plasmid DNA prime and a boost with DNA or recombinant pox vectors. This study indicates that the steady-state memory, rather than the peak effector vaccine-elicited CTL responses, may be the critical immune correlate of protection for a CTL-based HIV vaccine (Santra et al., 2004).</description>
		<adjuvant refs="reference322">IL-2/Ig (Santra et al., 2004)</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference322">The recombinant vaccinia viruses (rVac) expressing SHIV89.6P env and SIVmac239 gag were constructed by inserting these genes in the HindIII M region of TBC-Wy, Therion strain of vaccinia. rFPV viruses expressing these same genes were constructed by inserting the genes in the BamJHI region of POXVAC-TC (Schering-Plough) strain of FPV (Santra et al., 2004).</preparation>
		<route refs=""></route>
		<antigen refs="reference322">SHIV89.6P env and SIVmac239 gag (Santra et al., 2004)</antigen>

		<gene_engineering gene_engineering_id="gene_engineering1562" gene_id="gene1708">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1563" gene_id="gene98">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response240" host_id="host5">
			<immune_response refs="reference322">Recombinant vaccinia virus, MVA, and fowlpox were comparable in their immunogenicity. Magnitude of peak vaccine-elicited CTL responses in pox virus-boosted monkeys is substantially greater than that seen in monkeys immunized with plasmid DNA alone, but magnitudes of recombinant pox boosted CTL responses decayed rapidly and were comparable to those of the DNA-alone vaccinated monkeys by the time of viral challenge. Clinical protection seen in all groups of experimentally vaccinated monkeys is similar, indicating that steady-state memory, rather than peak effector vaccine-elicited T lymphocyte responses, may be the critical immune correlate of protection for a CTL-based HIV vaccine (Santra et al., 2004).</immune_response>
			<host_strain refs="">rhesus monkey (Macaca mulatta)</host_strain>
			<vaccination_protocol refs="reference322">Nonrecombinant wildtype vaccinia virus was designated VV-WT, wild-type fowlpox virus was designated FPV-WT, and wild-type MVA was designated MVA-WT. These wild-type viruses were used as control vector immunogens (Santra et al., 2004). One group of monkeys were vaccinated by separate i.m. injections of HIV-1. Half the dose was delivered to each quadriceps muscle. Seven of the 28 monkeys were vaccinated by both i.d. and i.m. injections of rFPV expressing HIV-1 89.6P Env and the same virus expressing SIV mac239 Gag. Seven monkeys received rMVA-HIV-189.6P Env and rMVA-SIVmac239 Gag, and another seven monkeys received rVac-HIV-1 89.6P Env and rVac-SIVmac239 Gag administered both i.d. and i.m. Another 28 monkeys received sham plasmid DNA and empty pox vectors (Santra et al., 2004).</vaccination_protocol>
			<persistence refs="reference322">Persistence levels were measured 2 weeks after challenge with results mentioned in Challenge Protocol section (Santra et al., 2004).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference322">Control monkeys developed tetramer-binding CD8 T lymphocyte responses that were maximal 2 weeks after viral challenge and no detectable p41A-specific CD8 T cells. In contrast, all four groups of vaccinated monkeys developed robust secondary p11C-specific CTL responses that were comparable in magnitude. Animals boosted with plasmid DNA had Gag p11C-specific CD8 T cell responses similar in magnitude to that seen in the recombinant pox virus-boosted animals. Magnitudes of the postchallenge IFN ELISPOT responses to both vaccine antigens were comparable in all four experimentally vaccinated groups of monkeys. Therefore, although the pre-challenge peak vaccine-elicited immune responses were greater in the groups of monkeys boosted with recombinant pox vectors, the pre-challenge plateau and post-challenge peak secondary responses were equivalent in magnitude in all four experimental groups of animals (Santra et al., 2004).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference322">Eighteen weeks after the final immunization, all animals were challenged with cell-free SHIV-89.6P i.v.  (Santra et al., 2004).</challenge_protocol>
			<description refs=""></description>
              <host_gene_response host_gene_response_id="host_gene_response344" gene_id="gene1200">
			    <description refs="reference322">There was a greater contraction of the vaccine-elicited IFN-γ-secreting T cell responses in the groups of monkeys boosted with recombinant pox vectors than in the group of animals boosted with plasmid DNA. Although the pre-challenge peak vaccine-elicited immune responses were greater in the groups of monkeys boosted with recombinant pox vectors, the pre-challenge plateau and post-challenge peak secondary responses were equivalent in magnitude in all four experimental groups of animals (Santra et al., 2004).</description>
			  </host_gene_response>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine149">
		<vaccine_name>DNA vaccine expressing multiple HIV epitopes</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000817</vo_id>
		<type>DNA vaccine</type>
		<status></status>
		<vector>Auxo-GTU vector system [Ref319:Malm et al., 2005]</vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference319">A significant limitation for HIV vaccine development is that there are no small animals in which actual productive HIV-1 infection can be established. DNA immunization with candidate vaccines comprising multiple genes of clades A, B, C, F, G, and H create strong cellular responses in BALB/c mice, especially after gene gun immunization (Malm et al., 2005).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference319">A vaccine platform was constructed with an HIV-1 subtype B DNA immunogen expressing full-length consensus sequences from HIV-1 rev, nef, tat, and gag with additional cellular epitope clusters from the env and pol regions. Furthermore, this platform has been extended to three additional plasmids expressing the same immunogens but originating from subtypes A or C consensus or FGH ancestral sequences (Malm et al., 2005).</preparation>
		<route refs=""></route>
		<antigen refs="reference319">The antigens are named MultiHIV-A (based on the subtype A consensus sequence), MultiHIV-B (subtype B consensus sequence), MultiHIV-C, and MultiHIV-FGH (based on ancestral sequence for subtypes F, G, and H). The MultiHIV DNAs encode polypeptides consisting of a fusion of the full-length regulatory proteins Rev, Nef and Tat as well structural proteins p17 and p24 (Malm et al., 2005).</antigen>

		<gene_engineering gene_engineering_id="gene_engineering1564" gene_id="gene1263">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1565" gene_id="gene707">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1566" gene_id="gene711">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1567" gene_id="gene713">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1568" gene_id="gene153">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1569" gene_id="gene1271">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response229" host_id="host3">
			<immune_response refs="reference319">Though the immune response detected was quite low, the majority of g.g. immunized animals responded with specific IFN production. Interestingly, the gag specific response in the same gene gun immunized animals was weaker than the envelope responses and also drastically weaker than the responses seen before the experimental challenge (Malm et al., 2005). The CTL response, following i.d. injection, was detected five weeks after the first immunization and persisted up to 12 weeks later. In contrast, i.m. immunization induced detectable IFNy only at week 17 (Malm et al., 2005).</immune_response>
			<host_strain refs="">C57BL/6, BALB/c</host_strain>
			<vaccination_protocol refs="reference319">C57BL/6 mice were divided into groups g.g. immunized or i.m. inoculated. Mice were bled 2 weeks after the last immunization, and individual blood and spleen samples were collected post-challenge and used fresh in ELISPOT assays (Malm et al., 2005).
BALB/c were immunized by MultiHIV/MultiClade DNA. Initially the immune response was evaluated after 3 immunizations by g.g. Equal amounts of clade A, B, C, and FGH MultiHIV plasmids were mixed together and coated onto the gold particles to construct the subtype cocktail MultiHIV DNA immunogen (MultiHIVmix). Mice were sacrificed 10 days after the last immunization and individual spleens were collected and the cells preserved at –70°C until used. In a second set of experiments a short-term immunization schedule was used to address three different administration routes; g.g., i.m., and i.d. Mice were immunized 3 times with MultiHIVmix DNA (Malm et al., 2005).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference319">The vaccine-induced immunity has in vivo efficacy. Here a mouse model showed that the HIV-1 GTU-MultiHIVmix vaccine induces virus-specific CD8 T cellular immunity and protects against experimental HIV-1 challenge (Malm et al., 2005).</protection_efficacy>
			<side_effects refs="reference319">no side effects occurred (Malm et al., 2005)</side_effects>
			<challenge_protocol refs="reference319">C57BL/6 mice transgenic for HLA-A201 were given an experimental challenge after a short-term immunization schedule. Amphotropic murine leukemia virus was used to prepare pseudovirus with HIV-1 isolate. Challenged animals were given i.p. injections of sHIV-1/MuLV infected cells (Malm et al., 2005).</challenge_protocol>
			<description refs="reference319">The cocktail of MultiHIV protected 19/24 animals against an experimental HIV-1 challenge. This experiment also demonstrates cross-clade protection, as the subtypes A and B viruses used for challenge were derived from different subtypes than the sequences found in the clade A or B specific MultiHIV constructs. Furthermore, it demonstrates that consensus approach used in Multi-HIVmix vaccine is functional and causes protection against naturally occurring isolates. Gene gun immunization was superior to intramuscular immunization in terms of both the T cell immunity induced, as well as higher frequency of protection. Data generated in this work support the hypothesis that DNA representing several HIV-1 subtypes and several genes are immunogenic and protective (Malm et al., 2005).</description>
              <host_gene_response host_gene_response_id="host_gene_response327" gene_id="gene1">
			    <description refs="reference319">IFN-gamma levels in mice immunized by gene gun or intramuscular delivery with HIV-1 subtype B DNA immunogen showed strong up regulation in response to an H-2d restricted gag peptide (AMQMLKETI) and even stronger up-regulation in response to an env epitope (RGPGRAFVTI) (Malm et al., 2005).</description>
			  </host_gene_response>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine156">
		<vaccine_name>Gag-VRPs</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000822</vo_id>
		<type></type>
		<status></status>
		<vector>VEE replicon particles (VRPs)</vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference324">Gag-VRPs is a cocktail vaccine of V3014-packaged VRPs expressing the SIVsm H-4i nonmyristylated matrix-capsid region, full-length gp160, and a secreted form of gp160 (gp140). Structural proteins for packaging of replicon RNA into VRPs are expressed from separate helper RNAs. VRPs expressing either the matrix-capsid portion of Gag, the full-length envelope gp160, or the secreted gp140 of cloned SIVsm H-4i were mixed in a cocktail and used to immunize macaques (Davis et al., 2002).</preparation>
		<route refs=""></route>
		<antigen refs="reference324">HIV matrix-capsid portion of Gag, envelope gp160, secreted gp140, cloned SIVsm H-4i, SIVsm E660 (Davis et al., 2002)</antigen>
		<host_response host_response_id="host_response244" host_id="host3">
			<immune_response refs="reference588">In BALB/c mice, the two vectors elicited cellular immune responses to MA/CA as determined by bulk CTL assays and precursor frequency analysis, but the humoral response induced by the downstream vector was significantly stronger. These findings suggest that VEE vectors can be optimized to elicit strong, balanced and long-lived immune responses to foreign viral proteins (Caley et al., 1999).</immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference324">VRPs with wild-type glycoprotein spikes were inoculated into the footpads of mice (Davis et al., 2002).</vaccination_protocol>
			<persistence refs="reference588">At 11 months post-boosting with the downstream vector, serum antibody levels against HIV MA/CA were undiminished, and MA/CA specific CTLp were detectable in all mice tested. These findings suggest that VEE vectors can be optimized to elicit strong, balanced and long-lived immune responses to foreign viral proteins (Caley et al., 1999).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response245" host_id="host5">
			<immune_response refs="reference324">Both humoral and cellular immune responses were induced. On the day of challenge, all vaccinated animals had neutralizing antibody to the homologous SIVsm H-4, most had CTL specific for Gag, Env, or both. The animals were followed for a period of 40 weeks postchallenge, and although vaccination did not prevent infection by the high dose IR challenge, several protective effects of vaccination were seen. Peak virus titers in plasma were reduced, and the range of peak titers was much smaller for the controls, suggesting that a clear protective effect against the acute phase of infection was induced in some of the vaccinated animals (Davis et al., 2002).</immune_response>
			<host_strain refs="">rhesus monkey (Macaca mulatta)</host_strain>
			<vaccination_protocol refs="reference324">A cocktail vaccine of V3014-packaged VRPs expressing the SIVsm H-4i nonmyristylated matrix-capsid region, full-length gp160, and a secreted form of gp160 (gp140) was used to immunize rhesus macaques. Animals were given each VRP subcutaneously in the arm and later were challenged by the intrarectal (IR) route. Control animals received an equivalent dose of HA-VRPs (Davis et al., 2002).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference324">Animals were followed for a period of 40 weeks postchallenge, and although vaccination did not prevent infection by the high dose IR challenge, several protective effects of vaccination were seen. Four of six vaccinated animals, as compared to one of six controls, showed virus loads below 1,700 copies per ml at the “set point” (23 weeks postchallenge). By 41 weeks postchallenge, when the experiment was terminated, there was a significant decrease in the mean plasma virus load in the vaccinated animals compared to that in the controls. Most vaccinated animals showed virus loads below the “set point” (23 weeks postchallenge). By 41 weeks postchallenge, when the experiment was terminated, there was a significant decrease in the mean plasma virus load in the vaccinated animals compared to that in the controls. Finally, the CD4C cells of the vaccinated animals were preserved and even increased postchallenge compared to those of the controls. In fact, in the vaccinated animals, there is a clear correlation between increased CD4C cells and lowered viral load (Davis et al., 2002).</protection_efficacy>
			<side_effects refs="reference324">No side effects were encountered (Davis et al., 2002).</side_effects>
			<challenge_protocol refs="reference324">Animals were given a dose of VRP subcutaneously in the arm and 1 month later were challenged by the intrarectal (IR) route. Control animals received an equivalent dose of HA-VRPs. The challenge virus was the highly virulent swarm SIVsm E660 (Davis et al., 2002).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3061">
		<vaccine_name>gp120 recominant with GMDP adjuvant</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004233</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>subcutaneous injection</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">subcutaneous injection</route>
		<antigen refs="reference1890">Recombinant HIV gp120 derived from CHO cells (Bomford et al., 1992).</antigen>
		<host_response host_response_id="host_response891" host_id="host3">
			<immune_response refs="reference1890">Mice immunized with gp120 and GMDP in combination with pluronic emulsion resulted in a secondary antibody response (Bomford et al., 1992).</immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference1890">Mice were subcutaneously immunized with antigen and adjuvant (Bomford et al., 1992).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3062">
		<vaccine_name>gp120 recominant with MDP adjuvant</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004234</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>subcutaneous injection</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">subcutaneous injection</route>
		<antigen refs="reference1890">Recombinant HIV gp120 derived from CHO cells (Bomford et al., 1992).</antigen>
		<host_response host_response_id="host_response892" host_id="host3">
			<immune_response refs="reference1890">Mice immunized with gp120 adjuvanted with MPD plus pleuronic emulsion resulted in a secondary antibody response (Bomford et al., 1992).</immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference1890">Mice were subcutaneously immunized with antigen and adjuvant  (Bomford et al., 1992).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3067">
		<vaccine_name>gp140, Gag and Tat Protein Vaccine with MF59</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004238</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="reference1301">gp140, Gag and Tat recombinant proteins (Bråve et al., 2007).</antigen>
		<host_response host_response_id="host_response897" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">C57Bl/6</host_strain>
			<vaccination_protocol refs="reference1301">The protein vaccine component consisted of 20 μg ro-gp140 delivered in the right tibialis muscle and 20 μg rGag and 5 μg rTat delivered in the left tibialis muscle. The proteins were formulated in 50% MF59 solution. Mock treatment consisted of MF59 adjuvant alone or empty DNA plasmid alone (Bråve et al., 2007).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1301">83% of mice were tested negative for HIV-1 after challenge (Bråve et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1301">Briefly, 3 weeks after the final immunization (week 12), the animals were injected intraperitoneally with 1 million syngeneic splenocytes infected with HIV-1/MuLV of subtype B (LAI) (Bråve et al., 2007).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine145">
		<vaccine_name>HIV DNA and adenoviral vector Ad5 expressing SIV gag protein</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000786</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>V1R plasmid and adenoviral vector (Ad5)</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs="reference263">Immunization and viral challenge studies were conducted in rhesus macaques (Macaca mulatta). Each of the test vectors expressed the identical SIVmac239 gag gene that had been codon optimized for expression in mammalian cells. The plasmid DNA vector was formulated in either PBS solution, a solution containing adjuvant, or a solution containing MPL/alum. All immunized animals were genotyped for the MHC class I Mamu-A*01 allele, allowing analysis of the responses of T cells (CD8+) to the test vaccines (Shiver et al., 2002).</description>
		<adjuvant refs="reference263">CRL1005 for DNA vaccine (Shiver et al., 2002)</adjuvant>
		<storage refs=""></storage>
		<virulence refs="reference263">No virulence has been reported associated with this vaccine (Shiver et al., 2002).</virulence>
		<preparation refs="reference263">The V1R DNA vector expressed the identical SIVmac239 gag gene that had been codon optimized for expression in mammalian cells (Shiver et al., 2002). The plasmid DNA vector was formulated in a solution containing a nonionic blocked copolymer adjuvant (CRL1005) (Shiver et al., 2002).
The adenoviral vector was based on a serotype 5 adenovirus that is incompetent to replicate with deletion of the E1 and E3 viral genes, and was propagated subsequently in E1-expressing 293 cells. Recombinant adenovirus expressing the codon-optimized SIV gag gene was then prepared. The recombinant adenovirus (Ad5-SIVgag) was grown in large quantities by multiple rounds of amplification in 293 cells. The virus was purified by caesium chloride gradient centrifugation (Shiver et al., 2002).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="reference263">SIVmac239 gag protein (Shiver et al., 2002)</antigen>

		<gene_engineering gene_engineering_id="gene_engineering238" gene_id="gene98">
			<type>Recombinant vector construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering104" gene_id="gene98">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response178" host_id="host5">
			<immune_response refs="reference263">In general, all of the monkeys developed p11CM-specific cellular immune responses after the initial immunization series. The p11CM (residues 181–189) is an immunodominant SIV gag epitope that is presented by the Mamu-A*01 MHC protein and is capable of binding T-cell receptors in the model monkeys. Administration of the third dose of the Ad5 vector resulted in an additional increase of p11CM-specific CD8+ T cells at the time of virus challenge. After the booster inoculation, these animals exhibited peak levels of p11CM-specific CD8+ T cells (Shiver et al., 2002).</immune_response>
			<host_strain refs="">rhesus monkey (Macaca mulatta)</host_strain>
			<vaccination_protocol refs="reference263">This study used 14 monkeys, 3 each in the immunized groups and 8 in the unimmunized control group. Each of the test vectors expressed the identical SIVmac239 gag gene that had been codon optimized for expression in mammalian cells. The DNA vector priming inoculations were administered, followed by viral vector boost inoculations (Shiver et al., 2002).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference263">Each of the animals in both control groups exhibited acute CD4+ T-cell lymphopenia and peak viral loads of viral RNA copies at about 3 weeks after challenge. All of the control monkeys experienced dramatic loss of CD4+ T cells. During the acute phase of the infection, most monkeys immunized with either the DNA or MVA vectors or with the DNA/CRL1005–MVA vector prime–boost combination exhibit an acute CD4+ T-cell lymphopenia. By about 70 d after challenge, many of the immunized monkeys exhibit some evidence of a positive immunization benefit, as manifested by control of viremia and recovery of CD4+ T-cell counts. However, the animals immunized with Ad5 vector exhibited the most pronounced attenuation of the infection with a pathogenic HIV–SIV hybrid virus (SHIV) (Shiver et al., 2002).</protection_efficacy>
			<side_effects refs="reference263">None of the vaccinated monkeys have yet exhibited any signs of immunodeficiency or suffered any consistent weight loss (Shiver et al., 2002).</side_effects>
			<challenge_protocol refs="reference263">At 6 weeks after the final immunization, all monkeys were challenged i.v. with the pathogenic HIV–SIV hybrid virus (SHIV) 89.6P16. The challenge of the control and immunized animals within the context of each of the two independent studies occurred concurrently (Shiver et al., 2002).</challenge_protocol>
			<description refs=""></description>
              <host_gene_response host_gene_response_id="host_gene_response348" gene_id="gene1200">
			    <description refs="reference263">Levels of interferon-gamma in monkeys stimulated intramuscularly with either the p11CM peptide or a pool of peptides derived from SIV gag were significantly upregulated and correlated well with the tetramer-staining results after the final boost. Intracellular IFN-[gamma]-staining assays confirmed that these responses were primarily mediated by CD8+ T cells (Shiver et al., 2002).</description>
			  </host_gene_response>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3426">
		<vaccine_name>HIV DNA vaccine Ad26/Ad5HVR48 encoding HIV or SIV env or gag</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004342</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering978" gene_id="gene1240">
			<type>Recombinant vector construction</type>
			<description refs="reference2195">This recombinant vector vaccine expressed env from HIV-1 (Barouch et al., 2012).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering979" gene_id="gene713">
			<type>DNA vaccine construction</type>
			<description refs="reference2195">This recombinant vector vaccine expressed gag from HIV-1 (Barouch et al., 2012).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering980" gene_id="gene1250">
			<type>Recombinant vector construction</type>
			<description refs="reference2195">This recombinant vector vaccine expressed env from SIV (Barouch et al., 2012).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering981" gene_id="gene98">
			<type>DNA vaccine construction</type>
			<description refs="reference2195">This recombinant vector vaccine expressed gag from SIV (Barouch et al., 2012).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1302" host_id="host39">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2195">After the high-dose vaginal SHIV-162P3 challenge, 7/8 control animals were infected. Similarly, 7/8 animals in the vaccine-only group (group V) were infected.  In the microbicide-only group (group M), 4/8 animals were infected. In the combination group (group V+M), only 2/7 animals were infected. The intervention efficacy in group V+M was 67%. In summary, the data supports that vaccines and microbicides used in combination may confer protection against sexual HIV-1 transmission to women by the vaginal route (Barouch et al., 2012).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3449">
		<vaccine_name>HIV DNA vaccine pCMN160</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004345</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pCMN160 [Ref2214:Boyer et al., 1997]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="reference2214">env and rev of HIV-1 strain MN and gag/pol from HIV-1 III8 (Boyer et al., 1997)</antigen>

		<gene_engineering gene_engineering_id="gene_engineering1389" gene_id="gene1261">
			<type>DNA vaccine construction</type>
			<description refs="reference2214">This DNA vaccine encoded env (Boyer et al., 1997).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1390" gene_id="gene1262">
			<type>DNA vaccine construction</type>
			<description refs="reference2214">This DNA vaccine encoded rev (Boyer et al., 1997).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1391" gene_id="gene1252">
			<type>DNA vaccine construction</type>
			<description refs="reference2214">This DNA vaccine encoded gag/pol from HIV-1 III8 (Boyer et al., 1997).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1322" host_id="host42">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2214">Animals were challenged with a heterologous chimpanzee titered stock of HIV-1 SF2 virus. Polymerase chain reaction coupled with reverse transcription results indicated infection in the control animal, whereas those animals vaccinated with the DNA constructs were protected from the establishment of infection (Boyer et al., 1997).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3481">
		<vaccine_name>HIV DNA vaccine pHIS-SHIV-B</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004348</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pHIS-64 [Ref2227:Dale et al., 2004]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="reference2227">full-length unmutated SIVmac239 Gag and Pol, HIV-1AD8, Tat, Rev, and Vpu, and the 5′ third of HIV-1AD8 Env (Dale et al., 2004)</antigen>

		<gene_engineering gene_engineering_id="gene_engineering1038" gene_id="gene1240">
			<type>DNA vaccine construction</type>
			<description refs="reference2227">The DNA vaccine strain, pHIS-SHIV-B, encoded full-length unmutated SIVmac239 Gag and Pol, HIV-1AD8, Tat, Rev, and Vpu, and the 5′ third of HIV-1AD8 Env (Dale et al., 2004).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1570" gene_id="gene98">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1571" gene_id="gene1245">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1572" gene_id="gene711">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1573" gene_id="gene1263">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1574" gene_id="gene1258">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1338" host_id="host39">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2227">DNA vaccination alone primed for protection almost as effectively as the DNA/fowlpox virus regimen (Dale et al., 2004).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
              <host_gene_response host_gene_response_id="host_gene_response349" gene_id="gene1428">
			    <description refs="reference2227">SIV Gag-specific CD8 T cells expressing IFN-γ were dramatically boosted after challenge. Mean Gag-specific CD8 T cells peaked 3 weeks following challenge at 11.7% of all CD8 T cells in these outbred pigtail macaques immunized with the 2DNA/FPV regimen. The other vaccine groups had lower mean postchallenge CD8 T-cell responses, with peak responses at week 2 following challenge numbering 3.8% in the 3DNA group, 1.1% responses in the 1DNA/FPV group, and 2.0% in the 2DNA/FPV-IFN-γ-immunized animals (Dale et al., 2004).</description>
			  </host_gene_response>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3439">
		<vaccine_name>HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004344</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pGA [Ref2205:Robinson et al., 2006]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference2205">GM-CSF (Robinson et al., 2006)</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1575" gene_id="gene1709">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1576" gene_id="gene1710">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1577" gene_id="gene1711">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1578" gene_id="gene1712">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1579" gene_id="gene1713">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1580" gene_id="gene1714">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1581" gene_id="gene1715">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1582" gene_id="gene1716">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1315" host_id="host39">
			<immune_response refs="reference2205">Co-delivery of GM-CSF and vaccine DNAs enhanced the temporal appearance of neutralizing Ab and broadened the specificity of the neutralizing activity to include SHIV-89.6P (Robinson et al., 2006).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2205">The GM-CSF-adjuvanted group showed a trend towards better control of the challenge infection and had better control of re-emergent virus (P &lt; 0.01) than the non-adjuvanted group. After 52 weeks, the non-GM-CSF group continued to show some peaks of re-emergent virus whereas the GM-CSF group continued to maintain control below our level of detection (Robinson et al., 2006).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3485">
		<vaccine_name>HIV DNA vaccine SIVmac239 Gag-Pol-Nef and mock Env with rAd5 boost</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004349</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pVR1012 prime, rAd5 boost [Ref2230:Mascola et al., 2005]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1583" gene_id="gene98">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1584" gene_id="gene1245">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1585" gene_id="gene1246">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1586" gene_id="gene1708">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1345" host_id="host39">
			<immune_response refs="reference2230">DNA priming-rAd5 boosting immunization platform can elicit potent anti-HIV-1 cellular immune responses and anti-HIV-1 neutralizing antibodies (Mascola et al., 2005).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2230">In a challenge study, all monkeys were immunized with DNA plasmids at 0, 4, and 8 weeks and boosted with rAd5 at week 26. Serial plasma dilutions were tested against four of the more neutralization-sensitive viruses, and the plasma dilution that produced 50% virus neutralization, which is required to protect 50% of the cells from virus-induced killing, was determined. The data clearly demonstrates that both the vaccine platform and these immunogens elicit IgG-mediated virus neutralization (Mascola et al., 2005).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3497">
		<vaccine_name>HIV DNA vaccine VlJns-tPA-gp120</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004351</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>VlJns [Ref2235:Lekutis et al., 1997]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1587" gene_id="gene1249">
			<type>DNA vaccine construction</type>
			<description refs="reference2235">This vaccine encoded gp120 from HIV IIIB (Lekutis et al., 1997).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1350" host_id="host5">
			<immune_response refs="reference2235">The secretion  of  IFN-y stimulated  CD4+ Th cell lines and rgp120-stimulated  PBL from the vaccinated monkeys suggest that an HIV-1 env plasmid DNA vaccine elicits a Thl-like immune response in primates as well as in rodents (Lekutis et al., 1997)</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2235">The secondary immune response that arose after repeated plasmid DNA administration was Thl-like, suggesting that the nature of the DNA vaccine-elicited Th cell response was maturation dependent. Evidence  from  vaccinated  nonhuman  primates  suggests that  a vigorous  Th  cell  response,  including  viral  Ag-specific  IFN-y production,  may be a correlate of  protection from  HIV- 1  and Simian Human  Immunodeficiency  Virus  infection  (Lekutis et al., 1997)</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine146">
		<vaccine_name>HIV priming with DNA vaccine expressing HIV gp160 protein and boosted with Ad5/35 vector expressing the same protein</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000789</vo_id>
		<type>DNA vaccine</type>
		<status></status>
		<vector>pCAGGS and a replication-defective chimeric Ad5 vector with the Ad35 fiber (Ad5/35)</vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference317">Replication-defective Ad5 HIV recombinants and replication-defective MVA elicit potent CD8+ T-cell responses and provide a high degree of protection in NHPs. The Ad5 (subgroup C) has well-defined biological properties and has been widely used as a vector for gene therapy and vaccine. The replication-defective Ad5 vector can easily be produced in high titers and is highly effective in boosting HIV-specific immunity. However, this virus uses CAR as its primary attachment receptor, which confers tropism for liver parenchymal cells. This raises important safety concerns. Thus, a replication-defective chimeric Ad5 vector with Ad type 35 fiber (Ad5/35) has been developed, which not only induces strong antigen-specific humoral and cellular immune responses and exhibits minimal hepatotoxicity in both mice and NHPs, but is also significantly less susceptible to the pre-existing Ad5 immunity than a comparable Ad5 vector (Xin et al., 2005).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs="reference317">This novel Ad5/35 vector showed minimal hepatotoxicity after intramuscular administration with the novel Ad5/35 vector (Xin et al., 2005).</virulence>
		<preparation refs="reference317">A replication-defective chimeric Ad5 vector with the Ad35 fiber (Ad5/35) was prepared and used to express HIV Env gp160 protein. The product is named Ad5/35-HIV (Xin et al., 2005).</preparation>
		<route refs=""></route>
		<antigen refs="reference317">HIV Env gp160 protein (Xin et al., 2005)</antigen>

		<gene_engineering gene_engineering_id="gene_engineering153" gene_id="gene153">
			<type>Recombinant vector construction</type>
			<description refs="reference317">An Ad5/35 vector was used to express HIV Env gp160 protein (Ad5/35-HIV) (Xin et al., 2005). </description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1645" gene_id="gene1240">
			<type>DNA vaccine construction</type>
			<description refs="reference317">The DNA vaccine contained env and rev from HIV-1 IIIB (Xin et al., 2005).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1646" gene_id="gene1263">
			<type>DNA vaccine construction</type>
			<description refs="reference317">The DNA vaccine contained env and rev from HIV-1 IIIB (Xin et al., 2005).</description>
		</gene_engineering>
		<host_response host_response_id="host_response216" host_id="host5">
			<immune_response refs="reference317">A detectable HIV-specific serum Ab response developed within 2 weeks of the first immunization. At 4 weeks post boosting, titers in excess of 1:50 000 were achieved. Similar results were observed in neutralizing Ab. A increase in the number of HIV-specific IFN-gamma-secreting T cells was also detected in the peripheral blood mononuclear cells (PBMCs). Boosting with Ad5/35-HIV vector further increased this T-cell response (Xin et al., 2005).</immune_response>
			<host_strain refs="">rhesus monkey (Macaca mulatta)</host_strain>
			<vaccination_protocol refs="reference317">10^11 vp of Ad5/35-HIV vector was injected i.m. into two rhesus monkeys (2 years old, male) at weeks 0 and 8 (Xin et al., 2005).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs="reference317">Liver infection with Ad5 vector was 20- to 40-fold stronger than that with Ad5/35 vector. Ad5-Luc vector was two- and four-fold higher, respectively, than that of the monkeys that received the Ad5/35-Luc vector. The Ad5/35 recombinants exhibits minimal hepatotoxicity in non-human primates but is also significantly less susceptible to the pre-existing Ad5 immunity than a comparable Ad5 vector (Xin et al., 2005).</side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response215" host_id="host3">
			<immune_response refs="reference317">The animals immunized with Ad5/35-HIV vector developed a high-titered anti-gp160 antibody (Ab) response. The magnitude of this response was not significantly altered by preimmunization with the DNA-HIV vaccine. DNA-HIV vaccination alone generated a low level of HIV-specific serum Ab. HIV-specific neutralizing Ab was only detectable in the Ad5/35-HIV vaccinated mice and DNA prime/Ad5/35-HIV boosted mice. HIV-specific cellular immune responses persisted through 7 months after final immunization (Xin et al., 2005).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference317">Mice were injected i.m. with Ad5-Luc or Ad5/35-Luc. Luciferase expression was monitored using an in vivo imaging system (IVIS). The expression of HIV gp160 was confirmed by Western blotting. Mice were immunized with Ad5/35-HIV vector, and the HIV-specific CMI was periodically monitored by the intracellular cytokine staining (ICS) assay (Xin et al., 2005).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference317">The animals that were vaccinated with the Ad5/35 vector alone or in combination with the DNA-HIV vaccine were completely protected from infection; however, the DNA-HIV vaccination alone had little impact on the susceptibility to infection by vPE16. DNA-HIV vaccination by itself was not protective, but the combination of DNA-HIV priming and Ad5/35-HIV boosting yielded a prolonged and complete protection (Xin et al., 2005).</protection_efficacy>
			<side_effects refs="reference317">The hepatotoxicity caused by the Ad5 vector was circumvented by the use of an Ad5/35 vector (Xin et al., 2005).</side_effects>
			<challenge_protocol refs="reference317">Immunized mice were challenged with vPE16 2 weeks after final immunization. Vaccinated mice were challenged with vPE16 7 weeks after final immunization. The strain vPE16 is HIVBH8 gp160-expressing replication-competent vaccinia virus (WR strain, vPE16; HIVBH8 gp160 has 97.32% amino-acid homology with HIVIIIB gp160) (Xin et al., 2005).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3108">
		<vaccine_name>HIV recombinant gp160 Protein Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004274</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>subcutaneous injection</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">subcutaneous injection</route>
		<antigen refs="reference2062">Recombinant gp160 (Barrett et al., 1989).</antigen>
		<host_response host_response_id="host_response937" host_id="host3">
			<immune_response refs="reference2062">The highest potency in mice was obtained using a preparation with 0.2% Al(OH)3 and 0.25% deoxycholate (Barrett et al., 1989).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference2062">The potency of the vaccine was determined by injecting mice with serial dilutions of gp160 alone or adjuvanted with different formulations. Groups of 10 mice were injected subcutaneously with 1 ml of fourfold dilutions of the test substance. A total of 50 mice were injected in each test (Barrett et al., 1989).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3478">
		<vaccine_name>HIV recombinant vector vaccine MVA-gag encoding gag</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004347</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector>pSC59 [Ref2225:Casimiro et al., 2003].</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference2225">CRL1005 (Casimiro et al., 2003)</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1032" gene_id="gene713">
			<type>Recombinant vector construction</type>
			<description refs="reference2225">This recombinant vector vaccine expressed gag from HIV-1 (Casimiro et al., 2003).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1335" host_id="host5">
			<immune_response refs="reference2225">Immunization of macaques with MVA-gag resulted in relatively weak antigen-specific T-cell responses; the levels did not exceed 150 spot-forming cells (SFC)/106 PBMCs after three doses and were significantly less than those observed in the Ad5-gag vaccinees. Only one of six MVA-gag vaccinees elicited any detectable Gag-specific antibody response (140 mMU/ml at 4 weeks post-dose 3 for monkey V215) (Casimiro et al., 2003).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2225">The study reports that SIV Gag delivered by DNA, MVA, or adenovirus type 5 vectors is able to inhibit viral replication and disease progression in rhesus macaques following challenge with the SHIV89.6P virus. However, only 50% of the animals that received MVA alone or in combination with DNA were able to effectively control viremia (Casimiro et al., 2003).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3491">
		<vaccine_name>HIV recombinant vector vaccine MVA.HIVA encoding env and rev</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004350</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1045" gene_id="gene1240">
			<type>Recombinant vector construction</type>
			<description refs="reference2232">This DNA vaccine encoded env from HIV-1 (Peters et al., 2007).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1046" gene_id="gene1263">
			<type>Recombinant vector construction</type>
			<description refs="reference2232">This DNA vaccine expressed rev from HIV-1 (Peters et al., 2007).</description>
		</gene_engineering>
	</vaccine>
	<vaccine vaccine_id="vaccine3101">
		<vaccine_name>HIV-1 gp120 with mCT E112K</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004268</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>intranasal immunization</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">intranasal immunization</route>
		<antigen refs="reference2041">HIV-1LAIEnv gp120 (Yoshino et al., 2004).</antigen>
		<host_response host_response_id="host_response930" host_id="host5">
			<immune_response refs="reference2041">Macaques given nasal gp120 with either mCT E112K or nCT showed elevated gp120-specific IgG and IgA Ab responses with virus-neutralizing activity in both their plasma and mucosal external secretions, as well as higher numbers of gp120-specific IgA Ab-forming cells in their mucosal and peripheral lymphoid tissues and of IL-4-producing Th2-type CD4-positive (CD4(+)) T cells than did controls. Even though significant mucosal adjuvanticity was seen with both mCT E112K and nCT, neuronal damage was observed only in the nCT-treated, but not in the control or mCT E112K-treated groups (Yoshino et al., 2004).</immune_response>
			<host_strain refs="">rhesus macaques</host_strain>
			<vaccination_protocol refs="reference2041">Rhesus macaques were divided into four groups and nasally immunized with vaccine containing: 1) 100 µg of gp120 alone, 2) 100 µg of gp120 plus 10 µg of nCT, 3) 100 µg of gp120 plus 25 µg of mCT E112K, or 4) 100 µg of gp120 plus 100 µg of mCT E112K. Macaques were anesthetized with ketamine and placed in dorsal recumbancy with head tilted back so that the nares were pointed upward. Vaccine solution (0.5 ml) was instilled dropwise into each nostril without inserting the syringe into the nasal cavity. Macaques were kept in that position for 10 min and then placed in lateral recumbancy until they recovered from anesthesia, as described previously (16). Nasal immunization was conducted on days 0, 7, 14, 28, 42, and 56 (Yoshino et al., 2004).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
              <host_gene_response host_gene_response_id="host_gene_response253" gene_id="gene1191">
			    <description refs="reference2041">Macaques given nasal gp120 with either mCT E112K or nCT showed significantly elevated IgA Ab responses with virus-neutralizing activity in both their plasma and mucosal external secretions, as well as higher numbers of gp120-specific IgA Ab-forming cells in their mucosal and peripheral lymphoid tissues compared to controls, who were vaccinated without the adjuvant (Yoshino et al., 2004).</description>
			  </host_gene_response>
              <host_gene_response host_gene_response_id="host_gene_response254" gene_id="gene1192">
			    <description refs="reference2041">Macaques given nasal gp120 with either mCT E112K or nCT showed significantly elevated gp120-specific IgG responses with virus-neutralizing activity in both their plasma and mucosal external secretions compared to controls, who were vaccinated without the adjuvant (Yoshino et al., 2004).</description>
			  </host_gene_response>
              <host_gene_response host_gene_response_id="host_gene_response255" gene_id="gene1193">
			    <description refs="reference2041">Vaccinated animals that received the adjuvant had a greater increase in IL-4-producing Th2-type CD4-positive (CD4(+)) T cells in mesenteric lymph nodes (MLNs) than did controls vaccinated without the adjuvant, which did not produce IL-4 (Yoshino et al., 2004),</description>
			  </host_gene_response>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3092">
		<vaccine_name>HIV-2 DNA vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004259</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pND-14 [Ref2023:Locher et al., 2004]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="reference2023">The DNA vaccine constructs were developed based on the gene sequences of the gp140 envelope, p55 Gag, Nef, and Tat proteins from the HIV-2UC2 isolate (GenBank accession number U38293) (Locher et al., 2004).</antigen>

		<gene_engineering gene_engineering_id="gene_engineering1588" gene_id="gene1717">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1589" gene_id="gene1718">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1590" gene_id="gene1719">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1591" gene_id="gene1720">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response921" host_id="host55">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference2023">Each baboon was immunized four times with the experimental or control DNA constructs formulated with Vaxfectin. The time intervals were chosen to permit maturation of the immune response (Locher et al., 2004).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2023">At 2 weeks post-HIV-2 challenge, viral loads ranged from 100 (below the threshold of detection) to 81,000 viral RNA copies in the plasma, with the lowest average viral loads in the group of baboons that received the HIV-2 DNA without the genetic adjuvants (a mean of 852 copies/ml), followed by the group of baboons the received the HIV-2 DNA and the genetic adjuvants (a mean of 2499 copies/ml) (Locher et al., 2004).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference2023">One month after the fourth immunization, the baboons were challenged twice (6 h apart) by the intravaginal route using 50 baboon infectious dosages (30,000 tissue culture infectious dosages) of HIV-2UC2/9429 for a total of 100 baboon infectious dosages. This virus isolate is a more virulent variant of the HIV-2UC2 isolate and was recovered from a baboon with an AIDS-like disease (Locher et al., 2004).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3071">
		<vaccine_name>Inactivated HIV-2 Vaccine with PMMA</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004242</vo_id>
		<type>Inactivated or "killed" vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>subcutaneous injection</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">subcutaneous injection</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response901" host_id="host3">
			<immune_response refs="reference1897">Mice immunized with PMMA adjuvant had higher antibody counts than mice immunized with an alum adjuvant (Stieneker et al., 1991).</immune_response>
			<host_strain refs="">NMRI</host_strain>
			<vaccination_protocol refs="reference1897">Mice received 0.5 ml of the specified vaccine preparations subcutaneously under the abdominal skin on day 0 (Stieneker et al., 1991).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine4097">
		<vaccine_name>L. T -HIV-1 Gag</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004629</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector>[Ref3082:Breton et al., 2007]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3082">A non-pathogenic protozoan parasitic vector, Leishmania tarentolae, which shares common target cells with HIV-1, was used to express full-length HIV-1 Gag protein (Breton et al., 2007).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1660" gene_id="gene713">
			<type>Recombinant vector construction</type>
			<description refs="reference3082">A non-pathogenic Leishmania tarentolae was used to express full-length HIV-1 Gag protein (Breton et al., 2007).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1724" host_id="host3">
			<immune_response refs="reference3082">Immunization of BALB/c mice with recombinant L. tarentolae led to the expansion of HIV-1 Gag-specific T cells and stimulated CD8(+) T cells to produce gamma interferon in response to specific viral Gag epitopes. A booster immunization with recombinant L. tarentolae elicited effector memory HIV-1 Gag-specific CD4(+) T lymphocytes and increased antibody titres against HIV-1 Gag (Breton et al., 2007).</immune_response>
			<host_strain refs="">Balb/c</host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3082">Immunization of human tonsillar tissue cultured ex vivo with Gag-expressing L. tarentolae vaccine vector elicited a 75% decrease in virus replication following exposure of the immunized tonsils to HIV-1 infection (Breton et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine153">
		<vaccine_name>MVA expressing HIV Gag, Pol and Env proteins</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000824</vo_id>
		<type>Recombinant vector vaccine</type>
		<status></status>
		<vector>modified vaccinia Ankara (MVA)</vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference323">An rMVA vaccine that expresses HIV Gag, Pol, and Env proteins was constructed (Liu et al., 2006).</preparation>
		<route refs=""></route>
		<antigen refs="reference323">HIV Gag, Pol, and Env proteins (Liu et al., 2006)</antigen>
		<host_response host_response_id="host_response241" host_id="host3">
			<immune_response refs="reference323">CD8 T cells were boosted more effectively than CD4 T cells with the ratio of elicited CD8 to CD4 cells for the immunodominant CD8 epitope in Gag increasing with boosts. The most effective boost for CD8 T cells resulted in the greatest skewing of the CD8 to CD4 T cell ratio. This could represent better access of CD8 than CD4 T cells to APCs (Liu et al., 2006). The dose–response studies showed good increases for antigen expression with increasing MVA dose. A 1000-fold increase in the dose of MVA resulted in a 300-fold increase in the frequency of antigen-expressing cells. In contrast, dose–response studies for in vivo immunogenicity showed &lt;10-fold increases in elicited T cells and Ab for 100–1000-fold increases in the dose of inoculated MVA. Shallow dose–response curves for immunogenicity were observed post priming as well as post boosting of an MVA or a DNA prime (Liu et al., 2006).</immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference323">Female BALB/c mice were used for immunizations. All were conducted on anesthetized mice. Immunizations with MVAs were accomplished by inoculating the desired amount of MVA into a single quadriceps muscle. Immunizations with DNA were accomplished by injecting the desired amount of DNA into the quadriceps, half in each leg (Liu et al., 2006).</vaccination_protocol>
			<persistence refs="reference323">Temporal CD8 responses were conducted in BALB/c mice using MVA. Responses were steady for &gt;10 weeks (&gt;6 weeks post-MVA) (Liu et al., 2006).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs="reference323">No adverse effects were encountered (Liu et al., 2006).</side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine4265">
		<vaccine_name>NYVAC-HIV-1</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004774</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3288">Attenuated poxvirus-HIV-1 recombinants followed by protein boosting (Patterson et al., 2000).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response1771" host_id="host39">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference3288">Twenty-four macaques were primed with NYVAC (a genetically attenuated Copenhagen vaccinia strain) recombinants with HIV-1 and HIV-2 env and gag-pol or NYVAC vector alone and boosted with homologous, oligomeric gp160 proteins or adjuvant only (Patterson et al., 2000).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000287</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3288">Virological assessments verified that both NYVAC-HIV-1 and NYVAC-HIV-2 immunization significantly reduced viral burdens and partially protected against HIV-2 challenge, although cross-protection was not at the level that had been previously reported. Humoral antibody and/or CTL and CD8AA were associated with protection against homologous HIV-2 challenge, while cellular immune responses seemed more important for cross-protection. No significant protection was observed in the SHIV-challenged macaques (Patterson et al., 2000).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference3288">One half of each immunization and control group were intravenously challenged with SHIV(HXB2) the other half was challenged with HIV-2SBL6669 (Patterson et al., 2000).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine4266">
		<vaccine_name>NYVAC-HIV-2</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004775</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3288">Attenuated poxvirus-HIV-1 recombinants followed by protein boosting (Patterson et al., 2000).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response1772" host_id="host39">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference3288">Twenty-four macaques were primed with NYVAC (a genetically attenuated Copenhagen vaccinia strain) recombinants with HIV-1 and HIV-2 env and gag-pol or NYVAC vector alone and boosted with homologous, oligomeric gp160 proteins or adjuvant only (Patterson et al., 2000).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="">Virological assessments verified that both NYVAC-HIV-1 and NYVAC-HIV-2 immunization significantly reduced viral burdens and partially protected against HIV-2 challenge, although cross-protection was not at the level that had been previously reported. Humoral antibody and/or CTL and CD8AA were associated with protection against homologous HIV-2 challenge, while cellular immune responses seemed more important for cross-protection. No significant protection was observed in the SHIV-challenged macaques, although NYVAC-HIV-1 immunization resulted in significantly lower viral burdens compared with controls (Patterson et al., 2000).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="">One half of each immunization and control group were intravenously challenged with SHIV(HXB2) the other half was challenged with HIV-2SBL6669 (Patterson et al., 2000).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine4271">
		<vaccine_name>NYVAC-SIV</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004779</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3291">The gag, pol, and env genes of SIV(K6W) were expressed in the NYVAC vector (Benson et al., 1998).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response1773" host_id="host39">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference3291">The macaques were immunized with NYVAC-SIV and NYVAC-IL-12 or NYVAC-SIV alone (Benson et al., 1998).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3291">Significantly, five of the eleven vaccinees exposed mucosally to SIV(mac251) showed a transient peak of viremia 1 week after viral challenge and subsequently appeared to clear viral infection. In contrast, all 12 animals inoculated intravenously became infected, but 5 to 6 months after viral challenge, 4 animals were able to control viral expression and appeared to progress to disease more slowly than control animals. Protection did not appear to be associated with any of the measured immunological parameters. Further modulation of immune responses by coadministration of NYVAC-cytokine recombinants did not appear to influence the outcome of viral challenge (Benson et al., 1998).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference3291">At the end of the immunization regimen, half of the animals were challenged with SIV(mac251) by the intravenous route and the other half were exposed to SIV(mac251) intrarectally (Benson et al., 1998).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3960">
		<vaccine_name>rBCG-SIVgag and rDIsSIVgag Prime-boost SHIV vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004600</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector>Mycobacterium bovis bacillus Calmette-Guérin (BCG)-Tokyo and a replication-deficient vaccinia virus strain (DIs) [Ref2794:Ami et al., 2005]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="">gag from simian immunodeficiency viruses</antigen>

		<gene_engineering gene_engineering_id="gene_engineering1650" gene_id="gene1709">
			<type>Recombinant vector construction</type>
			<description refs="reference2794">The SHIV gag gene was inserted to a recombinant BCG vector and a replication-deficient vaccinia virus strain (DIs) vaccine vector (Ami et al., 2005).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1605" host_id="host39">
			<immune_response refs=""></immune_response>
			<host_strain refs="">cynomologus macaque</host_strain>
			<vaccination_protocol refs="reference2794">cynomologus macaques were primed with rBCG-SIVgag, and then boosted with rDIsSIVgag (Ami et al., 2005).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2794">For the prime-boost vaccination group, plasma viremia levels remained undetectable and CD4+ T-cell counts stayed above 500 cells/μl for the entire year of testing (Ami et al., 2005).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference2794">Ten weeks after the second booster immunization, the macaques were challenged by intrarectal inoculation with 2 × 10^3 TCID50 or 50 50% monkey infectious doses (MID50) of SHIV KS661c, an SHIV-89.6 variant clone (Ami et al., 2005).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine310">
		<vaccine_name>Recombinant HIV gp120 with adjuvant NanoEmulsion</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000819</vo_id>
		<type>Subunit vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference707">An oil-in-water nanoemulsion (NE) (Bielinska et al., 2008).</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference707">The gp120 and NE vaccines were prepared by mixing NE with gp120 protein solution, using pyrogen-free saline as a diluent (Bielinska et al., 2008).</preparation>
		<route refs=""></route>
		<antigen refs="reference707">HIV glycoprotein 120, which has a role in facilitating coreceptor interaction and in mediating virus binding to cellular CD4 (Bielinska et al., 2008).</antigen>
		<host_response host_response_id="host_response397" host_id="host3">
			<immune_response refs="reference707">Immunized mice demonstrated robust serum anti-gp120 IgG, as well as bronchial, vaginal, and serum anti-gp120 IgA . The analysis of gp120-specific CTL proliferation, INF- induction, and prevalence of anti-gp120 IgG2 subclass antibodies indicated that nasal vaccination in NE also induced systemic, Th1-polarized cellular immune responses (Bielinska et al., 2008).</immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference707">BALB/c mice were immunized with two or three intranasal administrations of gp120/NE formulation at 3 weeks apart. The immunizations of 10 microliters were performed by slowly applying gp120/NE mixes to the nares.Control mice were immunized with gp120 in saline, with NE alone or saline. Intramuscular immunization was performed with two doses, 3 weeks apart, of 20 micrograms of gp120 injected in 50 microliters of either saline or 1% NE (Bielinska et al., 2008).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response398" host_id="host7">
			<immune_response refs="reference707">Immunization produced significant levels of serum anti-gp120 IgG antibodies in all animals, as was seen with the mice. The analysis of gp120-specific CTL proliferation, INF gamma induction, and prevalence of anti-gp120 IgG2 subclass antibodies indicated that nasal vaccination in NE also induced systemic, Th1-polarized cellular immune responses (Bielinska et al., 2008).</immune_response>
			<host_strain refs="">Hartley</host_strain>
			<vaccination_protocol refs="reference707">Hartley guinea pigs were immunized intranasally with two administrations (50 microliters per nare) of gp120/NE mix at 3 weeks apart (Bielinska et al., 2008).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3097">
		<vaccine_name>rgp120 HIV Vaccine with immunoliposomes</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004264</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>subcutaneous injection</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">subcutaneous injection</route>
		<antigen refs="reference2035">rgp120 (Ozpolat et al., 1998).</antigen>
		<host_response host_response_id="host_response926" host_id="host3">
			<immune_response refs="reference2035">Mice vaccinated with immunoliposomes were found to have a strong delayed-type hypersensitivity (DTH) response to the weakly immunogenic gp120 that was dependent on the presence of the MAbs. However, this vaccination protocol did not induce humoral immunity (Ozpolat et al., 1998).</immune_response>
			<host_strain refs="">C3H/HeN</host_strain>
			<vaccination_protocol refs="reference2035">Groups of five mice were immunized subcutaneously three times at 14-day intervals. The immunoliposomes were suspended in PBS and each mouse received 0.1 ml per injection. Each injection contained 380 &amp;mu;g of PC, 193 &amp;mu;g of CH, 10 pg of PE-B, 2.0 &amp;mu;g of MAb, and 10 &amp;mu;g of rgpl20 (Ozpolat et al., 1998).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine4302">
		<vaccine_name>rMVA-SIV-CD40L</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004792</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3317">Co-expressed the CD40L with our DNA/SIV vaccine such that the CD40L is anchored on the membrane of SIV virus-like particle (VLP) (Kwa et al., 2014).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response1768" host_id="host39">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference3317">The macaques were divided into 3 groups and group 1 was vaccinated with a DNA/MVA SIV vaccine, group 2 was vaccinated with the DNA/MVA SIV vaccine with CD40L in the DNA, and the third group was an unvaccinated control (Kwa et al., 2014).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3317">CD40L adjuvant enhanced the functional quality of anti-Env antibody response and breadth of anti-SIV CD8 and CD4 T cell responses, significantly delayed the acquisition of heterologous mucosal SIV infection and improved viral control. Notably, the CD40L adjuvant enhanced the control of viral replication in the gut at the site of challenge that was associated with lower mucosal CD8 immune activation, one of the strong predictors of disease progression (Kwa et al., 2014).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference3317">The macaques were intrarectally challenged with SIVE660 at a dose of 5000 TCID to test the level of protection of the vaccines (Kwa et al., 2014).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine4250">
		<vaccine_name>rMVTT-SIV-gpe</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004760</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3276">(Sun et al., 2013)  a modified replicating vaccinia virus Tiantan strain (MVTT(SIVgpe))</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1716" gene_id="gene1250">
			<type>Recombinant vector construction</type>
			<description refs="reference3276">A recombinant modified replicating vaccinia virus Tiantan strain (MVTTSIVgpe) and a recombinant, nonreplicating adenovirus type 5 strain (Ad5SIVgpe) expressing the SIVmac239 Gag, Pol, and Env structural proteins were generated (Sun et al., 2013).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1717" gene_id="gene1245">
			<type>Recombinant vector construction</type>
			<description refs="reference3276">A recombinant modified replicating vaccinia virus Tiantan strain (MVTTSIVgpe) and a recombinant, nonreplicating adenovirus type 5 strain (Ad5SIVgpe) expressing the SIVmac239 Gag, Pol, and Env structural proteins were generated (Sun et al., 2013).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1718" gene_id="gene1245">
			<type>Recombinant vector construction</type>
			<description refs="reference3276">A recombinant modified replicating vaccinia virus Tiantan strain (MVTTSIVgpe) and a recombinant, nonreplicating adenovirus type 5 strain (Ad5SIVgpe) expressing the SIVmac239 Gag, Pol, and Env structural proteins were generated (Sun et al., 2013).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1775" host_id="host5">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference3276">Eight monkeys were divided into two groups: (i) four monkeys received the MVTTioin+Adim testing regimen as in study I, and (ii) four monkeys received an empty MVTT control vector (10^9 PFU) through intraoral (0.5 ml) and intranasal (0.5 ml) routes and an empty Ad5 control vector (10^11 vp in 1 ml of PBS) through intramuscular injection (Sun et al., 2013).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3276">The reductions in peak and set-point viral loads were significant in most animals, with one other animal being protected fully from high-dose intrarectal inoculation of SIV(mac239). Furthermore, the animals vaccinated with this regimen were healthy, while ~75% of control animals developed simian AIDS. The protective effects correlated with the vaccine-elicited SIV-specific CD8(+) T cell responses against Gag and Pol (Sun et al., 2013).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference3276">At either week 30 after the initial vaccination or week 24 after the final vaccination, each animal was challenged intrarectally with 5 × 10^5 50% tissue culture infective doses (TCID50) of Chinese rhesus monkey-adapted and neutralization-resistant SIVmac239. In all cases, the challenge virus stock was administered in 1 ml of PBS (Sun et al., 2013).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3954">
		<vaccine_name>SHIV DNA vaccine encoding env and gag</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004596</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pSW3891 [Ref2784:Pal et al., 2006]</vector>
		<route>Gene gun</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Gene gun</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1634" gene_id="gene1748">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1635" gene_id="gene1749">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1636" gene_id="gene1750">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1637" gene_id="gene1747">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1638" gene_id="gene1751">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1600" host_id="host39">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2784">The immune response elicited by the multivalent DNA prime/protein boost vaccine was able to protect macaques from rectal challenge with SHIV-Ba-L isolate.  This polyvalent vaccine formulation was able to confer protection in four out of six animals against SHIV-Ba-L and significantly reduced plasma viremia in the two remaining animals (Pal et al., 2006).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3955">
		<vaccine_name>SHIV(Ba-L) DNA vaccine encoding env and gag</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004597</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pSW3891 [Ref2786:Pal et al., 2005]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1639" gene_id="gene1752">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1640" gene_id="gene1747">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1641" gene_id="gene1749">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1642" gene_id="gene1750">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1643" gene_id="gene1748">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1644" gene_id="gene1751">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1601" host_id="host39">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2786">one of six immunized animals was completely protected whereas all six naïve animals were infected. These results demonstrate that a vaccine based on priming with a polyvalent DNA vaccine from multiple HIV-1 subtypes followed by boosting with homologous Env proteins elicits anti-HIV-1 immune responses capable of controlling rectal transmission of SHIV(Ba-L) (Pal et al., 2005).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3059">
		<vaccine_name>V3 VLPs with Gamma inulin adjuvant</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004232</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="reference1889">gp120 V3 loop (Harris et al., 1996).</antigen>
		<host_response host_response_id="host_response889" host_id="host3">
			<immune_response refs="reference1889">Mice immunized with V3 VLPs adjuvanted with gamma inulin showed good CTL responses (Harris et al., 1996).</immune_response>
			<host_strain refs="">BABL/c</host_strain>
			<vaccination_protocol refs="reference1889">Mice were immunized with 10 μg of V3-VLPs without adjuvant in the muscle of the left leg. At the same time, the mice were immunized in the right leg with the other immunogens (Harris et al., 1996).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine4175">
		<vaccine_name>YF17D- HIV-1 p24</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004690</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3209">HIV-1 p24 (clade B consensus), was inserted near the 5' end of YF17D, in frame and upstream of the polyprotein (YF-5'/p24) (Franco et al., 2010).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response1723" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference3209">Mice were immunized two times subcutaneously at the base of the tail with PBS or 10^6 pfu of YF17D, YF-E/p24/NS1, or YF-5′/p24 in 100 μl on days 0 and 14 (Franco et al., 2010).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3209">The protective efficacy of the YF17D recombinants, particularly YF-E/p24/NS1, in mice challenged with a vaccinia expressing HIV-1 Gag was demonstrated (Franco et al., 2010).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference3209">Three weeks after the second immunization, half of the mice in each group were challenged intranasally with 5 × 10^5 pfu of Gag-expressing recombinant vaccinia virus (Vac-gag). The remaining animals in the groups were challenged intranasally with the same dose of wild-type vaccinia virus (Vac-wt) (Franco et al., 2010).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<gene gene_id="gene153">
        <gene_name>env</gene_name>
        <strain>Human immunodeficiency virus 1</strain>
        <vo_id>VO_0010937</vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>8218033</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:278917
CDD:295533
CDD:197369
GOA:Q9IBN3
HSSP:1MEQ
InterPro:IPR000328
InterPro:IPR000777
UniProtKB/TrEMBL:Q9IBN3</xrefs>
        <taxonomy_id>11676</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>ENV (gp160)</protein_name>
        <protein_pi>8.84</protein_pi>
        <protein_weight>92355.68</protein_weight>
        <protein_length>920</protein_length>
        <protein_note>HIV-1 GB8 isolated into the cell line JM and the provirus clone was derived by PCR off extracted high molecular weight DNA</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|8218025:6237-8786 Human immunodeficiency virus type 1 proviral genome, isolate GB8, clone 46R
ATGAAAGCGAAGGGGACCAGGAAGAATTATCAGCACTTGTGGAAATGGGGCATCATGCTCCTTGGGATGT
TGATGATCTGTAGTGCTACAGAAAAATTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAAAGAAGC
AACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGACACAGAAAAACATAATGTTTGGGCCACA
CATGCCTGTGTACCCACAGACCCCAACCCACAAGAGGTAGTATTGGGAAATGTGACAGAAAATTTTAACA
TGTGGAAAAATAACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAGCC
ATGTGTAAAATTAACCCCACTCTGTGTTACTTTAAATTGCACTGATTTGAGGAATGATACTAATACCGAT
AATAGTATAATGGAGGGAGGAGAAATGAAAAACTGCTCTTTCAATATCACCACAAGCATAAGGGATAAGA
TGCAGAAAGAATATGCACTTTTGTATAAACTTGATATAGTATCAATAGGTAGTGATAATACTAGCTATAT
ATTGACAAAGTGTGACGCCTCAGTCATTACACAGGCCTGTCCAAAGATATCCTTTGAGCCAATTCCCATA
CATTTTTGTGCCCCGGCTGGTTTTGCGATTCTAAAGTGTAACAATAAGACATTCGATGGAAAAGGACCAT
GTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTGTCAACTCAACTGCTGTTAAA
TGGCAGTCTAGCAGAAGAAAAGGTAGTAATTAGATCTGACAATTTCATGGACAATACTAAAACCATAATA
GTACAGCTGAAAGAAGCTGTAGAAATTAATTGTACAAGACCCAACAACAATACAAGAAAAGGTATATACA
TAGGACCAGGGAGAAGATTTTATACAACAGGAAGAATAATAGGAGATATAAGACAAGCACATTGTAACAT
TAGTAAAGAAAAATGGAATAATACTTTACACCAGATAGTTATAGAATTGAGGAAACAATTTAGGAATAAA
ACAATAGTCTTTAATCAATCCTCAGGAGGGGACCCAGAAATTGTAATGCACAGTTTTAATTGTGGAGGGG
AATTTTTCTACTGTAAGACAGCACAACTGTTTAATAGTACTTGGAATAGTACTGGAAATGGTACTATAAA
GTCAAATACCACTGAAATTATCACACTCCCATGTAGAATAAAACAAATTGTAAACATGTGGCAGGAAGTA
GGAAAAGCAATGTATGCCCCTCCCATCACAGGACAAATTAGATGTGCATCACATATTACAGGGCTACTAT
TAACAAGAGATGGAGGTAGGGAGAACAATACCAACGAGACCGAGACCTTCAGACCTGGAGGAGGAGATAT
GAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCC
ACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATGATAGGAGCTATGTTCCTTG
GGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCACTGACGCTGACGGTACAGGCCAGACTATT
ATTGTCTGGTATAGTGCAACAGCAAAATAATTTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCGA
CTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAGTCCTGGCTGTGGAAAGATACCTAAAGGATCAAC
AGCTCCTAGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTACTGTGCCTTGGAATGTTAGTTG
GAGTAATAAATCTCTGGATAAGATTTGGAATAACATGACCTGGATGGAGTGGGAAAGAGAAATTGACAAT
TACACAAACACAATATACACCTTAATTGAAGAATCGCAGAACCAACAAGAAAAGAATGAACAAGAATTAT
TGGAATTGGATAAGTGGGCAAATTTGTGGAATTGGTTTGACATAACAAACTGGCTGTGGTATATAAAAAT
ATTCATAATGATAATAGGAGGCTTAATAGGTTTAAGAATAATTTTTGCTGTAATTTCTATAGTGAATAGA
GTTAGGCGGGGATACTCACCATTATCATTGCAGACCCACCTCCCAACCCCAAGGGGACCCGACAGGCCCG
AAGGAATCGAAGAAGAAGGTGGAGAGCAAGACAGAGACAGATCCATCAGATTGGTGAATGGATTCTTAGC
GCTTTTCTGGGACGACCTGCGGAGCCTGTGCCTCTTCAGCTACCACCGATTGAGAGACTTACTCTTGATT
GTGACGAGGATTGTGGGACTTCTGGGACGCAGGGGGTGGGAAGCCCTCAAGTATTGGTGGAATCTCCTGC
AGTATTGGATCCAGGAACTAAAGAATAGTGCTATTAGCTTGCTTAATACCACAGCTATAGCAGTAGCTGA
GGGGACAGATAGGGTTATAGAAGTAGTACAAAGAGCTTATAGAGCTATTCTCCACATACCTACAAGAATA
AGACAGGGCTTAGAAAGGGCTTTGCAATAA</dna_sequence>
        <protein_sequence>>CAB92793.1 ENV (gp160) [Human immunodeficiency virus 1]
MKAKGTRKNYQHLWKWGIMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEKHNVWAT
HACVPTDPNPQEVVLGNVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNCTDLRNDTNTD
NSIMEGGEMKNCSFNITTSIRDKMQKEYALLYKLDIVSIGSDNTSYILTKCDASVITQACPKISFEPIPI
HFCAPAGFAILKCNNKTFDGKGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEKVVIRSDNFMDNTKTII
VQLKEAVEINCTRPNNNTRKGIYIGPGRRFYTTGRIIGDIRQAHCNISKEKWNNTLHQIVIELRKQFRNK
TIVFNQSSGGDPEIVMHSFNCGGEFFYCKTAQLFNSTWNSTGNGTIKSNTTEIITLPCRIKQIVNMWQEV
GKAMYAPPITGQIRCASHITGLLLTRDGGRENNTNETETFRPGGGDMRDNWRSELYKYKVVKIEPLGVAP
TKAKRRVVQREKRAVGMIGAMFLGFLGAAGSTMGAASLTLTVQARLLLSGIVQQQNNLLRAIEAQQHLLR
LTVWGIKQLQARVLAVERYLKDQQLLGIWGCSGKLICTTTVPWNVSWSNKSLDKIWNNMTWMEWEREIDN
YTNTIYTLIEESQNQQEKNEQELLELDKWANLWNWFDITNWLWYIKIFIMIIGGLIGLRIIFAVISIVNR
VRRGYSPLSLQTHLPTPRGPDRPEGIEEEGGEQDRDRSIRLVNGFLALFWDDLRSLCLFSYHRLRDLLLI
VTRIVGLLGRRGWEALKYWWNLLQYWIQELKNSAISLLNTTAIAVAEGTDRVIEVVQRAYRAILHIPTRI
RQGLERALQ

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1240">
        <gene_name>env</gene_name>
        <strain>Human immunodeficiency virus 1</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>155971</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>9629363</ncbi_protein_id>
        <gene_locus_tag>HIV1gp8</gene_locus_tag>
        <gene_refseq>AF033819</gene_refseq>
        <protein_refseq>NP_057856</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>11676</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>5770</gene_start>
        <gene_end>8340</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>Envelope surface glycoprotein gp160, precursor</protein_name>
        <protein_pi>9.19</protein_pi>
        <protein_weight>91753.45</protein_weight>
        <protein_length>856</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_001802.1:5770-8340 Human immunodeficiency virus 1, complete genome
AATGAGAGTGAAGGAGAAATATCAGCACTTGTGGAGATGGGGGTGGAGATGGGGCACCATGCTCCTTGGG
ATGTTGATGATCTGTAGTGCTACAGAAAAATTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAAGG
AAGCAACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGC
CACACATGCCTGTGTACCCACAGACCCCAACCCACAAGAAGTAGTATTGGTAAATGTGACAGAAAATTTT
AACATGTGGAAAAATGACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAA
AGCCATGTGTAAAATTAACCCCACTCTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATAC
CAATAGTAGTAGCGGGAGAATGATAATGGAGAAAGGAGAGATAAAAAACTGCTCTTTCAATATCAGCACA
AGCATAAGAGGTAAGGTGCAGAAAGAATATGCATTTTTTTATAAACTTGATATAATACCAATAGATAATG
ATACTACCAGCTATAAGTTGACAAGTTGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCCTT
TGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACGTTC
AATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTATCAA
CTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCACGGACAA
TGCTAAAACCATAATAGTACAGCTGAACACATCTGTAGAAATTAATTGTACAAGACCCAACAACAATACA
AGAAAAAGAATCCGTATCCAGAGAGGACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGAAATATGA
GACAAGCACATTGTAACATTAGTAGAGCAAAATGGAATAACACTTTAAAACAGATAGCTAGCAAATTAAG
AGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAAATTGTAACG
CACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGTACTTGGTTTA
ATAGTACTTGGAGTACTGAAGGGTCAAATAACACTGAAGGAAGTGACACAATCACCCTCCCATGCAGAAT
AAAACAAATTATAAACATGTGGCAGAAAGTAGGAAAAGCAATGTATGCCCCTCCCATCAGTGGACAAATT
AGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAGCAACAATGAGTCCGAGA
TCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAA
AATTGAACCATTAGGAGTAGCACCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTG
GGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCCTCAATGACGC
TGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGA
GGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTG
GAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTG
CTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGGAATCACACGACCTGGATGGA
GTGGGACAGAGAAATTAACAATTACACAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAA
GAAAAGAATGAACAAGAATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAA
ATTGGCTGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTTTTGC
TGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGACCCACCTCCCAACC
CCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCCATTC
GATTAGTGAACGGATCCTTGGCACTTATCTGGGACGATCTGCGGAGCCTGTGCCTCTTCAGCTACCACCG
CTTGAGAGACTTACTCTTGATTGTAACGAGGATTGTGGAACTTCTGGGACGCAGGGGGTGGGAAGCCCTC
AAATATTGGTGGAATCTCCTACAGTATTGGAGTCAGGAACTAAAGAATAGTGCTGTTAGCTTGCTCAATG
CCACAGCCATAGCAGTAGCTGAGGGGACAGATAGGGTTATAGAAGTAGTACAAGGAGCTTGTAGAGCTAT
TCGCCACATACCTAGAAGAATAAGACAGGGCTTGGAAAGGATTTTGCTATA

</dna_sequence>
        <protein_sequence>>NP_057856.1 Envelope surface glycoprotein gp160, precursor [Human immunodeficiency virus 1]
MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWA
THACVPTDPNPQEVVLVNVTENFNMWKNDMVEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTNT
NSSSGRMIMEKGEIKNCSFNISTSIRGKVQKEYAFFYKLDIIPIDNDTTSYKLTSCNTSVITQACPKVSF
EPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSVNFTDN
AKTIIVQLNTSVEINCTRPNNNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKLR
EQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTWSTEGSNNTEGSDTITLPCRI
KQIINMWQKVGKAMYAPPISGQIRCSSNITGLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVK
IEPLGVAPTKAKRRVVQREKRAVGIGALFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQQQNNLLRAIE
AQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLEQIWNHTTWME
WDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWYIKLFIMIVGGLVGLRIVFA
VLSIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVNGSLALIWDDLRSLCLFSYHR
LRDLLLIVTRIVELLGRRGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQGACRAI
RHIPRRIRQGLERILL

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1261">
        <gene_name>env</gene_name>
        <strain>Human immunodeficiency virus 1 MN</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>3342812</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:278917
CDD:295533
CDD:197369</xrefs>
        <taxonomy_id>11676</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>envelope glycoprotein</protein_name>
        <protein_pi>8.75</protein_pi>
        <protein_weight>92117.65</protein_weight>
        <protein_length>938</protein_length>
        <protein_note>MN neutralization phenotype variant clone</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAC31819.1 envelope glycoprotein [Human immunodeficiency virus 1]
MRVKGIRRNYQHWWGWGTMLLGLLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEAHNVWAT
HACVPTDPNPQEVELVNVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNCTDLRNTTNTN
NSTDNNNSNSEGTIKGGEMKNCSFNITTSIGDKVQKEYALLYKLDIESIDNDSTSYRLISCNTSVITQAC
PKISFEPIPIHYCAPAGFAILKCNDKKFSGKGSCKNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSE
DFTDNAKTIIVHLKESVQINCTRPNYNKRKRIHIGPGRAFYTTKNIKGTIRQAHCIISRAKWNDTLRQIV
SKLKEQFKNKTIVFNPSSGGDPEIVMHSFNCGGEFFYCNTSPLFNSTWNGNNTWNNTTGSNNNITLQCKI
KQIINMWQKVGKAMYAPPIEGQIRCSSNITGLLLTRDGGIDTDTNDTEIFRPGGGDMRDNWRSELYKYKV
VTIEPLGVAPTKAKRRVVQREKRAAIGALFLGFLGAAGSTMGAASVTLTVQARPLLSGIVQQQNNLLRAI
ESQQHMLQLTVWGIKQLQARVLAVERYLKDQQLLGFWGCSGKLICTTTVPWNASWSNKSLDDIWNNMTWM
QWEREIDNYTSLIYSLLEKSQTQQEKNEQELLELDKWASLWNWFDITNWLWYIKIFIMIVGGLVGLRIVF
AVLSIVNRVRQGYSPLSLQTRPPVPRGPDRPEGIEEEGGERDRDTSGRLVHGFLAIIWVDLRSLFLLSYH
HLRDLLLIAARIVELLGRRGWEVLKYWWNLLQYWSQELKSSAVSLLNAAAIAVAEGTDRVIEVLQRAGRA
ILHIPTRIRQGLERALL

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1708">
        <gene_name>env</gene_name>
        <strain>Simian-Human immunodeficiency virus strain SHIV89.6P</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>72398919</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:278917</xrefs>
        <taxonomy_id>57667</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>envelope protein</protein_name>
        <protein_pi>9.92</protein_pi>
        <protein_weight>40473.44</protein_weight>
        <protein_length>461</protein_length>
        <protein_note>Envelope glycoprotein GP120; pfam00516</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAZ72871.1 envelope protein, partial [Simian-Human immunodeficiency virus]
LNCTNLNITKNTTNPTSSSWGMMEEGEIKNCSFYITTSIRDKVKKEYALFNRLDVVPVENTSYRLISCNT
SVITQACPKVSFQPIPIHYCVPAGFAILKCNNKTFNGSGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEE
DIVIRSENFTNNVKNIIVQLNESVVINCTRPNNNTRERLSIGPGRAFYARRNIIGDIRQAHCNISRAKWN
NTLQQIVIKLREKYRNKTIAFNQSSGGDPEIVMHSFNCGGEFFYCNTAQLFNSTWNVTGGTNGTKGSDII
TLQCRIKQIINMWQKVGKAMYAPPIKGQIRCSSNITGLLLTRDGGSSTETEPEIFRPGGGDMRDNWRSEL
YKYKVVRIEPIGVAPTRAKRRTVQREKR

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1711">
        <gene_name>env</gene_name>
        <strain>Simian-Human immunodeficiency virus strain SHIV-89.6</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>2828045</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:278917
CDD:295533
CDD:197369</xrefs>
        <taxonomy_id>57667</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>env</protein_name>
        <protein_pi>9.04</protein_pi>
        <protein_weight>91775.38</protein_weight>
        <protein_length>922</protein_length>
        <protein_note>Envelope glycoprotein GP120; pfam00516</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAB99966.1 env [Simian-Human immunodeficiency virus]
MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWREATTTLFCASDAKAYDTEVHNVWA
THACVPTDPNPQEVVLGNVTENFNMWKNNMVDQMHEDIISLWDESLKPCVKLTPLCVTLNCTNLNITKNT
TNPTSSSWGMMEKGEIKNCSFYITTSIRNKVKKEYALFNRLDVVPIENTNNTKYRLISCNTSVITQACPK
VSFQPIPIHYCVPAGFAMLKCNNKTFNGSGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEDIVIRSENF
TDNAKTIIVQLNESVVINCTRPNNNTRRRLSIGPGRAFYARRNIIGDIRQAHCNISRAKWNNTLQQIVIK
LREKFRNKTIAFNQSSGGDPEIVMHSFNCGGEFFYCNTAQLFNSTWNVTGGTNGTEGNDIITLQCRIKQI
INMWQKVGKAMYAPPITGQIRCSSNITGLLLTRDGGNSTETETEIFRPGGGDMRDNWRSELYKYKVVRIE
PIGVAPTRAKRRTVQREKRAVGIGAVFLGFLGAAGSTMGAASVTLTVQARLLLSGIVQQQNNLLRAIEAQ
QHMLQLTVWGIKQLQARVLALERYLRDQQLMGIWGCSGKLICTTSVPWNVSWSNKSVDDIWNNMTWMEWE
REIDNYTDYIYDLLEKSQTQQEKNEKELLELDKWASLWNWFDITNWLWYIRLFIMIVGGLIGLRIVFAVL
SIVNRVRQGYSPLSFQTLLPASRGPDRPEGTEEEGGERDRDRSGPLVNGSLALIWDDLRSLCLFSYHRLR
DLLLIVTRIVELLGRRGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQGACRAIRH
IPRRIRQGLERILL

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1720">
        <gene_name>env</gene_name>
        <strain>Human immunodeficiency virus 2</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>1845209</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:278917
CDD:278918
CDD:197369</xrefs>
        <taxonomy_id>11709</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>envelope polyprotein</protein_name>
        <protein_pi>8.65</protein_pi>
        <protein_weight>93936.04</protein_weight>
        <protein_length>945</protein_length>
        <protein_note>similar to HIV2BEN, GenBank Accession Number M30502, and to HIV2D194, GenBank Accession Number J04542</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAB47784.1 envelope polyprotein [Human immunodeficiency virus 2]
MEPGRNQLLAVILLTSACLIYCKQYVTVFYGVPVWRNASIPLFCATKNRDTWGTIQCLPDNDDYQEIPLN
VTEAFDAWDNTVTEQAIEDVWRLFETSIKPCVKLTPLCVAMNCNPVTGNNTNATAKPTAARPTTNPSYLT
IINESSTCVGADNCTGLGDEGMVNCKFNMTGLEQDKIKGYTDTWYSDDVVCDSTNKTGTNTTCYMRHCNT
SVIKESCDKHYWDSMKFRYCTPPGYALLRCNDTNYSGFAPNCPKVVAASCTRMMETQTSTWFGFNGTRAE
NRTYIYWHGRDNRTIISLNKHYNLTMHCKRPGNKTVVPITLMSGHRFHSQAVINKKPRQAWCWFKGNWKG
AMQEVKQTLAGHPRYKGTNDTSKINFVKPGVGSDPEVTYMWTNCRGEFFYCNMTWFLNWVENRTSQKQRN
YAPCHIRQIINTWHKVGQYVYLPPREGELTCNSTVTSIIANIDTDGNQTNITFSAEVAELYRLELGDYKL
IEITPIGFAPTSEKRYSSAPARNKRGVFVLGLLGFLATAGSAMGAASLTLSAQSRTLLAGIVQQQQQLLD
IVKRQQELLRLTVWGTKNLQARVTAIEKYLKDQAQLNSWGCTFRQVCHTTVPWVNDSLTPRWNNMTWQEW
EKQVRYLEANISQSLEEAQIQQEKNMYELQKLNSWDVFGNWFDLTSWIKYIQYGVYIVVGIIALRIAIYV
VQLLSRFRKGYRPVFSSPPGYLQQIHIHTDRGQPANEETEGDAGDASGYDFWPWPINYIQLLIHLLTRLL
TGLYSICRDLLSANSPTRRLISQNLTAIRDWLRLKAAYLQYGCEWIQEAFQAIARTARETLAGAWRGLCK
AVQRIGRGILAVPRRIRQGAEIALL

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1747">
        <gene_name>env</gene_name>
        <strain>Human immunodeficiency virus 1 isolate 715 from Baltimore clone 6</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>475647</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:278917
CDD:295533
CDD:197369</xrefs>
        <taxonomy_id>11676</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>envelope glycoprotein</protein_name>
        <protein_pi>8.4</protein_pi>
        <protein_weight>91460.08</protein_weight>
        <protein_length>942</protein_length>
        <protein_note>Envelope glycoprotein GP120; pfam00516</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAB04079.1 envelope glycoprotein, partial [Human immunodeficiency virus 1]
VTGIRKNCQHWWKWGIMLLGILMICNATEKLWVTVYYGVPVWKEANTTLFCASDAKAYDTEVHNVWATHA
CVPTDPDPQEVELENVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNCTNLRNDTNTTRN
ATNTTSSETMMEEGEIKNCSFNITTSIRDKVQKEFALFYKLDVVPIENDTTSYRLISCNTSVLTQACPKV
SFEPIPIHFCAPAGFAILKCKDKKFNGTGPCTNVSTVQCTHGIKPVVSTQLLLNGSLAEEEVVIRSANLS
DNAKTIIVQLNESVQMNCTRPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAHCNLSRTKWNETLKRIVIKL
REQYENKTIVFNQSSGGDPEIVMLSFNCGGEFFYCNSTKLFNSTWNGTESNNTGDDPIVLPCRIKQVINM
WQEVGKAMYAPPIRGQIRCSSNITGLLLTRDGGNSNETNTTEIFRPGGGNMKDNWRSELYKYKVVRIEPL
GIAPTRAKRRVVQREKRAAGLGVMFLGFLGAAGSTMGAASIALTVQARQLLSGIVQQQNNLLRAIEAQQH
MLQLTVWGIKQLQARVLAVERYLRDQQLLGIWGCSGKLICTTTVPWNASWSNKSHDQIWQNMTWMQWEKE
IDNYTSLIYNLIEVSQNQQEKNEQELLELDKWASLWNWFDITNWLWYIKIFIMIVGGLIGLRIVFIVLSI
VNRVRQGYSPLSFQTHLPARRGPDRPEGIEEEGGERDRDRSGQLVTGFLAIIWVDLRSLCLFSYHRLRDL
LLIVARIVELLGRRGWEILKYWWNLLQYWSQELKSGAVSLLNATAIAVAEGTDRVIEVLQRAGRAILHIP
RRIRQGFERALL

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1748">
        <gene_name>env</gene_name>
        <strain>Human immunodeficiency virus 1 strain Ba-L subtype B</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id>326367</ncbi_nucleotide_id>
        <ncbi_protein_id>326371</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:278917
CDD:295533
CDD:197369</xrefs>
        <taxonomy_id>11676</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name></protein_name>
        <protein_pi>8.87</protein_pi>
        <protein_weight>91185.73</protein_weight>
        <protein_length>918</protein_length>
        <protein_note>Envelope glycoprotein GP120; pfam00516</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAA44191.1 env [Human immunodeficiency virus 1]
MRVTEIRKSYQHWWRWGIMLLGILMICNAEEKLWVTVYYGVPVWKEATTTLFCASDRKAYDTEVHNVWAT
HACVPTDPNPQEVELKNVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNCTDLRNATNGN
DTNTTSSSRGMVGGGEMKNCSFNITTNIRGKVQKEYALFYKLDIAPIDNNSNNRYRLISCNTSVITQACP
KVSFEPIPIHYCAPAGFAILKCKDKKFNGKGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSAN
FADNAKVIIVQLNESVEINCTRPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAHCNLSRAKWNDTLNKIVI
KLREQFGNKTIVFKHSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWNVTEESNNTVENNTITLPCRIKQ
IINMWQEVGRAMYAPPIRGQIRCSSNITGLLLTRDGGPEDNKTEVFRPGGGDMRDNWRSELYKYKVVKIE
PLGVAPTKAKRRVVQREKRAVGIGAVFLGFLGAAGSTMGAAAMTLTVQARLLLSGIVQQQNNLLRAIEAQ
QHLLQLTVWGIKQLQARVLAVERYLRDQQLLGIWGCSGKLICTTAVPWNASWSNKSLNKIWDNMTWIEWD
REINNYTSIIYSLIEESQNQQEKNEQELLELDKWASLWNWFDITKWLWYIKIFIMIVGGLIGLRIVFSVL
SIVNRVRQGYSPLSFQTHLPSSRGPDRPGGIEEEGGERDRDRSGPLVNGFLALIWVDLRSLFLFSYHRLR
DLLLIVMRIVELLGLAGGWEVLKYWWNLLQYWSQELKNSAVSLLNATAVAVAEGTDRVIEVLQRAVRAIL
HIPRRIRQGLERALL

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1749">
        <gene_name>env</gene_name>
        <strain>Human immunodeficiency virus 1 strain 96ZM651</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>13569225</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:278917
CDD:197369</xrefs>
        <taxonomy_id>11676</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>envelope glycoprotein</protein_name>
        <protein_pi>8.71</protein_pi>
        <protein_weight>93508.85</protein_weight>
        <protein_length>949</protein_length>
        <protein_note>isolated in 1996</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAK30970.1 envelope glycoprotein [Human immunodeficiency virus 1]
MRVREILRNWQRWWTWGILGFWMLMICNVWGNLWVTVYYGVPVWKEAKTTLFCASDAKSYEKEVHNVWAT
HACVPTDPNPQEIVLGNVTENFNMWKNDMVDQMHEDIISLWDQSLKPCVKLTPLCVTLNCTEVNVTRNVN
NSVVNNTTNVNNSMNGDMKNCSFNITTELKDKKKNVYALFYKLDIVSLNETDDSETGNSSKYYRLINCNT
SALTQACPKVSFDPIPIHYCAPAGYAILKCNNKTFNGTGPCHNVSTVQCTHGIKPVVSTQLLLNGSLAEE
GIIIRSENLTNNVKTIIVHLNRSIEIVCVRPNNNTRQSIRIGPGQTFYATGDIIGDIRQAHCNISRTNWT
KTLREVRNKLREHFPNKNITFKPSSGGDLEITTHSFNCRGEFFYCNTSGLFSINYTENNTDGTPITLPCR
IRQIINMWQEVGRAMYAPPIEGNIACKSDITGLLLVRDGGSTNDSTNNNTEIFRPAGGDMRDNWRSELYK
YKVVEIKPLGIAPTEAKRRVVEREKRAVGIGAVFLGFLGAAGSTMGAASITLTAQARQVLSGIVQQQSNL
LRAIEAQQHLLQLTVWGIKQLQTRVLAIERYLKDQQLLGLWGCSGKLICTTAVPWNISWSNKSKTDIWDN
MTWMQWDREISNYTNTIYRLLEDSQSQQEQNEKDLLALDSWNNLWNWFDITKWLWYIKIFIMIVGGLIGL
RIIFAVLSIVNRVRQGYSPLSFQTLIPNPREPDRPGRIEEEGGEQDKERSVRLVSGFLALAWDDLRSLCL
FSYHRLRDFILVTARAVELLRRSSLKGLQRGWEALKYLGSLVQYWGLELKKSAISLLDTIAIAVAEGTDR
IIELIQGICRAIRNVPRRIRQGFETALL

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1750">
        <gene_name>env</gene_name>
        <strain>Human immunodeficiency virus 1 strain 976 clone 17</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>475668</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:278917
CDD:295533
CDD:197369</xrefs>
        <taxonomy_id>11676</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>envelope glycoprotein</protein_name>
        <protein_pi>8.59</protein_pi>
        <protein_weight>92331.19</protein_weight>
        <protein_length>944</protein_length>
        <protein_note>Envelope glycoprotein GP120; pfam00516</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAB04093.1 envelope glycoprotein, partial [Human immunodeficiency virus 1]
VKETQMNWPNLWKWGTLILGLVIICSASDNLWVTVYYGVPVWKDADTTLFCASDAKAHETEVHNVWATHA
CVPTDPNPQEIHLENVTENFNMWKNKMVEQMQEDVISLWDQSLKPCVKLTPLCVTLTCTNATLNCTNLTN
GNKTTNVSNIIGNLTDEVRNCSFHMTTELRDKKQKVYALFYKLDIVQINSSEYRLINCNTSVIKQACPKI
SFDPIPIHYCTPAGYAILKCNDKNFNGTGPCKNVSSVQCTHGIKPVVSTQLLLNGSLAEEEIIISSENLT
NNAKTIIVHLNKSVEISCTRPSTNTRTSIRIGPGQVFYRTGDITGDIRKAYCEINETKWNEALKQVAGKL
KEHFNKTIIFQPPSGGDLEITMHHFNCRGEFFYCDTTQLFNRTWGENETREGRNITLPCKIKQIVNMWQG
AGQAMYAPPISGIIKCVSNITGILLTRDGGANNSASETFRPGGGNIKDNWRSELYKYKVVQIEPLGIAPT
RAKRRVVEREKRAVGIGAMIFGFLGAAGSTMGAASITLTVQARQLLSGIVQQQSNLLRAIEAQQHLLQLT
VWGIKQLQARVLAVERYLKDQKFLGLWGCSGKIICTTAVPWNSTWSNKSYEEIWNNMTWIEWEREISNYT
NQIYEILTESQDQQDRNEKDLLELDKWASLWNWFDITNWLWYIKIFIMIVGGLIGLRIIFAVLSIVNRVR
QGYSPLSFQIPFHHQREPDRPERIEEGGGEQGRDRSVRLVSGFLALAWDDLRSLCLFLYHRLRDLLLIAT
RTVEILGHSSLKGLRRGWEGLKYLGNLLIYWGQELRISAISLLNATAIAVGGWTDRIIEVAQRAWRAILR
IPRRIRQGLERSLL

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1752">
        <gene_name>env</gene_name>
        <strain>Human immunodeficiency virus 1 isolate 037 clone 08</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>487257</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:278917
CDD:295533
CDD:197369</xrefs>
        <taxonomy_id>11676</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>envelope glycoprotein</protein_name>
        <protein_pi>8.4</protein_pi>
        <protein_weight>91749</protein_weight>
        <protein_length>946</protein_length>
        <protein_note>Envelope glycoprotein GP120; pfam00516</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAB05027.1 envelope glycoprotein, partial [Human immunodeficiency virus 1]
VMGIERNYPCWWTWGIMILGMIIICNTAENLWVTVYYGVPVWKDAETTLFCASDAKAYDTEVHNVWATHA
CVPTDPNPQEIYMENVTEEFNMWKNNMVEQMHTDIISLWDQSLKPCVQLTPLCVTLDCSYNITNNITNSI
TNSSVNMREEIKNCSFNMTTELRDKNRKVYSLFYKLDVVQINNGNNSSNLYRLINCNTSALTQACPKVTF
EPIPIRYCAPAGYAILKCNDKEFNGTGLCKNVSTVQCTHGIRPVVSTQLLLNGSLAEGKVMIRSENITNN
VKNIIVQLNETVTINCTRPNNNTRKSVRIGPGQTFYATGDIIGDIRQAHCNVSGSQWNRALHQVVGQLRE
YWNTTIIFKNSSGGDLEITTHSFNCGGEFFYCNTSGLFNSNWTHNDTASMKPNDTITLPCRIKQIINMWQ
RVGQAIYAPPIQGVIRCESNITGLILTRDGGGNINESQIFRPGGGDMRDNWRSELYKYKVVRIEPLGVAP
TKAKRRVVEREKRAVVELGAVFIGFLGTAGSTMGAASITLTVQVRKLLSGIVQQQSNLLRAIEAQQHLLK
LTVWGIKQLQARVLAVERYLRDQQLLGIWGCSGKLICTTNVPWNSSWSNKSEREIWENMTWLQWDKEISN
YTHIIYELIEESQKQQEKNEQELLELDKWANLWNWFDISNWLWYIKIFIMIVGGLIGLRIVFAVLSVINR
VRQGYSPLSFQTLTPNPRDPDRPGRIEGEGGEQDRGRSIRLVSGFLALAWDDLRNLCLSSYHQLRDFILI
VARTVELLGHSSLKGLRLGWEGLKYLGNLLLYWGRELKTSAINLFDTIAIVVAGWTDRVIEVGQRLGRAI
LNIPRRIRQGLERALL

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1250">
        <gene_name>env from SIV</gene_name>
        <strain>Simian immunodeficiency virus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>1490007</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>9627208</ncbi_protein_id>
        <gene_locus_tag>SIVgp6</gene_locus_tag>
        <gene_refseq>M58410</gene_refseq>
        <protein_refseq>NP_054372</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>11723</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>6201</gene_start>
        <gene_end>8765</gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>envelope protein</protein_name>
        <protein_pi>8.73</protein_pi>
        <protein_weight>91594.7</protein_weight>
        <protein_length>854</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_001549.1:6201-8765 Simian immunodeficiency virus, complete genome
TATGGGGAGATTGCTTATAAAAATACTAATAATAGCAATAGGGATAAGTATAGGAATAGGTAACCTGTAT
GTGACAGTGTTTTATGGAATCCCAGTATGGAAAAATTCAACAGTTCAGGCATTTTGCATGACGCCCAATA
CCAATATGTGGGCAACCACCAACTGCATACCAGATGATCATGATAATACAGAGGTGCCTCTAAACATTAC
AGAAGCTTTCGAGGCTTGGGATAATCCGCTGGTAAAACAAGCAGAGAGTAATATACATCTACTCTTTGAA
CAAACGATGAGGCCTTGTGTTAAGCTCTCCCCCATATGTATTAAAATGTCCTGTGTAGAGCTGAATGGTA
CAGCCACGACAAAGGCCACCACTACTGCAACTACAACAATGACTACCCCCTGTCAGAATTGCAGTACAGA
GCAGATAGAAGGAGAAATGGCAGAGGAACCAGCATCCAACTGCACTTTTGCAATTGCAGGATATCAAAGA
GATGTAAAAAAGAATTATAGCATGACCTGGTATGATCAGGAGTTAGTCTGCAATAATAAAACAGGAAGTG
AAAAGGGAAGTAAGGATTGTTACATGATACATTGTAATGATTCAGTGATAAAAGAAGCTTGTGATAAAAC
ATATTGGGATACTTTAAGAGTAAGATACTGTGCACCAGCAGGGTATGCTTTGCTAAAATGTAATGATAAG
GATTATAGAGGCTTTGCTCCAAAGTGCAAGAATGTTTCAGTAGTGCATTGTACTAGATTAATCAATACTA
CTATAACTACAGGGATAGGATTAAATGGTAGTAGATCAGAAAATAGAACAGAGATATGGCAGAAAGGAGG
AAATGATAATGATACAGTTATAATAAAGTTGAATAAGTTTTACAACTTGACAGTGAGATGCCGAAGACCT
GGTAATAAAACAGTGTTGCCAGTAACAATCATGGCAGGGTTAGTATTTCACTCTCAGAAATATAATACCA
GGTTAAAACAAGCGTGGTGCCACTTCCAAGGAGATTGGAAAGGGGCATGGAAAGAAGTCAGAGAAGAAGT
AAAGAAAGTGAAAAATCTTACAGAAGTAAGCATAGAAAATATACATCTGAGAAGGATATGGGGAGATCCA
GAATCAGCGAATTTTTGGTTCAATTGTCAAGGTGAATTTTTCTATTGTAAGATGGACTGGTTTATCAATT
ATCTAAACAATCGAACAGAAGATGCAGAAGGTACTAATAGGACCTGTGACAAAGGGAAGCCAGGACCAGG
ACCATGTGTTCAGAGAACTTATGTTGCCTGCCATATACGACAAGTAGTAAATGATTGGTACACTGTCTCT
AAAAAGGTATATGCTCCACCAAGGGAAGGTCATTTGGAGTGTAACTCATCAGTCACGGCACTATACGTGG
CAATAGATTATAACAACAAGTCTGGCCCAATAAATGTGACCCTAAGTCCTCAGGTACGCAGCATATGGGC
GTACGAACTGGGAGACTATAAATTAGTAGAGATAACACCAATTGGCTTTGCTCCTACAGATGTAAGAAGA
TATACTGGCCCCACAAGAGAAAAAAGGGTGCCATTCGTGCTAGGGTTTCTAGGCTTCTTGGGAGCTGCTG
GAACTGCAATGGGCGCAGCGGCAACAACGCTGACAGTCCAGTCTCGGCATTTGCTTGCTGGGATATTGCA
GCAGCAGAAGAACTTGCTGGCGGCTGTGGAACAGCAACAACAGTTGTTGAAGCTGACCATTTGGGGTGTG
AAAAACCTCAATGCCCGCGTCACAGCTCTCGAGAAGTACCTAGAGGATCAGGCACGGCTAAATTCATGGG
GATGTGCGTGGAAACAAGTATGTCACACCACAGTGCCATGGAAGTATAATAACACTCCTAAGTGGGACAA
TATGACTTGGTTGGAGTGGGAGAGACAAATTAATGCCTTGGAAGGCAACATAACTCAACTATTGGAAGAA
GCACAAAATCAGGAATCAAAGAATCTGGATCTGTACCAGAAATTGGATGATTGGTCAGGGTTCTGGTCAT
GGTTCTCACTGTCAACTTGGTTAGGCTATGTTAAAATAGGATTTTTAGTGATAGTGATTATTCTAGGATT
AAGATTTGCATGGGTATTATGGGGATGTATCAGAAATATTAGGCAGGGATATAATCCTCTCCCCCAGATC
CATATCCACAGTTCAGCGGAACGGCCAGACAACGGAGGAGGGCAAGACAGAGGTGGAGAAAGCAGCAGCA
GCAAATTGATAAGATTGCAGGAAGAGTCCTCAACACCTTCGAGGATCAACAACTGGTGGCTCAACTTCAA
GAGCTGCAGCTTGAGAATAAGGACTTGGTGTTACAACATCTGCCTGACCCTCCTCATATTCATCAGGACA
GCAGTGGGATACCTGCAGTATGGGCTCCAGCAACTCCAAGAGGCAGCAACAGGGCTTGCTCAAGCTCTGG
CGAGGGCTGCGAGGGAAGCCTGGGGCAGACTGGGTGCTATTGTCCGATCCGCTTATCGGGCAGTCATCAA
CAGTCCAAGAAGAGTGCGGCAAGGCCTTGAAAAAGTCCTGGGGTA

</dna_sequence>
        <protein_sequence>>NP_054372.1 envelope protein [Simian immunodeficiency virus]
MGRLLIKILIIAIGISIGIGNLYVTVFYGIPVWKNSTVQAFCMTPNTNMWATTNCIPDDHDNTEVPLNIT
EAFEAWDNPLVKQAESNIHLLFEQTMRPCVKLSPICIKMSCVELNGTATTKATTTATTTMTTPCQNCSTE
QIEGEMAEEPASNCTFAIAGYQRDVKKNYSMTWYDQELVCNNKTGSEKGSKDCYMIHCNDSVIKEACDKT
YWDTLRVRYCAPAGYALLKCNDKDYRGFAPKCKNVSVVHCTRLINTTITTGIGLNGSRSENRTEIWQKGG
NDNDTVIIKLNKFYNLTVRCRRPGNKTVLPVTIMAGLVFHSQKYNTRLKQAWCHFQGDWKGAWKEVREEV
KKVKNLTEVSIENIHLRRIWGDPESANFWFNCQGEFFYCKMDWFINYLNNRTEDAEGTNRTCDKGKPGPG
PCVQRTYVACHIRQVVNDWYTVSKKVYAPPREGHLECNSSVTALYVAIDYNNKSGPINVTLSPQVRSIWA
YELGDYKLVEITPIGFAPTDVRRYTGPTREKRVPFVLGFLGFLGAAGTAMGAAATTLTVQSRHLLAGILQ
QQKNLLAAVEQQQQLLKLTIWGVKNLNARVTALEKYLEDQARLNSWGCAWKQVCHTTVPWKYNNTPKWDN
MTWLEWERQINALEGNITQLLEEAQNQESKNLDLYQKLDDWSGFWSWFSLSTWLGYVKIGFLVIVIILGL
RFAWVLWGCIRNIRQGYNPLPQIHIHSSAERPDNGGGQDRGGESSSSKLIRLQEESSTPSRINNWWLNFK
SCSLRIRTWCYNICLTLLIFIRTAVGYLQYGLQQLQEAATGLAQALARAAREAWGRLGAIVRSAYRAVIN
SPRRVRQGLEKVLG

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1709">
        <gene_name>gag</gene_name>
        <strain>Simian-Human immunodeficiency virus strain SHIV-89.6</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>2828037</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:249943
CDD:279002
CDD:331526</xrefs>
        <taxonomy_id>57667</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>gag</protein_name>
        <protein_pi>9.12</protein_pi>
        <protein_weight>54236.02</protein_weight>
        <protein_length>573</protein_length>
        <protein_note>gag gene protein p17 (matrix protein); pfam00540</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAB99958.1 gag [Simian-Human immunodeficiency virus]
MGVRNSVLSGKKADELEKIRLRPNGKKKYMLKHVVWAANELDRFGLAESLLENKEGCQKILSVLAPLVPT
GSENLKSLYNTVCVIWCIHAEEKVKHTEEAKQIVQRHLVVETGTTETMPKTSRPTAPSSGRGGNYPVQQI
GGNYVHLPLSPRTLNAWVKLIEEKKFGAEVVPGFQALSEGCTPYDINQMLNCVGDHQAAMQIIRDIINEE
AADWDLQHPQPAPQQGQLREPSGSDIAGTTSSVDEQIQWMYRQQNPIPVGNIYRRWIQLGLQKCVRMYNP
TNILDVKQGPKEPFQSYVDRFYKSLRAEQTDAAVKNWMTQTLLIQNANPDCKLVLKGLGVNPTLEEMLTA
CQGVGGPGQKARLMAEALKEALAPVPIPFAAAQQRGPRKPIKCWNCGKEGHSARQCRAPRRQGCWKCGKM
DHVMAKCPDRQAGFLGLGPWGKKPRNFPMAQVHQGLMPTAPPEDPAVDLLKNYMQLGKQQREKQRESREK
PYKEVTEDLLHLNSLFGGDQ

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1717">
        <gene_name>gag</gene_name>
        <strain>Human immunodeficiency virus 2</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>1845205</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:249943
CDD:279002
CDD:197667</xrefs>
        <taxonomy_id>11709</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>gag polyprotein</protein_name>
        <protein_pi>9.25</protein_pi>
        <protein_weight>55390.11</protein_weight>
        <protein_length>591</protein_length>
        <protein_note>similar to HIV2BEN, GenBank Accession Number M30502, and to HIV2D194, GenBank Accession Number J04542</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAB47780.1 gag polyprotein [Human immunodeficiency virus 2]
MGARNSVLRGKKADELEKIRLRPGGKKKYRLKHIVWAANELDRFRLAENLLESKEGCQKILTVLDPLVPT
GSENLKSLFNTVCVIWCLHAEEKVKDTEEAKKLVQRHLVAETGTAEKMPNTSRPTAPPSGKGGNFPVQQA
GGNYVHVPLSPRTLNAWVKLVEEKKFGAEVVPGFQALSEGCTPYDINQMLNCVGDQQAAMQIIREIINEE
AADWDAQHPIPGPLPAGQLRDPRGSDIAGTTSTVDEQIQWMYRQQNPVPVGNIYRRWIQIGLQKCVRMYN
PTNVLDVKQGPKESFQSYVDRFYKSLRAEQADPAVKNWMTQTLLVQNANPDCKLVLKGLGMNPTLEEMLT
ACQGVGGPGQKARLMAEALKEALTPPPIPFAAAQQRRTIRCWNCGKEGHSAKQCRAPRRQGCWKCGKPGH
IMANCPDRQAGFLGMGSRGKKPRNFPVAQAPQGLIPTAPPADPAADLLEKYLQQGRKQREQRERPYKEVT
EDLLHLEQGETPRREATEDLLHLNSLFGKDQ

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene713">
        <gene_name>Gag from HIV 1</gene_name>
        <strain>Human immunodeficiency virus 1</strain>
        <vo_id>VO_0011263</vo_id>
        <ncbi_gene_id>155030</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>9629360</ncbi_protein_id>
        <gene_locus_tag>HIV1gp2</gene_locus_tag>
        <gene_refseq>AF033819</gene_refseq>
        <protein_refseq>NP_057850</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>11676</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>335</gene_start>
        <gene_end>1837</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>Pr55(Gag)</protein_name>
        <protein_pi>9.42</protein_pi>
        <protein_weight>53447.94</protein_weight>
        <protein_length>500</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_001802.1:335-1837 Human immunodeficiency virus 1, complete genome
GATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGATGGGAAAAAATTCGGTTAAGGCCA
GGGGGAAAGAAAAAATATAAATTAAAACATATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTA
ATCCTGGCCTGTTAGAAACATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGAC
AGGATCAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGAG
ATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGAAAAAAGCACAGC
AAGCAGCAGCTGACACAGGACACAGCAATCAGGTCAGCCAAAATTACCCTATAGTGCAGAACATCCAGGG
GCAAATGGTACATCAGGCCATATCACCTAGAACTTTAAATGCATGGGTAAAAGTAGTAGAAGAGAAGGCT
TTCAGCCCAGAAGTGATACCCATGTTTTCAGCATTATCAGAAGGAGCCACCCCACAAGATTTAAACACCA
TGCTAAACACAGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAGACCATCAATGAGGAAGCTGC
AGAATGGGATAGAGTGCATCCAGTGCATGCAGGGCCTATTGCACCAGGCCAGATGAGAGAACCAAGGGGA
AGTGACATAGCAGGAACTACTAGTACCCTTCAGGAACAAATAGGATGGATGACAAATAATCCACCTATCC
CAGTAGGAGAAATTTATAAAAGATGGATAATCCTGGGATTAAATAAAATAGTAAGAATGTATAGCCCTAC
CAGCATTCTGGACATAAGACAAGGACCAAAGGAACCCTTTAGAGACTATGTAGACCGGTTCTATAAAACT
CTAAGAGCCGAGCAAGCTTCACAGGAGGTAAAAAATTGGATGACAGAAACCTTGTTGGTCCAAAATGCGA
ACCCAGATTGTAAGACTATTTTAAAAGCATTGGGACCAGCGGCTACACTAGAAGAAATGATGACAGCATG
TCAGGGAGTAGGAGGACCCGGCCATAAGGCAAGAGTTTTGGCTGAAGCAATGAGCCAAGTAACAAATTCA
GCTACCATAATGATGCAGAGAGGCAATTTTAGGAACCAAAGAAAGATTGTTAAGTGTTTCAATTGTGGCA
AAGAAGGGCACACAGCCAGAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGAAAGGAAGG
ACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTTTTTAGGGAAGATCTGGCCTTCCTACAAGGGA
AGGCCAGGGAATTTTCTTCAGAGCAGACCAGAGCCAACAGCCCCACCAGAAGAGAGCTTCAGGTCTGGGG
TAGAGACAACAACTCCCCCTCAGAAGCAGGAGCCGATAGACAAGGAACTGTATCCTTTAACTTCCCTCAG
GTCACTCTTTGGCAACGACCCCTCGTCACAATA

</dna_sequence>
        <protein_sequence>>NP_057850.1 Pr55(Gag) [Human immunodeficiency virus 1]
MGARASVLSGGELDRWEKIRLRPGGKKKYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQT
GSEELRSLYNTVATLYCVHQRIEIKDTKEALDKIEEEQNKSKKKAQQAAADTGHSNQVSQNYPIVQNIQG
QMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAA
EWDRVHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPT
SILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTAC
QGVGGPGHKARVLAEAMSQVTNSATIMMQRGNFRNQRKIVKCFNCGKEGHTARNCRAPRKKGCWKCGKEG
HQMKDCTERQANFLGKIWPSYKGRPGNFLQSRPEPTAPPEESFRSGVETTTPPQKQEPIDKELYPLTSLR
SLFGNDPSSQ

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>HIV-1 DNA plasmids expressing Env, Gag and Tat, either alone or combined with the corresponding protein immunogens formulated in the MF59 adjuvant, resulted in protection against an experimental HIV-1 infection in C57Bl/6 mice [Ref1301:Bråve et al., 2007].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1751">
        <gene_name>gag from HIV-1 vector pNL4-3</gene_name>
        <strain>HIV-1 vector pNL4-3</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>12831136</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:249943
CDD:279002
CDD:331526
CDD:312289</xrefs>
        <taxonomy_id>11676</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>gag polyprotein</protein_name>
        <protein_pi>9.31</protein_pi>
        <protein_weight>54183.8</protein_weight>
        <protein_length>569</protein_length>
        <protein_note>from sequence deposited in GenBank Accession Number M19921</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAK08483.1 gag polyprotein (plasmid) [HIV-1 vector pNL4-3]
MGARASVLSGGELDKWEKIRLRPGGKKQYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQT
GSEELRSLYNTIAVLYCVHQRIDVKDTKEALDKIEEEQNKSKKKAQQAAADTGNNSQVSQNYPIVQNLQG
QMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAA
EWDRLHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTHNPPIPVGEIYKRWIILGLNKIVRMYSPT
SILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPGATLEEMMTAC
QGVGGPGHKARVLAEAMSQVTNPATIMIQKGNFRNQRKTVKCFNCGKEGHIAKNCRAPRKKGCWKCGKEG
HQMKDCTERQANFLGKIWPSHKGRPGNFLQSRPEPTAPPEESFRFGEETTTPSQKQEPIDKELYPLASLR
SLFGSDPSSQ

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene98">
        <gene_name>Gag protein from SIV-mnd 2</gene_name>
        <strain>Simian immunodeficiency virus SIV-mnd 2</strain>
        <vo_id>VO_0010949</vo_id>
        <ncbi_gene_id>956108</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>27311167</ncbi_protein_id>
        <gene_locus_tag>Siv2gp1</gene_locus_tag>
        <gene_refseq>AF367411</gene_refseq>
        <protein_refseq>NP_758886</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>159122</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>736</gene_start>
        <gene_end>2289</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>gag protein</protein_name>
        <protein_pi>8.78</protein_pi>
        <protein_weight>55072.29</protein_weight>
        <protein_length>517</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_004455.1:736-2289 Simian immunodeficiency virus 2 isolate SIVmnd-2, complete genome
AATGGGCGCGAGCGCGTCAGGTCTTAGGGGAGAAAAATTGGACGAGCTGGAAAAGATTAGGTTACGGCCC
TCCGGAAAAAAGAAATACCAGCTGAAACACATAATATGGGTAAGCAAGGAACTAGACAGATTTGGCCTTC
ATGAAAAGCTGTTAGAAAGTAAGGAAGGATGCGAGAAAATTCTTAGCGTACTCTTTCCACTAGTTCCTAC
AGGGTCAGAAAATTTAATCTCGCTGTACAACACCTGCTGCTGCGTATGGTGCGTACATGCGAAAGAGAAA
GTAACAGATACAGAGGAAGCGAAAGAGAAAGTAAAACAAAAGCTCCATCTAGTGGCCGAAAAGGAAAATG
CAGCATCAGAAAAAGAACAAAGAGCAATAGTGACACCTAGTGGCCGCTCAAAAAATTACCCAATACAGAT
AATAAATCAGACCCCAGTCCATCAGGGAATTTCACCGCGCACGCTGAATGCGTGGGTAAAATGCATAGAA
GAGAAGAAGTTTAGCCCAGAAATAGTGCCCATGTTCATAGCCTTGTCTGAAGGGTGCCTCCCCTATGATC
TCAATGGCATGCTCAATGCTATTGGAGACCATCAGGGAGCGCTTCAAATAGTGAAGGATGTCATCAATGA
GGAAGCTGCAGACTGGAACTTGAGACACCCACAAGTGGGTCCTATGCCCCAAGGTGTCTTGAGAAACCCA
ACGGGCAGTGATATTGCTGGAACAACAAGCTCCATAGAAGAGCAGATAGAATGGACTACAAGGGAGCAAG
ATGCAGTAAATGTGGGAGGAATATATAAACAATGGATAGTTTTAGGGCTTCAGAAGTGTGTAAGCATGTA
TAATCCAGTAAACATCCTGGACATAAAGCAAGGACCAAAGGAGCCGTTCAAGGACTATGTGGACAGGTTT
TACAAAGCTCTGCGGGCGGAGCGGACTGATCCACAAGTCAAAACCTGGATGACACAAACTTTGCTCATCC
AGAATGCTAACCCAGATTGTAAATCCATCCTTAAAGGGCTAGGCATGAATCCCTCTTTAGAAGAGATGCC
GCTAGCCTGCCAAGGGGTAGGAGGCCCTAAATATAAAGCACAAATGATGGCAGAGGCTATGAAGGAAGCC
CAGTCAGCTGTAATGATGCAGAATTCGGGAGGGCCACCGCGGGGCCCCCCGAGACAACCTCCTAGAAACA
TCAGATGCCCTAACTGTGGAAAATTTGGTCATGGGCTGAGGGACTGTATAAGCCCTCGAAAAAAGGGATG
CTTCAAGTGTGGAGATCTAGGACACATAATGAGAAATTGCCCAAAGATGGTGAATTTTTTAGGGAATACC
CCCTGGGGCAGTGGCAAACCCAGGAACTTCCCGGCGATGCCATTGACCCCAACGGCCCCTCCAATGCCAG
GGATGGAAGACCCAGCAGAGAGAATGCTGTTAGATTACATGAAGAAAGGGCAACAGCAGAAAGCGGAAAG
CAAACAGGAAAAGAAAGAGAGGGGTCCATACGAGGCAGCTTACAACTCCCTCAGTTCTCTCTTTGGAACA
GACCAACTACAGTA

</dna_sequence>
        <protein_sequence>>NP_758886.1 gag protein [Simian immunodeficiency virus SIV-mnd 2]
MGASASGLRGEKLDELEKIRLRPSGKKKYQLKHIIWVSKELDRFGLHEKLLESKEGCEKILSVLFPLVPT
GSENLISLYNTCCCVWCVHAKEKVTDTEEAKEKVKQKLHLVAEKENAASEKEQRAIVTPSGRSKNYPIQI
INQTPVHQGISPRTLNAWVKCIEEKKFSPEIVPMFIALSEGCLPYDLNGMLNAIGDHQGALQIVKDVINE
EAADWNLRHPQVGPMPQGVLRNPTGSDIAGTTSSIEEQIEWTTREQDAVNVGGIYKQWIVLGLQKCVSMY
NPVNILDIKQGPKEPFKDYVDRFYKALRAERTDPQVKTWMTQTLLIQNANPDCKSILKGLGMNPSLEEMP
LACQGVGGPKYKAQMMAEAMKEAQSAVMMQNSGGPPRGPPRQPPRNIRCPNCGKFGHGLRDCISPRKKGC
FKCGDLGHIMRNCPKMVNFLGNTPWGSGKPRNFPAMPLTPTAPPMPGMEDPAERMLLDYMKKGQQQKAES
KQEKKERGPYEAAYNSLSSLFGTDQLQ

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>A novel primate lentivirus was identified in Mandrillus sphinx. One of the newly isolated SIV strains was intravenously inoculated into two rhesus macaques and resulted in chronic infection. These SIVs do not cluster with SIVmndGB1, the former representative strain of SIVmnd, but form a new, independent lineage. These results indicate that these SIVmnds are a novel type of SIVmnd and have infected Cameroonian mandrills for a long time. To date, M. sphinx is the only primate species other than humans that is naturally infected with two different types of SIV [Ref265:Takehisa et al., 2001].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1252">
        <gene_name>gag-pol</gene_name>
        <strain>Human immunodeficiency virus 1</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>155348</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>28872819</ncbi_protein_id>
        <gene_locus_tag>HIV1gp1</gene_locus_tag>
        <gene_refseq>AF033819</gene_refseq>
        <protein_refseq>NP_057849</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>11676</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>335</gene_start>
        <gene_end>4641</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>Gag-Pol</protein_name>
        <protein_pi>9.02</protein_pi>
        <protein_weight>152515.27</protein_weight>
        <protein_length>1435</protein_length>
        <protein_note>Pr160</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_001802.1:335-4641 Human immunodeficiency virus 1, complete genome
GATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGATGGGAAAAAATTCGGTTAAGGCCA
GGGGGAAAGAAAAAATATAAATTAAAACATATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTA
ATCCTGGCCTGTTAGAAACATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGAC
AGGATCAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGAG
ATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGAAAAAAGCACAGC
AAGCAGCAGCTGACACAGGACACAGCAATCAGGTCAGCCAAAATTACCCTATAGTGCAGAACATCCAGGG
GCAAATGGTACATCAGGCCATATCACCTAGAACTTTAAATGCATGGGTAAAAGTAGTAGAAGAGAAGGCT
TTCAGCCCAGAAGTGATACCCATGTTTTCAGCATTATCAGAAGGAGCCACCCCACAAGATTTAAACACCA
TGCTAAACACAGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAGACCATCAATGAGGAAGCTGC
AGAATGGGATAGAGTGCATCCAGTGCATGCAGGGCCTATTGCACCAGGCCAGATGAGAGAACCAAGGGGA
AGTGACATAGCAGGAACTACTAGTACCCTTCAGGAACAAATAGGATGGATGACAAATAATCCACCTATCC
CAGTAGGAGAAATTTATAAAAGATGGATAATCCTGGGATTAAATAAAATAGTAAGAATGTATAGCCCTAC
CAGCATTCTGGACATAAGACAAGGACCAAAGGAACCCTTTAGAGACTATGTAGACCGGTTCTATAAAACT
CTAAGAGCCGAGCAAGCTTCACAGGAGGTAAAAAATTGGATGACAGAAACCTTGTTGGTCCAAAATGCGA
ACCCAGATTGTAAGACTATTTTAAAAGCATTGGGACCAGCGGCTACACTAGAAGAAATGATGACAGCATG
TCAGGGAGTAGGAGGACCCGGCCATAAGGCAAGAGTTTTGGCTGAAGCAATGAGCCAAGTAACAAATTCA
GCTACCATAATGATGCAGAGAGGCAATTTTAGGAACCAAAGAAAGATTGTTAAGTGTTTCAATTGTGGCA
AAGAAGGGCACACAGCCAGAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGAAAGGAAGG
ACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTTTTTAGGGAAGATCTGGCCTTCCTACAAGGGA
AGGCCAGGGAATTTTCTTCAGAGCAGACCAGAGCCAACAGCCCCACCAGAAGAGAGCTTCAGGTCTGGGG
TAGAGACAACAACTCCCCCTCAGAAGCAGGAGCCGATAGACAAGGAACTGTATCCTTTAACTTCCCTCAG
GTCACTCTTTGGCAACGACCCCTCGTCACAATAAAGATAGGGGGGCAACTAAAGGAAGCTCTATTAGATA
CAGGAGCAGATGATACAGTATTAGAAGAAATGAGTTTGCCAGGAAGATGGAAACCAAAAATGATAGGGGG
AATTGGAGGTTTTATCAAAGTAAGACAGTATGATCAGATACTCATAGAAATCTGTGGACATAAAGCTATA
GGTACAGTATTAGTAGGACCTACACCTGTCAACATAATTGGAAGAAATCTGTTGACTCAGATTGGTTGCA
CTTTAAATTTTCCCATTAGCCCTATTGAGACTGTACCAGTAAAATTAAAGCCAGGAATGGATGGCCCAAA
AGTTAAACAATGGCCATTGACAGAAGAAAAAATAAAAGCATTAGTAGAAATTTGTACAGAGATGGAAAAG
GAAGGGAAAATTTCAAAAATTGGGCCTGAAAATCCATACAATACTCCAGTATTTGCCATAAAGAAAAAAG
ACAGTACTAAATGGAGAAAATTAGTAGATTTCAGAGAACTTAATAAGAGAACTCAAGACTTCTGGGAAGT
TCAATTAGGAATACCACATCCCGCAGGGTTAAAAAAGAAAAAATCAGTAACAGTACTGGATGTGGGTGAT
GCATATTTTTCAGTTCCCTTAGATGAAGACTTCAGGAAGTATACTGCATTTACCATACCTAGTATAAACA
ATGAGACACCAGGGATTAGATATCAGTACAATGTGCTTCCACAGGGATGGAAAGGATCACCAGCAATATT
CCAAAGTAGCATGACAAAAATCTTAGAGCCTTTTAGAAAACAAAATCCAGACATAGTTATCTATCAATAC
ATGGATGATTTGTATGTAGGATCTGACTTAGAAATAGGGCAGCATAGAACAAAAATAGAGGAGCTGAGAC
AACATCTGTTGAGGTGGGGACTTACCACACCAGACAAAAAACATCAGAAAGAACCTCCATTCCTTTGGAT
GGGTTATGAACTCCATCCTGATAAATGGACAGTACAGCCTATAGTGCTGCCAGAAAAAGACAGCTGGACT
GTCAATGACATACAGAAGTTAGTGGGGAAATTGAATTGGGCAAGTCAGATTTACCCAGGGATTAAAGTAA
GGCAATTATGTAAACTCCTTAGAGGAACCAAAGCACTAACAGAAGTAATACCACTAACAGAAGAAGCAGA
GCTAGAACTGGCAGAAAACAGAGAGATTCTAAAAGAACCAGTACATGGAGTGTATTATGACCCATCAAAA
GACTTAATAGCAGAAATACAGAAGCAGGGGCAAGGCCAATGGACATATCAAATTTATCAAGAGCCATTTA
AAAATCTGAAAACAGGAAAATATGCAAGAATGAGGGGTGCCCACACTAATGATGTAAAACAATTAACAGA
GGCAGTGCAAAAAATAACCACAGAAAGCATAGTAATATGGGGAAAGACTCCTAAATTTAAACTGCCCATA
CAAAAGGAAACATGGGAAACATGGTGGACAGAGTATTGGCAAGCCACCTGGATTCCTGAGTGGGAGTTTG
TTAATACCCCTCCCTTAGTGAAATTATGGTACCAGTTAGAGAAAGAACCCATAGTAGGAGCAGAAACCTT
CTATGTAGATGGGGCAGCTAACAGGGAGACTAAATTAGGAAAAGCAGGATATGTTACTAATAGAGGAAGA
CAAAAAGTTGTCACCCTAACTGACACAACAAATCAGAAGACTGAGTTACAAGCAATTTATCTAGCTTTGC
AGGATTCGGGATTAGAAGTAAACATAGTAACAGACTCACAATATGCATTAGGAATCATTCAAGCACAACC
AGATCAAAGTGAATCAGAGTTAGTCAATCAAATAATAGAGCAGTTAATAAAAAAGGAAAAGGTCTATCTG
GCATGGGTACCAGCACACAAAGGAATTGGAGGAAATGAACAAGTAGATAAATTAGTCAGTGCTGGAATCA
GGAAAGTACTATTTTTAGATGGAATAGATAAGGCCCAAGATGAACATGAGAAATATCACAGTAATTGGAG
AGCAATGGCTAGTGATTTTAACCTGCCACCTGTAGTAGCAAAAGAAATAGTAGCCAGCTGTGATAAATGT
CAGCTAAAAGGAGAAGCCATGCATGGACAAGTAGACTGTAGTCCAGGAATATGGCAACTAGATTGTACAC
ATTTAGAAGGAAAAGTTATCCTGGTAGCAGTTCATGTAGCCAGTGGATATATAGAAGCAGAAGTTATTCC
AGCAGAAACAGGGCAGGAAACAGCATATTTTCTTTTAAAATTAGCAGGAAGATGGCCAGTAAAAACAATA
CATACTGACAATGGCAGCAATTTCACCGGTGCTACGGTTAGGGCCGCCTGTTGGTGGGCGGGAATCAAGC
AGGAATTTGGAATTCCCTACAATCCCCAAAGTCAAGGAGTAGTAGAATCTATGAATAAAGAATTAAAGAA
AATTATAGGACAGGTAAGAGATCAGGCTGAACATCTTAAGACAGCAGTACAAATGGCAGTATTCATCCAC
AATTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAG
ACATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTTCGGGTTTATTACAGGGACAG
CAGAAATCCACTTTGGAAAGGACCAGCAAAGCTCCTCTGGAAAGGTGAAGGGGCAGTAGTAATACAAGAT
AATAGTGACATAAAAGTAGTGCCAAGAAGAAAAGCAAAGATCATTAGGGATTATGGAAAACAGATGGCAG
GTGATGATTGTGTGGCAAGTAGACAGGATGAGGATTA

</dna_sequence>
        <protein_sequence>>NP_057849.4 Gag-Pol [Human immunodeficiency virus 1]
MGARASVLSGGELDRWEKIRLRPGGKKKYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQT
GSEELRSLYNTVATLYCVHQRIEIKDTKEALDKIEEEQNKSKKKAQQAAADTGHSNQVSQNYPIVQNIQG
QMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAA
EWDRVHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPT
SILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTAC
QGVGGPGHKARVLAEAMSQVTNSATIMMQRGNFRNQRKIVKCFNCGKEGHTARNCRAPRKKGCWKCGKEG
HQMKDCTERQANFLREDLAFLQGKAREFSSEQTRANSPTRRELQVWGRDNNSPSEAGADRQGTVSFNFPQ
VTLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYDQILIEICGHKAI
GTVLVGPTPVNIIGRNLLTQIGCTLNFPISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEK
EGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGD
AYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQY
MDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWT
VNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSK
DLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKITTESIVIWGKTPKFKLPI
QKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTNRGR
QKVVTLTDTTNQKTELQAIYLALQDSGLEVNIVTDSQYALGIIQAQPDQSESELVNQIIEQLIKKEKVYL
AWVPAHKGIGGNEQVDKLVSAGIRKVLFLDGIDKAQDEHEKYHSNWRAMASDFNLPPVVAKEIVASCDKC
QLKGEAMHGQVDCSPGIWQLDCTHLEGKVILVAVHVASGYIEAEVIPAETGQETAYFLLKLAGRWPVKTI
HTDNGSNFTGATVRAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIH
NFKRKGGIGGYSAGERIVDIIATDIQTKELQKQITKIQNFRVYYRDSRNPLWKGPAKLLWKGEGAVVIQD
NSDIKVVPRRKAKIIRDYGKQMAGDDCVASRQDED

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1249">
        <gene_name>gp120</gene_name>
        <strain>Human immunodeficiency virus 1</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>2326505</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:278917
GOA:O40515
InterPro:IPR000777
UniProtKB/TrEMBL:O40515</xrefs>
        <taxonomy_id>11676</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name></protein_name>
        <protein_pi>9.81</protein_pi>
        <protein_weight>11668</protein_weight>
        <protein_length>172</protein_length>
        <protein_note>Envelope glycoprotein GP120; pfam00516</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>CAA74764.1 gp120, partial [Human immunodeficiency virus 1]
NGSLAEGEVVIRSENFTDNAKTIIVQLNESVVINCTRPNNNTRKNIHLGRGRSVYATEKIIGNVKQAHCN
ISRAKWNDTLKQIVEKLREQFGKNKTIVFNQSSGGDPEI

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1200">
        <gene_name>IFNG</gene_name>
        <strain>Macaca mulatta</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>574282</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>74136365</ncbi_protein_id>
        <gene_locus_tag>EGK_03901</gene_locus_tag>
        <gene_refseq>CM001263</gene_refseq>
        <protein_refseq>NP_001028077</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>9544</taxonomy_id>
        <chromosome>11</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>65143979</gene_start>
        <gene_end>65148219</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>interferon-gamma</protein_name>
        <protein_pi>9.92</protein_pi>
        <protein_weight>18339.63</protein_weight>
        <protein_length>165</protein_length>
        <protein_note>Also known as IFN-gamma</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|109156580:65143979-65148219 Macaca mulatta chromosome 11, Mmul_051212, whole genome shotgun sequence
ATTATTGGGATGCTCTTCGACCTCGAAACATCTGACTCCTTTTTCGCTTCCCTATTTTAGCTGCTGGCGA
CAGTTCAGCCATCACTTGGATGAGTTCATGTACTGCTTTGCGTTGGACATTTGAGTCAGTTACCTATTGG
GAAAGAAAAGAGCAAAATTAATTTCAGGCATATAAGCCATCAGGATATTCAGTTAATGGCATGATGGTCA
GTGAAAATAAAACTATTCCTTTAAAAAAATGGACCATATTACCTTAATATACAATATTTACTTCTTCAGC
AGTTGAGGCTAAAAATTACAATTACATTACTAGTTGTGCAATGATGTGGTGGAGTCCGTCACATATCTTT
AAATCTACTCCCATAGAATTCTTGAAATCATATAGTGAAAAGACCCCTGGTGTGGAGTCAATGTAAAAAG
GTGGATCTGAATCTCATGCGTGCAATAATTCTGACCTTGAGCCAGCTACTTAACCTTTTGGAACCTCTAT
TTTCTCATCTAAAGGAAGAGAAGACTGTTTCTATGACCTCTCTATCATCAATCTACCAATTATATCACTT
TATACTTTAGTCTCTCCTGTATGTATCAAACGAGTAACTATAGGTCAATGATTCTCACTGTTGTGCATAG
CAGATTAACCTGGAAACCTAATAAAGACCTCAGAGATCCAGGGGCACGAATTGGAAGGACTGTGCCCTGT
GCATTCACTAAGCTCCCCAGGTGATTCTGACATCCACCTAAGTTTGAGAACCACTGATCTAGGTTAGGTA
CCCTAGAAAACATCAAATCCAAAACAAGTGAAAACTGTAATTTTTAATTTCTCCCAGATTAGATCAGTCT
CTCAATTTCCATAATAGGTTTTAAAATAACCACCAATCATATTTATATATGGCTTACTGATATATAAAGT
TTAAAATTAGGAATTGCAACAACTTTTTCAGTACCCTACCTTCTAGGCCAGCAAATTGAACTACTTGCAT
TTCCTCACTCTAACTAATAGGGCCATTTAGGTGATTTCATTCTTCCTAAAATGTGGACCATTTACTTTCC
TCTTGACTCTGCCATTATATTTTTTCTAATCTTGGGAACACTATGGCTACCTCGCCACATTTCTGAGGAT
GGCTGGGGGATTACAGGCTACAGAGCTAATTATGAAAGGGCATAACATACCTCAGCTTAGCAACTGAGCC
AAAGAGAACAATAATTAATAGAGCTCACTCAAGATTGCCCATCAAGAAACAGGAGGTTTGTAGCTTCCAG
AAGGAAGAAACCCACAGATTTTTTTTTCACTTTTTTAAGGCCCAGTTCCTGCGGAGTAGAAAAAGTTTTC
TACAAGCTGTGTGTTTGCAAGTGACAGATTTTACTTTCCAGTGTTCAAATCATCACCAAGAAACTAAGAG
ACTTATCCAGGACGGAACAGTAAGCCAGGGGCACCACTGGGTTGGTGGCAAGTGCTGAGTGTCTAGTTTC
TAACCAAAGGAGACCTGTTGCCATGTCCCTCCTTTCAGTTTCTGGGGGTTCACATGAGAGGAGTGAGAGG
CAGGCCCGGCAATAGTGAAAGCTGAGCACAAATCCTAAGAGCACAAATGCCAGCTTGAGCTCTCATTTGA
GCCCATTTATATCAAAGCCAATCCCAAAGGAATCTAGAGGTCTTTGTCTTCTAGATAAAATTTTGAAAAA
CGTGTTTTGTCTTTATGCCTCAATGTTATCTTTCTGTTTATAGAAGGCATAATTTAAAGATAATTTAAAG
ATACAAGTTCATGAGGTATGACTTAGGAGTCTAAGGAGTTCTCCAGCTGAGATATTCTGAAAGTTGATAG
AGACTTGATAGAACAATGTTTTCATAAGCTATAAATTCTACCTATTTTTCCCTAAAAACAAACAGCAACC
ATTCTTGCTTCTAATTAGGCAGTACAATCTGATAGGTTGGCTAGAGAATTGCAGTGGGGTGCACTGGTAC
CTACTCAAAGGCTGTAGCTTTCTTCTATCTCATTCTCATTTTCTATTCTTGGCATTGTAGAGTTTTGGAG
CAAAGAATGTCATCAAACTTATGCAGTGAACCTAACAGTTTCCTTTTAAGATGAGGGCACTGAGCCCCAG
CCAGCCATGTGATTCATCACAGTTCCCTGGTGGCTGAGATGGGAGGAGAACACACATCTTCTCAGCTCCT
CCCACTGCTCTTTCCATTAAGACAGACAGCCTCTCATTCAAAGTAAGAGAATTTCCATCATATGAGCAAA
GGACAATGAGAGAATTGCTTCTCAGTACTCCCCACTACTTCCTCACCTACTTCCTCTTCATTGGATTTGT
CAATTCACCTGTCTTTACACAATAGTTACAATGCCAGCACTTTTCCTACATTACATACTTCAGTGATTCC
CATACTGGCTTTGCAAAGTCATCCAAACACAAATAGAATTAGTAAGAGTTTCAGCTACGGGTTGAGTTCA
TAGCTTTAGCAACTGTTAAATAGCTAATGTCTACTTTCTGGAGAACAAATGCTTTGCAAGACCTTCCGCA
ATGAAACCAAAGAAAGAATTTAAAGAGCCTTACCGAATAATTGGTCAGCTTTTCAAAGTCATCCCGTTTC
TTTTTGTTGCTATTGAAAAACTTGACATTAATGTCTTCCTTGATGGTCTCCACACTCTTTTGGATCCTCT
GGTCATCTTTGAAGTTTTTAAAAAGTTTGAAGTAAAAGGAGACAATTTGGCTCTGCATTATTTTTCTGTC
ACTCTCCTTGGAAGGAAAGAACACAAACAGAGGATGATGTGTATTTATCCATCAGAAAGCAAGCAACAGG
AAAATTAGCCAAATGGGAATATTCAGCTTACCTCTTTCCAATTCCTCAAGATGTCTAAGAAAAGAGTTCC
ATTATCTGCTACATCTGGATCACCTGCATTCTGGGGGAAAAAAAAGGGTTTACAATTAGCCCATAAATTG
TCTTAAAAATATATTTCAAGTTTCATTAAACTCAGATGTGACAATATTCACTGATTTCCTTTTCAATTCT
TCTGCTTAGTTCTAACAATAAGTGTTCACAAAATGTTTATGTGAGATATAGCCAAAGACTACTATGCTCT
TTTAGCTTTTTTATTTTCCAACATAACCATTAAATTGCAATGTCACAAAGGAGTTAAACAAAGCTGATGA
TACTCCAAGGGTCTCAAAAACTATAGTAGGCTAAAGAAAGTATTTTCAAGCTAGGCTAAAAAATACAGAA
CAAAAAACAGCAAAGCCACCCCACTATAAAATACTGCCCCCCAATGGCACAGGTTTCTATTACATCTACT
ATGCCTTCCTGTAGGGTATTATGTCAACTTTAAAAGATAGTTCCAAACGTGTGCGTGCGTGTGTGTGTGT
GTGTGTGTGTGTGGTCTGATTTTGTGTTGTAGGAATAAAATTAATTGTGAATGTCTGAATATTAGTATGA
CAGCTATAATTATAACTAAGTTTTAAATAAATAATGAAATATTTAAAATGTAAAAACTTTTCATTAACCA
TCAATAAAATTTTAAAAGAAACTCAAAAAACTCACTTAAAATTTTTAAACATTCCATAGCCAGAATCATA
ATTCCTACAAAATCCCAGTGAGCAACTAAGTTCAGGAGTAATTCACAAGGAATATAGATAGAGCAGCAGA
ATGTTGAAATAACTTTTTGGAGAAAATCACCTATCAGTGATTTTTTTTAAGCCAAAACTTTAAGGACCTT
TTTTACTTTAATTTGTAAACGTTTCCTATTAACTTTTGAATGCTAATCTTGACCTTAGAGTCTGAGAAGT
CAAAAACTAATAGCCAATCATTTTTTTCAATATGCATACTCCTTGACTTATCACATCTGAATGAGTTCTC
ACCACAAAATTATTAACATCATTATGCTTCATATCCATATTATGCCCATCTTTGGGAAGATTCATAAATC
CCTTTTAAGTCTCTATACAAACTGAGCAGAAGGTTAAAACAATATCTAGATTATGTAGTCAAGAAACTCA
TCCAGTCAATAATTAACAAAATAAAACCAGATCTCAAAATGACTGCGTACGAGAGGACAGTCTATCAGAG
ATGCTACAGCAAGTCAATATTCAGACATTTTCAACCACAAAAAAGTACTATTAAAAAGCCATACTTACAA
AATATTTCTTAAGGTTTTCTGCTTCTTTTACATATGGGTCCTGGCAGTAACAGCCAAGAGAACCCAAAAC
AATGCAGAGCTGAAAAGCCAAGATATAACTTGTGTATTTCA</dna_sequence>
        <protein_sequence>>gi|74136365|ref|NP_001028077.1| interferon gamma precursor [Macaca mulatta]
MKYTSYILAFQLCIVLGSLGCYCQDPYVKEAENLKKYFNAGDPDVADNGTLFLDILRNWKEESDRKIMQS
QIVSFYFKLFKNFKDDQRIQKSVETIKEDINVKFFNSNKKKRDDFEKLTNYSVTDSNVQRKAVHELIQVM
AELSPAAKIGKRKRSQMFRGRRASQ</protein_sequence>
        <phi_function>Vaximmutor</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1">
        <gene_name>Ifng (Interferon gamma)</gene_name>
        <strain>Mouse</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>15978</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>33468859</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>NM_008337</gene_refseq>
        <protein_refseq>NP_032363.1</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>MGI:107656; UniProt:P01580</xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name></protein_name>
        <protein_pi></protein_pi>
        <protein_weight></protein_weight>
        <protein_length></protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|145966741|ref|NM_008337.3| Mus musculus interferon gamma (Ifng), mRNA
ATAGCTGCCATCGGCTGACCTAGAGAAGACACATCAGCTGATCCTTTGGACCCTCTGACTTGAGACAGAA
GTTCTGGGCTTCTCCTCCTGCGGCCTAGCTCTGAGACAATGAACGCTACACACTGCATCTTGGCTTTGCA
GCTCTTCCTCATGGCTGTTTCTGGCTGTTACTGCCACGGCACAGTCATTGAAAGCCTAGAAAGTCTGAAT
AACTATTTTAACTCAAGTGGCATAGATGTGGAAGAAAAGAGTCTCTTCTTGGATATCTGGAGGAACTGGC
AAAAGGATGGTGACATGAAAATCCTGCAGAGCCAGATTATCTCTTTCTACCTCAGACTCTTTGAAGTCTT
GAAAGACAATCAGGCCATCAGCAACAACATAAGCGTCATTGAATCACACCTGATTACTACCTTCTTCAGC
AACAGCAAGGCGAAAAAGGATGCATTCATGAGTATTGCCAAGTTTGAGGTCAACAACCCACAGGTCCAGC
GCCAAGCATTCAATGAGCTCATCCGAGTGGTCCACCAGCTGTTGCCGGAATCCAGCCTCAGGAAGCGGAA
AAGGAGTCGCTGCTGATTCGGGGTGGGGAAGAGATTGTCCCAATAAGAATAATTCTGCCAGCACTATTTG
AATTTTTAAATCTAAACCTATTTATTAATATTTAAAACTATTTATATGGAGAATCTATTTTAGATGCATC
AACCAAAGAAGTATTTATAGTAACAACTTATATGTGATAAGAGTGAATTCCTATTAATATATGTGTTATT
TATAATTTCTGTCTCCTCAACTATTTCTCTTTGACCAATTAATTATTCTTTCTGACTAATTAGCCAAGAC
TGTGATTGCGGGGTTGTATCTGGGGGTGGGGGACAGCCAAGCGGCTGACTGAACTCAGATTGTAGCTTGT
ACCTTTACTTCACTGACCAATAAGAAACATTCAGAGCTGCAGTGACCCCGGGAGGTGCTGCTGATGGGAG
GAGATGTCTACACTCCGGGCCAGCGCTTTAACAGCAGGCCAGACAGCACTCGAATGTGTCAGGTAGTAAC
AGGCTGTCCCTGAAAGAAAGCAGTGTCTCAAGAGACTTGACACCTGGTGCTTCCCTATACAGCTGAAAAC
TGTGACTACACCCGAATGACAAATAACTCGCTCATTTATAGTTTATCACTGTCTAATTGCATATGAATAA
AGTATACCTTTGCAACC</dna_sequence>
        <protein_sequence>>gi|33468859|ref|NP_032363.1| interferon gamma [Mus musculus]
MNATHCILALQLFLMAVSGCYCHGTVIESLESLNNYFNSSGIDVEEKSLFLDIWRNWQKDGDMKILQSQI
ISFYLRLFEVLKDNQAISNNISVIESHLITTFFSNSKAKKDAFMSIAKFEVNNPQVQRQAFNELIRVVHQ
LLPESSLRKRKRSRC</protein_sequence>
        <phi_function></phi_function>
        <phi_annotation>IFN-gamma plays a critical role in Th1 type immune response. It is important for protection against infections by various viruses and intracellular bacteria.</phi_annotation>
        <phi_function2>Vaximmutor</phi_function2>
        <phi_annotation2>The experimental data demonstrated that three time vaccinations with BCG in BALB/c mice induced strong TB Ag-specific IFN-gamma immune responses in splenocytes  [Ref2101:Wang et al., 2009].</phi_annotation2>
    </gene>
	<gene gene_id="gene1428">
        <gene_name>IFNG from Macaca nemestrina</gene_name>
        <strain></strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id></ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id></taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand></gene_strand>
        <protein_name></protein_name>
        <protein_pi></protein_pi>
        <protein_weight></protein_weight>
        <protein_length></protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence></protein_sequence>
        <phi_function></phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1191">
        <gene_name>IgA Fc fragment</gene_name>
        <strain>Macaca mulatta</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>664734</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>90265825</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq>NP_001035039</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>9544</taxonomy_id>
        <chromosome>19</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>60887587</gene_start>
        <gene_end>60904465</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>Fc fragment of IgA, receptor for</protein_name>
        <protein_pi>7.75</protein_pi>
        <protein_weight>30407.11</protein_weight>
        <protein_length>287</protein_length>
        <protein_note>Also known as CD89</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|109156886:60887587-60904465 Macaca mulatta chromosome 19, Mmul_051212, whole genome shotgun sequence
GATGGACCCCAAAGAGACCACCCTCCTGTGTCTCGGTGAGTTTCAGAGTAAAAGTGGGTTAGAGGGGAAA
ACAGGGAAATCCCAAAATAATCCGGGTGTCTCTTGACAGTATGACTAGGAGATTTTAGTGGCTGCCAAGG
AGATTCTGACCTCCTTAGTGGAAAGGCAGTCTTTATCAATATGTCTATAACTTTGTCTCTGCCCAAGTCC
AACCTAGCTTGTGGGACTCAAGGGTTAATATTTTTATTAAACCTATAGTGTGTTATCTGGGATTAATGAT
GGTTCCAAGGTTCCCATCAAAGACAGACTTAGGGGCTGGAATCTGAAAGGTAAAAATAAAGAATGAGCCT
CAAAACTGTGATTGTTGTGGAATGAAAAAATATGATTGAACCCCATATAGAAATATGGTTACTAGTATTT
TGTTGAAGATTTTTGCATTTATGTTCAACAAAGACGTTATCCCGAAGTTTTCTGGTTTTGTTGCGTCTCT
GCCACGTTTTGTTATCAGGATGATGCTGGCCTCATAGAATGAGTTGGGGAGGAGTCCCTCCTCCTGGATT
TTTTCAATAGTTTCAGTAGGAATAATACTAGTTCTTCTTGGCCAGGTGCAGTGGCTCACGCCTATAATCC
CAGCACTTTGGGAGGCCAAGGCAGGTGGAACACACGGTCAGGAGATCACATCCTGCCTAACACAGTGAAA
CCCCGTCTACTAAAAATACAAAAAAATTAGCCAGATGTGGTGGCGGGCACCTGTAGTCCCAGCTACTCGG
GAGGCTGAGGCAGGAGAATGGCATGAACCTGGGAGGCAGAGCTTGCAGTGAGCTGAGATCGCACCACTGC
ACTTCAGCCTGGGCGACAGAGCGAGACTCTGTCTCAAAAAAAAAAAAATACTAGCTCTTCTTTATATATC
TAGTGGGACTGAGCTGTGTCTCCATCTGGTACTGGTCTTTTCCTGGTCTATCATTACAGAGGGTGATTTG
TCATAAAGATTGGAAATGGAAGCTTGATTTTTCATAAATCTCTCTCTTCCAGTGCTCTGTCTGGGCCAGA
GGATTCAGGCACAGGAAGGTAAGTGTCCTGTAAATCTCTCCCAGCCCCTTTAGACTCTCTTGGAAGCTCA
GGATAAAGAAATTGAGGAATAGCCTGAAGTACAGATTCTTATTTTAGTCCCCATTCCAGTTGTTTCTGCT
GTGCTTCTCTTGCATAATTTCTATCACACTTTGTTATAGCCAAATCCTTCAGACTCATTAATGCTCAGAC
CTGGATTTATAGTTAGTCCTTGCCTGTGTTAGACTGCCCATGAAGGATCTGTAATCTACTGAATGCTCAA
AACTGCAAGAATGAGGAAATCAGGAGTCATTTGCCCAACATCCTTCCTTATGCTTTGTTTTAGCAACCTA
CTTCCTCCTGTCACTTCATTTAAAGGGATACTGCCATAGTCTAATCCTACTGAACATTCTACTATTCTAT
AGTACTACTGCAGTACTAAGCATGCAGTAGTCTTAAGAGTACTACTGAATATTCTGCCACCCCAACTACT
ACTGCCTTAGCCTCCTAATGGGTGTAAGCCCCATGTCCATCCATGTCTGCTCTCTTCCAGCTCCTTCTAT
AGCCTGAATTATTTGTGTGTTGAACAATATTCATTCTTCCTATCCATGAGCATGGAATGTTTTTCCATCT
GTTTGTGTCATCTATGATTTCTTTGAGCAGCGTTTTGTAGTTCTCCTTGCAGATATCTTCCACCTCCCTG
GTTAGCTGTATTCCTAGGTATTTTATTCTTTTTGTGGTAATTGTGAATGGATTCTGTTCTTGATTTGGCT
CTTAGCTGAGACGTTTTTGGTGCATAGGAATGCTACTGATTTTTGTATATTGATTTTGTGTCCTGGAACT
TTGTCAGAGTCGTTTATCAGATTAAGAAGTGTTTGGGCAGAGATTGTGGTTTTCTAGGTATAGAATCACA
TCATCTGCAAACAGGGATGGTTTGACTTCCTTTCTTCCTATTTGGATGCCTTTCATTTCTTTCTCGCCTG
ATTGCTTTGGCTAGGACTTCCAGTACTATGTTGAATAGAAGTAGTGACAGAGGGTATCCATGTCTTGTGT
CAGTTTTCAAGGGGAATACTCCCAGCTTTTGCCCATTCAATATTATGTAGGCTGTGAGTTTGTCATAGAT
CTTCCTTATTATTTTGAAGTACGTTTCTTCAATGCCTAGTTTGTCGAGGTTTTTTAGCATAAAGGGATGT
TGGATTTTATCAAAAGCTCTATTGAGATGATTATATGTGTGTGGCCGGGGGATTGTTCTATGAATCACAT
TTAAGATTTGTGTATATTGAATCAACCTTGCATCCCAGAAATAAAGCCTACCTCATGGTGGTGGACTGGC
TTTCTGATGTGCTGCTGGATTGTTTGCTAGTATTTTCTTGAGGATTTTTGCATTTATGTTCAACAAGGAT
ATTGTCCTGAAGTTTTCTGGTTTTGTTGTGTCTCTGCCATGTTTTTGCATCTATGCGGGTCTCATAGAAT
GACTTGGGGAGGCATTCCTCTTCCTGAATTTTCTGGAAAGCTTCAGTAGATATAGTACCAGCTCTTCTCT
ATGTATCTGATGGGATTCAGCAGTGAGTTTGTCTGGTACTGGCCTTTTTCTTCTTTTGAAGAGGCCTTTT
TATTACTGATTCAATTTTGGAGTTCATTATTGGTCTGGTTCATGGAATCAGTTTGTTCTTGGTTCAATCT
CAGAAGGATGTATGTGTCCAGGAATCTCTCCATTTATTCTGGATTTTCTAGTTTGTGTGCACAGAGGTGT
TCCTAATATTCTCTGATGATTGTATTTCTGTGGGGTCAGTGGTAATATCCCCTTTGTTGTTTCTAATTGT
GTTTATCTGGATCATCTCTCTTTTCTTCTTAATTAGTCTAACTAGTCACCTGTCTTACTAATTTTTTTCA
AAAATCCAACTCCTGGATTTGCTGATCTTCTGAATGGTTTTTTGCATCTCAATCTCCTTCTGTTCAGCTC
TGGTTTTGGTTATTTCTCGTTTTCTACGAGCTTTGGGGTTGATTTCCTCTTGGTTCTCTCAGTTCCTCTC
GTTGTGATGTTAGGTTGTTAATTTGAACTTTTTCTAACTTTTTGACGTGGGAGTTTAGTACTATAAACTT
CCCCCTTAACACTGCCTTAGTTGTGTCCCAGAGATTCTGCTGTATTTACCCACAAATTCCAGAACAGACT
GTTTAATTTCCATGCATTGTACAGTTTTGAGTGGTTTTCTTAGTATCTATTCCTATTTTTATTCCACTGT
GCTCTGAGAATGTGCCTGGTATGATTTCACTATTCTGGATTTGTTAAGGATTGTTGTATGTCTGATTGCA
TGATTGACTTTAGAGTATGTGCCACGGGGCAATGAAAACAATGTAGATTCTGTTGTTTTGGGGGTGGAGA
GTTCTGTAGATGTCCATCAGGTCCCTTTGGTCCAGTGCTGAGTTCAGGTCCTGAATATCTTTGTTTGCCT
CAGTGATCTAACACTGTTGACGAGATGTTAAAGTCCCCCCCTATTATTGTGTGGTTGTCTAAGTCTCTTT
GTTGGTCTCTCAGAACACGCTTTATGAATCTGGGTGCTTCTGTGTTAGATGCATGATATTTAGGATAGTT
AGGTCTTCATGTTCTGTCTTTATTTTTTTCTTTTTCTTTTCCTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TGAGATGGAGTCTCACTCTGTTGCCCAGGCTAGAGTGCAGTGGTGCAATCTCGGCTCACTGCAAGCTTCA
CCTCCCGGGTTCACGCCATTCTCCTGCTTCAGCCTCCCGAGTAGCAGGGACTACAGGTGCCTGCCACCAC
GCCCGGCTAGTTTTCCAACATGGAAAACTATGTTTTCCATATTGCTTGCTTTCTCCCCATCTCTTTCGGG
GACCCCAATGGGTTGCCTATTTGGTCTCTTTACATAATCCCATGTTTCTTAGAGGTTTCAAATTTCATTC
ATTCTTTTGTATTCTTTTGTCTTCATTTTTGTCTGACTGAATTAGTTCAGAGAGCCAGTATTCATGCTCT
GAGATTCCTTCCTCGTTTTGCTTTATTCTGCCGTTAATACTTGTGATTGCATTATGAAATCTTGCAGTGT
GTTTTTCAGCTCTATCAGATCCGTTCGGTTCTTTCAAAATGACCGTTTCTTAGATTAGCCCCTGTGTCAT
TTTATCGTAATCTTTCGATTCCTCGCATTGGGTTTCAACTTTCTCCTGAATTTGATGACCTTGATTTCTA
CTCATATTCTGAATTCTATTTCTGTCATTTCAGCCACTTCCTCCTGGTAAAGAGCCCTTGCTGGGAAGCT
CATGTGGGAATTTGGAGGAAGGAAGACACTTGCTTTTTGAGTCTTGTGCTAATTCTTTCTCATCCGTGTG
GGCTAATGTTCTTTTAAGTGTGGTGCAATTGGAGTGTTTTTCTTTTTTCTTTTAACTGTGGTGTAATTTG
AGTACAGTCAGTAGACTTCTTTTCTGGGTGGTTTCAGAGGGCTGGGGCTTCGCACAGGGTCTTTACTGAT
AGCTAAATTCTTGTCCTTGGTATAACGGGGGGTATATTAGCAAGCATTTTTGGTGTTGAAGTTTGGGCTG
CAATCCAGTAAGTGATGCTTAAGCATAATGGCCAGTAGGTCATTCCTCATGACGGCCGCTGTGCTCCCTC
TCATGCTCTGAATGTGTGGGCTCCTCTCCCACTCAAGCACTGGCTGCAGATCTGGGCTCCGCACTCCCAG
GCTGCCCATCACAGCGCTGGGGTGAGCTCAGGTTTTATGTTCCCTCCGTGGCTTGGGGGCAGCAGGGGAA
GGGACCTCAGCAGTGGCTGTGGCAGATGGCCTTTCACTTGTCCCTTGGGACTCCACCCCAGAGAGATGTG
GAACCACTATCAGTAGTGTGATGAGCCAAGAGTGGGGCGACTGCGCTGTGGGCCCAAGCTAGGGGCCCTG
CCTAGTGATGAGCAGCGGGGACAGGTGGGTCACAGGGGTGACAGACTGGCCTCTTCTCCTTAGGGCAGCT
TGCGGGAGGTGTGGTTAAGGCACTCAGAGTCTTTGCTCCTTCCCCAGTCTGAGGGCAGCAAGGCCAGGAC
CACCGCAGTGGCAGCCGCAGAGGGGCTGTGAGTTGCCTCTGGGAGCTCCGCCACAGAGAAATGCAGACCC
ACAGCTCCCAGGCACGCTCCGCAGAGGGTGGGGCTGCTGTGCTGCGGGCTCAGGCTGGGGTTTGGTGAAG
AGCAGGGGGCTGAGGGCTCGCAGGGAGAGGAGACTGAGCTCCTCTCTTACGGTGACTGTGGTGTGCTAGA
GGCATGAATGAAGGCTGGGGCTCGGCGGCTCACACCTGTCATCCCAGCACTTTGGGAGGCCGAGGCGGGC
GGATCACGAGGTCAGGAGATCGAGGCCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACA
AAAAACTAAGCCGGGCGTGGTGGCAGGTGCTTGTAGTCNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNCTACAAA
TGCTCAGTAAAAAAAATACTAATAATAAAATAAAATAAAATAAAGCATGAATGAAGCTCCTAGGCTCCTT
GTTCTTCCTCAGACCACAGGCAGCAGGGGCAGAATCCTTGCCATGGCGGTGGCAGAGGGGCCGTCAGTTG
CCTCTGGGAGCCATTCCCCAGGGAAACACGGAGCCACCACCAGTGAGGATGCTGAGGGTAGGGCAGCTGC
TCTGCAGTCCCAAGCTGGGGGCTCTGCCTGGTAAAGTGGGGGTGGGGGCTCACGGGGAAGAGAGACTAGA
CTCCTCTCTGTCTGATGGCTGTGGCATAATGACCAGTCCCCAACACGTGAAAAAGAATTGTGGGAACTCA
GAAACCCAGTTTGTCCCCACCATGGACTCCTTGCACTGCGTTTCAAATTTCTCCTCAATCTCCATGAGCT
TCCCAGCCATCCAGATTCTGAATTCTATGTCCCTCGTTTCATTCATCTCAATCTAGCTAAGAACCAGATT
TCCAGGGGACTATCGAGTTGCCAGAGTTCTTGTGTTCCTTTTATTTTTTCCTTTTGTGTGACAAGAGTCT
TACTCTGTTACCCAGGCTGGGGTGCGGTGGCGTGATCTCAGCTCACGGCTGCAACTTTCACCTCCCAGGT
TCAAGCTATTCTCCTGTCTCAGCCTCCCAAGTAGCTGGGATTACAGCTGCGTGCCACCACACACAGCTAA
TTTTTGTATGTTTAGTAGAACCCAGGTTTTGTCAGGTTGGTCAGGCTGGTCTTGAACTCTTGACCTCCGG
TGATCCGCCCGCCTGGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCACCGTGCCCGGCCTTGGTGT
CGATTCTTTCTCTTGTGTGAGGGCTGGTGTTCCTTTAACTGTGATGTCAGTTGAATACAGTCACTTAGCT
TCATTTCTGGGTGTTTTCAGATGCCAGGACTCTGCACGGAATCTTTATTTGTGGCTGGATTTTTCACTTC
GTTGTCTACTGGCAAAATATTTCAGTCTTGTATTTTGACGTGTGATCCAGTAGGTGGCACTTAAAAGGGG
CTGGCCAGCATACAGGATCTTAGCCACAAGGCTGTTTTGTAGTTTTGTTTCGTTTTTTGTTTTGTTTTTT
GACACAGGGTCTTGCTCTGTCACCCAGGCTGGAGCGCAGTGGCACAGTCTCGGCTCACTGCAGCCTCCAT
CTATCAGGCTAAGTGATCCTCCTGCCTCAGCCTCCTAAGTAGCTGGGACTACAAGCACATACCACCATAC
CAAGAAAATGTTTGTAATTTTTTTTTTTTTTTTTTTTTAGAGATGGGGTTTCACCATGTCTGCCAGGCTG
GTCTCAAACTCCTGGGTTTAAGTGATCTGCCTCCCTTGGCCCCCCAACTCTTGTATTTTGACAAAGTTAG
CAGTAGTGCTCTGTGGTTGTGGGGAGGGGTGACTTCCTCACCTGGTCCATTCCTGGGCCTTGGAGGAGCC
TCCTACAATCACTAGCTCTGCACCCACCGTTTCCTTTGTTAGGATTGTTCTGCCCACGGGGTTCCTTCAG
GCAGTGCATGGTGGGAAGACAGGCTGTATCCTTCCCCAGCCAGCCTACGGAGGGAGGACCACCCCACTCC
TCTGCAGACTGATGAAATCACGTGTTTCATTCTTCTGAGTGTTCTGAGAATGAGGGCTCCTCACCGCTCA
GTCGCCACCCAAGCTGGTGAGTCCTTCTCAGCAAGGGCGGTTGGAACCACCTGATCTGCCATCTCAGTGC
TTCCCAGGGGAACCCAGAGCTGCTGGGGCATGGCAGCTCATGCCTGTAATCTCAGTACTTTGGGAGGCCA
AGGCGGGCAGATCACGAAGTCAGGAGATCGAGACCATCCTGGATAACATGGTGGAACCACATTTCTACTA
AAAATACAAAAATTATCCAGGCATGTGGCGGGCACCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGA
GAATTGCTTGAACCCGGGAGGCGGAGTTTGCAGTGGGTCGAGATTGCGCCACTGCACTGCAGCCTGGGCG
ACAGAGCGAGACTCTGTCTCGAAAAATAATAACAAAAAAAAATAAAGATGGCAACCACAGACACTGGAGA
CGACTAGACGGGGAGGAAGAGAGGGGCTTGAAAAACTAACTGCCTACTGGGTACTACGCTCAGCACCTGG
GTGACAGGATCCACCGTACCCCAAACCTCAGCATCATAAATTATTTACATGTTTATTTTTATTTATTTAT
TTATTTTAATTGAGACAGAGTCTCACTCTGTGGCCCAGGCTGGAGTGCCATGGCGGGATCTCAGCTCACT
GCAAGCTCCGCCTCCTGGGTTCACGCCACTCTCCTGACTCATCCTCCCAAGTAGCTGGGACTACAGTCGC
CCACCCCCACGCCTGGCTAATTTTTTGTATTTTTAGTAGAGACGAGGTTTCACCATGTTAGCCAAGATGG
TCTCGATCTCCTGACCTCGTGTTCCACCCGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCA
CCACACCTGGCCTAAATTTTTCTTTAAATAAAGAATGACAGGTTCTTCATACCCTAATTTTCTTCCAGGG
AACTTTTCCACGCCTTTCATATCTACCAGGTCAAGTCCTGTGGTTCCCTGGGGTGGGTCTGTGAGAATCC
AGTGCCAGGCCATTCCTGACGCTTACCTGATCTGGCTGATGATGCTAAAAAACTCCACGTACGAGAAGAG
AGACGAAAAACTGGGGTTTTGGAATGATACTACGCCTGAGTTCGTCATTGACCACATGGACGCGAACAAA
GCAGGGCGCTATCAGTGCCGATATAGGATAGGGTTCTCCAGGTTCCGGTACAGTGACACCCTGGAGCTAG
TGGTGACAGGTAAGGAAACATCCAGGGTCCACAGCCCTGGTGTGATTTTTTTTCTTATTTTTAATAGAGT
ATTTTTCGATAAGTTTTAGATTTACAGAAAAAAGAAAAATTGAGATGACTGCTTCACAGAGTTCTCAGCT
ATCTGGCCACTTCCCCCAGAGTTAACATCTGACATTACTATGGCACATTTCTTTTTTTTTTTTTTTTTTA
ATTTTTTTTTTTTTTTTTTTGAGACGGAGTCTCACTCTGTCGCCCAGGCTGGAGTGCAGTGGCCGGATCT
CAGCTCACTGCAAGCTCCGCCTCCCGGGTTTACACCATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGAC
TACAGGTGCCCGCCACCTCGCCTGGCTAGTTTTTTGTATTTTTTAGTAGAGACGGGGTTTCACCGTGTTA
GCCAGGATGGTCTCGATCTCCTGACCTCGTGATCCGCCCGTCTCGGCCTCCCAAAGTGCTGGGATTACAG
GCGTGAGCCACCGCGCCNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNCACACACAC
ACACACACACACACAGAGGTTACACACACACACACACACACACAGAGGTTACACACACACACACACACAG
AGGTTACACACACACACAAACACACACACACAGAGGTTACACACACACACACACACACACAGAGGTTACA
CACACACACACACACACACAGAGGTTACACACACACACACACACACAGAGGTTACACACACACACAAACA
CACACAGAGGTTACACACACACACACACACAGAGGTTACACACACACACACACACAGAGGTTACACAAAC
ACACACACACACAGAGGTTACACACACACACACACAAACACACACACACACACACACACACACACAGGTT
TCACTTTGCATTCAGGTGTCATGTATCTTTAGCTTTCTCCCGGCTCTCACAGCTTCTCCGATGTTGCTGG
TTTTCCATGGCCTTGTCAGTTTTGAGAGTAGAAGTCCATCACTTTCATTGGCCGGGCGCGGTGGCTCAAG
CCTGTAATCCCAGCACTTTGGGAGGCCGAGACGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGG
CTAACACGGTGAAACCCCGTCTCTACTAAAAAATACAAAAAAACTAGCCGGGCGAGGTGGCGGGCGCCTG
TAGTCCCAGCTACTCGGGAGTCTGAGGCAGGAGAATGGCGGGAACCCCGGAGGCGGAGCTTGCAGTGAGC
TGAGATCCGGCCACTACACTCCAGCCTGGGCGGCAGAGCCAGACTCCGTCTCAAAAAAAAAAAAAAAAGT
CCATCACTTTCAAGGGTACTCCCACTATTGGAAATTGTCCGATGTGTTGCTCATGACTAGACTGAGTTAT
GGGTTGTTGAAGACCACAGAAGCAAAGTGCCGTTTCATCTCCTCATAGCAAAGGTTTAAACTGTCCATGG
GAATATGACTGTTGATGCTGAACTGGCTGTTGTTGAAAGCCTGGCTGAAGTAGTGACTGTGACCAGGCAC
CGAGGCTCACGCCTGTAATCCCAGCGCTTTGAGAGGCCGGGCGCAGTGGCTCACGCCTGTAATCCCAGCA
CTTTGGGAGGCCGGGCGCAGTAATCCCAGCGCTTTGAGAGGCCAAGACAGGCGGATCACTTAAGCCCAGG
AGACCAGCCGAGGCAACATAGTAAGACCCCATCTGTACAAAAAAAACAAAAAATTAGCTGGGCATGGTGG
CACCCACCTGTAGTCTCAGCTACTTGAGAGGCTGAGATGGTAGGATCACTTGAGCCTGGGAGGTCGAGGC
TGCAGTGAGCCGCGATTATGCCACTGCCCTCAGCCTGGGCGACGGAGTGAGACCCTCTCTAAAATAAATA
AATAAATAAAATTTTAAAAAGAAAAAAGAGGCTGGGCACTGTGGTTCACGCCTGTAATCCCAGCACTTTG
GGAGGCTGAGGCGGGTGGATCACCTGAGGTCAGAGATTCAAGACCAGCCTGACCAACATGGTGAAACCTC
GTCTCTACTAAAAATACAAAAATTAGCTGGGCGTGGTGGGAGGTGCCTGTAATCCCAGCTACTCAGGAGG
CTGAGGCAGGAGAATCACTTGAACCTCGGAGGTGGAGGTTGTGGTGAGCCAAGATTGTGCCACTGCACTG
CAGCCTCGGTGACAGATCGAGACTCCATCTCAAAACACAATAATAGGCCGGGTGCGGTGGCTCACGCCTG
TAATCCCAGCACTTTGGGAGGCCAAGATGGGCAGATCACTTGAGGTCAGGAGTTCGAGACCAGCCTGACC
AACATGGAGAAACCCCATCTCTACTAAAAATACAAAAATTAGCTGGGCGTGGTGGTGCACACCTGTAATC
CCAGCTTCTCAGGAGGCTGAGGCAGGAGAATCACTTGAACCCAGGAGGCAGAGGTTGTAGTGAGCCGAGA
TCACACAATTGCTCTCCAGCTTGGGCAACAAGAGCAAAGCTCCGTCTCAAAAAATATATATAATAATAGC
AATAATCAGAAGAAGAAAAAAATAAAGGAGAAAAGGTCTTGCTAACAGCTCACTCTTCTCTCTCTTAGGC
TTGTATGGCAAACCTTCCCTCTCTGTGGATCGGGGTCCAGTGTTGATGCCGGGAGAGAATATTTCCGTCA
CGTGCAGCTCAGCACACATCCCATTTGATAGATTTTCACTGGCCAAGGAGGGAGAACTTTCTCTGCCACA
GCACCAAAGTGGGGAACACCCGGCCAACTTCTCTCTGGGTCCTGTGGACCTCAATGTCTCAGGGAGCTAC
AGGTGCTACGGCTGGTACAACAGGAGCCCCTACCTGTGGTCCTTCCCCAGTAATGCCCTGGAGCTTGTGG
TCACAGGTAGGTACCTCCCCATCCAGCCCTGTGTCCGGGTTGGCTGTCCAGGCCCTTGTCACTGGGCAGG
AATATGAATATGAAGAGGTGCACTGAGAATAATGTGAAGAGAGGCAAAGACTCACCCACTCCAGGACAGT
GGAGAAAGAAAGTCTTCCCATCACACTTTCCACCTTCACTTCCTCGCTAGAGTTCTCCAGACAGTGTTCA
TTGAAAACTTGTGGTCTATGGAGAAAAGAAGGACTGACTCATTTTATTTTATTTTATTTTCTGTGATGGA
GTCTTGTTCTGTCGCCAAGGCTGGAGTGCAGTGGCGCGATCTCGGCTCACTGCAAGCTTCGCCTCCCGGG
TTCAAGCAGTTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGACCATGCAGAGTTTCACCATGTTGTTCAGG
CTGGTCTCGATCTCATGACCTTGTGATCCACCCACCTCAGCTTCCCAAAGTGCTGGAATTACAGGCGTGA
GCCACCGTGCCCAGTCAAAAAAGGCTAACTTAGAGTCACAGGTTTATGGGCTATGTTGAGACAGTAGATA
CCAGGCTCAACCTTGTCTACCACACCTCTCCTTTCCAGTTGCAGCTGGAAATCCTCGAACTCACCAACCG
TACTGGAATTTACCATGAGTAATCAAATGGTCATTCATGGTGACCATTTAGTGACCAAATAGTGAGTGAG
GGGTCAAATAGTGACATATTTGGTGACCAAATAGTGAGTGAGAGGTCATAGGAAAGACTTTTAAAACCTC
TATCATGAGCCCCATTTTTATTTTATTCATTTATTTATTTTGAGACAGAATCTCGTTCTGTCGCCCAGGC
TGGAGTGCAGTGGCACAATCTCTGTTCACACTGCAACCTCCACCTCCCAGGTTGAAGCAATTCTCGTGCG
TCGGCCTCCTAAGTAACTGGGACCACAGGCGTGCACCACCGCACCAGGCTACTTTTTGTATTTTTAGTAG
AGATGGGGTTTTGCCATGTCGCCCAGGCTAGTCTCAAACTCCTGGCCTCAAGTGATCTGTCTGCCTCAGC
CTCACAACGTGCTGGGATTACAGGCGTGAGCCACCACGCCTGGTGGTGAAGACTCTAAAGGCTCTTCTCA
GACCAGCCTTTGTCCTGAGGGTCACATGCCCGTGTCCAGTTACCTCTCCAGCATCTTTTCAGGAGTTCCA
CGGACTCGCCCCTTCATTATCCAGGGTTGAGCTACAGATATTCTGATTAGGATTCCACCTAGTTCTGGTG
GTGGTGTAGAGATATGATTAGATATTTAGTGAAATCACCAAGTGAGGAGAGAATGAAAAGAAAACACAAC
TTGCCTGGCCGGGTGTGGTGGCGTGAGCCTGTGGTCCCAGCTACGCAGGAGGCTGAGGCAGGAGAATCGC
TTGAACCCAGGAGGCGTTGGTTGCACTGAGCCAAGATTGCGCCATTGCACTCCAGCCTGGGTGACAGAAT
GAGACTCCATCTCAAGAAAAAAAAAAAAAAACATGGCTGGGCACGGTGGCTCACGCCTGTAATCCCAGCA
CATTGGGAGGCTGAGACGGGCGGATCACTTGAGGTCGGGAGTTCGAGACCAGCCTGGCCAACATGGTGAA
ACCCCATCTCTACTAAAAATACAAAAATTAGCCAGGCATGGTGGCGGGCGCCTGTAATCCCAGCTACTTG
GGAGGCTGAGGCAGGAGAATCGTTTGACCAAGGAGGTGGAGGTAGTAGTGAGCCGAGATCGCGCCACTGC
ACTCCAGCCTGGGCGACAGAACAAGACTCCGTCTCCAAAAAAAAAAAAAAAACAACCTGCCCGTAATCAC
TCCCTTCCCAGTTTATGGAACTTCCCTGCCTGTGGACACAGTCCTGCTGACTGATCAATGTGGTGCTTGC
AAAGTGTGAGCCCATCGAGGAGATGCCTGAGGGAGTCACATTTTGGCAAGCGAATAGGGAAATGGGCTCC
CGTTTCAGGGCTCTGGGGTTGGGATGGAATGGAACACACCCGCCAACCATTCATCTCCCCGAATTGTGTC
TCCAGACTCCATAAACCGAGATTACACGACGCAGAACTTGATCCGCATGGCCATGGCAGGACTGGTCCTC
GTGGCTCTCTTGGCCATACTGGTTGAAAATTGGCACAGCCATAAGGCGCTGAACAAGGAAGCCTCGGCAG
ATGTGGCTGAACCGAGCTGGAGCCACCAGATGTGTCAGCCAGGATGGACCTTTGCACGAACACCAAGTGT
CTGCAAGTA</dna_sequence>
        <protein_sequence>>gi|90265825|ref|NP_001035039.1| immunoglobulin alpha Fc receptor precursor [Macaca mulatta]
MDPKQTTLLCLVLCLGQRIQAQEGNFSTPFISTRSSPVVPWGGSVRIQCQAIPDAYLIWLMMLKNSTYEK
RDEKLGFWNDTTPEFVIDHMDANKAGRYRCRYRIGFSRFRYSDTLELVVTGLYGKPSLSVDRGPVLMPGE
NISVTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSLGPVDLNVSGSYRCYGWYNRSPYLWSFPSNA
LELVVTDSINRDYTTQNLIRMAMAGLVLVALLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFA
RTPSVCK</protein_sequence>
        <phi_function>Vaximmutor</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1192">
        <gene_name>IgG Fc fragment</gene_name>
        <strain>Macaca mulatta</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>718859</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>383873191</ncbi_protein_id>
        <gene_locus_tag>EGK_10892</gene_locus_tag>
        <gene_refseq>CM001271</gene_refseq>
        <protein_refseq>NP_001244449</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>9544</taxonomy_id>
        <chromosome>19</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>55776057</gene_start>
        <gene_end>55793029</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>3</protein_name>
        <protein_pi>6.71</protein_pi>
        <protein_weight>38189.56</protein_weight>
        <protein_length>365</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|109156886:55776057-55793029 Macaca mulatta chromosome 19, Mmul_051212, whole genome shotgun sequence
AGAAGGATATTAAAGAGCACCTGCAGGACCTTTCTAACGGGATGTCGGGGGAAGGGCTTGAAGGAGGATC
TAGGGAGGCTTCCATAAGATTTTGATTAACATCCAGCGCTAGGGAAGGTCACAGGGATACAAAAGGGTAG
GAGGAGGATCCAGAGACCTGCATGTTGTGGACTTCGAAGGCATCCGGTTCCTTTCCCAGCTTTGTCAAGA
ATTCCCTGGGCGGCGGACACCCTCATAATAAAAAAAACGGGAACCACAGGGAAGGGGAATAGAAGAACCA
CAAGCGTTTTGAGAAACATACATAGGCTGGGCCTAGGGCCTGGGGTGTGCCCTGCAACTGGGGGGGGTGG
GGCTGGATGTTCTTGGAGTCAGGGAGCAGCAGCCTCCCACAGGATGTGAGAGAGGAACTGGGGTCTCCAG
TCACGGGAGCCAGGAGCCGGCCAGGGCCGCAGGCAGGAAGGGAGCGAGGCTGAAGGGAACGTGAGCCGAC
CAGGCCCCGATTGAGGGAGGAGGGAAGGGCCTGGACCCCTGGGCCTGAGGGAGGAGGGGCTGGGGGTCTG
GACAGTGCGTCTGAGGGAGGAGGGGCTGGGGGGGTCTCGACACTGGTTCTGAGGGAGGAGGGGCTGGGGG
CCTGGACGCCTGGGACGGAGGGAGGAGGCACTGGGGGTCTGGACACTGGGTCCGAGGGAGGAGGGGCTGG
GGGCCCGGACTCCTGGGTCCGAGGGAGGAAGGGTTGGGGGCCCGGACTCCTCGGTCGGAGGGTGGAGGGG
CTGGTGGCCCGGACTCCTGGGTCCGAGGGAGGAAGGGTTGGGGGCCCGGACTCCTGGGTCAGAGGGTGGA
GGGGCTGGTGGCCCGGACTCCTGGGTCCGAGGGAGGAAGGGTTGGGGGCCCGGACTCCTCGGTCGGAGGG
TAGAGGGGTTGGGGGCCCGGACTCCTCGGTCGGAGGGTGGAGGGGCTGGCGGCCCGGACTCCTGGGTCCG
AGGGAGGAAGGGTTGGGGGCCCGGACTCCTCGGTCGGAGGGTGGAGGGGCTGGTGGCCCGGACTCCTGGG
TCCGAGGGAGGAGGAGCTGGGGGCCCGGACTCCTCGGTCGGAGGGTGGAGGAGCTGGGGGCCCGGACTCC
TCGGTCGGAGGGTGGAGGGGCTGGGGGCCCGGACTTCTCGGTCGGAGGGTGGAGGGGCTGGGGGCCCGGA
CTCCTCGGTCGGAGGGTGGAGGGGCTGGGGGCCCGGACTTCTCGGTCGGAGGGTGGAGGGGTTGGGGGCC
CGGACTCCTGGGTCCGAGGGAGGAGGGGCTGGGGCCTGAGGGGGACGGAAGGGGCGTGGCCGAGCTCGGG
GCCGGGACTCTCAGCCTATCAAGTTTCTGTAATTAATTAACTAACTGAGATCCAGTTCAGGGGTGAAAGT
TCTTCAGGTAGGAGGAGGGCATTGTTGTCAGTCTGGACCGAGCCCGCAGAGCCCCTCCTCGGCGTCCTGG
TCCCGGCCCCTGCCCCGGTACCCCGGGAGGAAGGGCGGGGCCGGGGGTTTTTCGGGAGGAGTCACGTGCC
CCCTCCCGCCCCAGGTCGTCCTCTCAGCATGAGGGTCCCGCGGCCTCAGCCCTGGGCGCTGGGGCTCCTG
CTCTTTCTCCTGCCCGGGAGCCTGGGCGCAGGTGAGGGCCGCTGCGGGCCGGGGCCCTGCTGCAGGCGGG
CGGTGGGAGGCGGCCCCAGGCAGGCAGGGGCGAAGCCAGCGGGACCCGAGTTCCCCGCGAGTCCCGGGCG
CTGCCTTCTCCGCTCAGTTCACTTTCTCAGCGTCTCCTGCTGGGCCTGAGGCTGAGAACCACCTGTCGCT
TCTGTGTCTCTGTTTCCCTCTCTCTCTCTCTGGGTCTCTGTCCTCTCTCTCTCTCTGGGTCTCTGTCCTC
TCTCTCTCTCTGGGTCTCTGTCTCTGTCTCCCTCTCTCTCTCTGGGTCTCTGTCCCCTCCCTCTGAATCT
TCCCTCTCCATAATAGATTCTTCTCCCTCCCTGGATATCTGTCCCACTGCAATCTAGTTCCCCGCCCATG
TTCTCCCTTCAGCTCTGTCTCTGTCTGCAGAAAGTCACCTCTCCCTCCTGTACCACCTCACCGCGGTGTC
CTCGCCTGCCCCGGGGACGCCTGCCTTCTGGGTGTCCGGCTGGCTGGGCCCGCAGCAGTACCTGAGCTAC
GACAGCCTGAGGGGCCAGGCGGAGCCCTGTGGAGCTTGGGTCTGGGAAAACCAAGTGTCCTGGTATTGGG
AGAAAGAGACCACAGATCTGAGGATCAAGGAGAAGCTCTTTCTGGAAGCTTTCAAAGCTTTGGGGGGAAA
AGGTGAGATTCGAATCCGGAGGGGCAAGGGGCTGGGTCCATGCTCCTGGGCCCCACTTACATGTGTGTGG
GCGCCCCAGGCCCCTACACTCTGCAGGGCCTGCTGGGCTGTGAACTGAGCCCTGACAACACCTCGGTGCC
CACCGCCAAGTTCGCCCTGAACGGCGAGGAGTTCATGAATTTCGACCTCAAGCAGGGCACCTGGGGTGGG
GACTGGCCCGAGGCCCTGGCTATCAGTCAGCGGTGGCAGCAGCAGGACAAGGCGGCCAACAAGGAGCTCA
CCTTCCTGCTATTCTCTTGCCCACACCGGCTGCGGGAGCACCTGGAGAGGGGCCGTGGAAACCTGGAGTG
GAAGGGTGAGCCGGATCTGCAGCCACAGGCTGTTCTGTCCTCTCTGCCATCACGCCCACCTGCCTCAGTT
CCCCTGTCAGGACCCTCAGTCAGCCTCCCACTGCAGCCCACGCTCTGCCCCCATTCCTCAGGGGTTTTTC
TACATTCAGCCCTCCCATGGCTCCCCAGCGCCCCCCAAGACAAACTCTTGGCTTCCTTGCCTTTTTTTGT
TGAGACGAAGTTTCACTCTTGTTGCCCAGGCTGGAGTGCAATGGTGTGATCTCGGCTCACTGTAACCTCC
GCCTCCCGGGTTCAAGTGATTCTCCTGCCTCAGCCTCCCTAGTAACTGGATTACAGGCATGCATCACCAT
GCCTGGCTAATTTTGTATTTTTAGTAGAGGCGGGGTTTCTTCATGCTGGTCAGGCTGGTCTCAAATTCCC
AACCGCAGGTGATCCGCCCGTCTCAGCCTCCCAAAGTGCTGGGATTACAAGCGTGAGCCATCGCACCTGG
CTGTCTTTTTTTTTTTTTTTTTTTTTTTTTTTTGAGACAGATTCTCTGTCACCCCAGGCTGGAGTGTGGT
GGCACAATCTCAGCTCACTGCAGCCTGAACCTCCCAGGCTCAAGCAATCCTCCCACGTCAGCCTCCCAAG
TAGCTGCGACCACAGCATCGTCACACCTGGCTGACTTTAATTTTTATAGACACAGTGTCTCACTACGTTG
CCCAGGCTGGTCTTGAACTCCTAGGCTCAAGCAGTCTTACTGCTTTGGCCTCCTGAATAGCTGAGATTAC
AGGTGCATACCACCATAACTGGCTAATTTTTTTTTTAGTTTTCCGCACAGTCTGCCTCCCAGGCTAGTGT
GCAGCAGCGTGATCTCAGCTCGCTGCACACTCTGCCTCCTGGGTTTAAGCGATTCTCCTGCTGCAGCCTC
ATGAGTAGCTGGCACTACAGGCACATCCACCATCTCTGGCTAATTTTTGTAGTTTTAGTAGAGACAGGGT
TTCGTCATGTTAGCTAGGCTGGTCTCAAACTCTTGACCTCAAGTGATCCACTCACCTCAGCCTCCCAAAG
TGGTGGGATTACAGGCGTGAGCCACCGCATTTGACCATAACTGGCTAATTTTTAAAATTTGTTGTAGAGA
TGGCATCTCGCTGTGCTGCCCAGGCCAGACTCAAACTCCTGGCCTCAAGTGATTCTCCCACTTTGGCCTC
TCAGGGTGCTGGGATGACAGGTGTGAACCACTGTGCTTGGCCTTCCTTGCCTTAATGCCCTCGTCAGACC
CACGCAGCAGCACTTGTCTCTACACAGCTGTCAGAGTCTAGGCTCCAGCCACCCAACATGAGCAATCTTC
TCCCTCTGAGCATTTGTTCATCCAGTTCCCCCGGCCCCTCTCTGTTCCACCCTTCCCCCTCTCTGCATAT
ACTCCAGCCCTCCTTATTCTTCAAGGTCGGGGCTGGATATCACTTCCTCTGAGAAGCCTTCTCTCAGCTC
TGTAGGGCAGAGTTCACTGTTTCCTCCCCAGCGGCCCCAGATCCCCATTCATTCAGCTGTTGGCCAAGAG
CATTTGCACTGCCAGACACCGCTCTGGGACGCCGCTCTGGGCCTTGAGCAAAGAGGGAAGTGACACACGT
TCACCCTCTGTGGCTTCCAGGCTGCTGGACAAAGATAGATATCGGCTGGGGATTTGCACAGATGTTCATT
CCAAGTGCCACAAAGGAGAAGTTGAGACTTAACCAGGTAGTTTTTCTTTGATCGTCTTCTTTCTTTTTTA
AGTAGGGAAAATTTCCTTTTTTTTGAGATGGAGTCTCGCTCTTGTCGCCCAGGCTGGAGTGCAATGGCGC
AATCTCGGCTCACTGCAACCTCCGCCTCCCAGCTTCAAGTGATTTCTGCCTCAGCCTCCCGAGTTGCTGG
GACTACAGGCACGTACCACCATACCTGGCTAATTTTTGTATTTTTTTTAGTAGAGACAGGGTTTCACCAT
GTTGGCCGGGATGGTCTTGATCTCTTGACCTTGTCATCCGCCTGCCTCGGCTTCCCAAAGTGCTGGGATT
ACAGACATGAGCCACTGTGCCCGGCCTTTTTTTTTTTTTTTTTTTGAGACAGACTTTTGCATTGTTGCCC
AGGCTGCAGTGCAGTGGCACAGTCTTGGCTCACTGCAACCTCCACCTCCCAGGGTCAAGCAATTCTCCTA
CCTCAGCCTCCCGAGTAGCTGGGAATACGGGCACGCACCACCCTGCCTGGCTAACTTTTGTATTTTTAGT
AGAGACGGGTTTCACCATGCTGGCCAGGCTGGTCTCGAACACCTGATCTCGTGATCCGCCCACCTTGGCC
TCCCAAAGTGCTGGGATTATAGGCGTGAGCCACCACACCTGGCCTAAGTAGGGAAAGTTTCAAACCACAC
TTAAGTAGACACAATAGTATAAAAAGGACCAGGCATGGTGGCTCATGCCTGTAATCACAGCATTTTGGGA
GGCCAAGGCAGGTGGATTGCTTCATCCCAGGAGTTCAAGACCAGCCTGGGCAACATAGCAAGACCTCATC
TCTACTAAAAACTCAAAAAATTAGCCTGGCATGGTGGTATGTGCCTCTAGTCCCAGCCACTGGGGAGGCT
ATGGTGGGAGGATCACTTGAGCTCAGGAGTTTGAGGCAGTAGTGAACTGTGATTGCAATCCTGCACTCCA
GCCCAGACTACAGAGCCAGACCCTGTCTCAAAAAGAAAAAAAATATGATGGCCAGACGCGGTGGCTCATG
CCTGAATTCCAACACTTTGGGAGGCTGAGGTGGGCAGATCACTTAACAGGAGTTTGAGATAAGCCTGGCC
GACATAGTGAAACCCCATCTCTACTAAAAATACAAAAATTAGCCAGGTGCGGTGGTGGGCGCTTGTAATC
CCAGCTACCCTCCACTTCAAGTGATCCACCCTCCTTGGCCTCCCAAAGTGCAAGAGTCACGGTGCCCGGC
CAGAGTGTTTTGTTGATAAGTACTTTAGTATGTAACTCTACTAGGTAAGGGCATGTAAAAAAAATTAATA
CCAAAACCATTATCACACCTACGATCAATTAACTGTAACTCCTTAATGGCATCAGATGTCTAGTTTTTGT
TCACATTTTCCTGACTGTAAATTTTTTTTTTTTTTTTTTGAGACAGTCTCTTTCTCTGTCACCCAGGCTG
GAGTGCAGTGGCCGGATCTCAGCTCACTGCAAGCTCCGCCTCCCAGGTTTACGCCATTCTCCTGCCTCGG
CCTCCTGAGTAGCTGAGACTACAGGCGCCTGTCACCTTGCCCGGCTAGTTTTTTGTATTTTTTTTTTTTT
TGTTTGTTTGTTTTTTTTGAGACGGAGTCTGGCTCTGTCGCCCAGGCTGGAGTGCAGTGGCCGGATCTCA
GCTCACTGCAAGCTCTGCCCCCCGGGTTTACGCCATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGACTA
CAGGCGCCCGCCGCCTCGCCCGGCTAGTTTTTTGTATTTTTTAGTAGAGACGGGGTTTCACCGTGTTCGC
CAGGATGGTCTCGATCTCCTGACCTAGTGATCCGCCCGTCTCGGCCTCCCAAAGTGCTGGGATTACAGGC
TTGAGCCACCGCGCCCGGCCGTTTTTTGTATTTTTTTAGTAGAGACGGGGTTTCACCGTGTTAGCCAGGA
TGGTCTCGATCTCCTGACCTCGTGATCTCCCCGTCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNGCACACCACCATGCCTGGCTATTTTTTGTATCTTTAATAGAGACAGAGTTTCACCAT
GTTGGCCAGGCAGGTTTTGAACTCCCGACCCCAGGTGATCCACCTCCCTCGGCCTCCCAAAGTGTTGGGA
TTACAGGCATGAGCCACCGCGCTCAGCCGTATTTTTGTTTTCTTTTTTTTTTTTTGGAGACGGAGTCTCG
CTCTCTCGCCCAGGCTGGAGTGCAGGGGTGCCATCTCAGCTCACTGCAACCTCCACCTCCCGGGTTCAAG
CGATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGATTACAGGCGCCTGCCACCACGCCTGGCTAATTTTT
GTATTTTTAGTAGAGATGGGGTTTCACGTGTTAGCCAGGATGGTCTCGATCTCTTGACTCGTGATCCGCC
CTCCTCGGCCTCCCAAAGTGCTGGAATTACAGGCATGAGCCACTGTGCCTGGCCATAATTTTTGTATTTT
TAGTAGAGACAAGGTTTCACCATGTTGGTCAGGCTGGTCTTGAACTCCTGACCTCATGATCCGCCTACCT
CGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCTACTGTGCCCGGCTGGATTCCAATTTTTTATCAGA
TAGGTGTTTTGCAAATATTCCTTACACTCTCTAAGTTGTCTTTTCATTGTTTTAACTGTGCCTTTCAGAA
AGAAAAAGTTTTTAACTTCGATAAAATAGTTTATTCTTTTTTTTTTTTTTTTTTAAATCATGGGTTATGC
TTTTGGTGTCTTATTTCAGAAGTAAGCACTAAACCCAAAATCAGCTAGATCTTCTCCTGTGTATTTTACG
AGTTTTAAAGTTTTGCATTTTATAGTTAGGTCTGTGATTCATTTTGAGGTAATTTGAGTTACTTGTGATC
TTGAGTGTCTTTTGATTTACAGGTTTCCCATTTTCTTTTTTTTTTTTCCCCTCGTAATTGTGGTTTGAAG
AAAGTCCGTTTATGTCCTATTGAGTTTCCCTCAGACTGGATTTTACCCTTTGCATCCTCTGATGTTGCTG
GACATAGTCCTCCTTCTCTTCTTTAAAGGAGCAGCTCGATCTGCAAGCTTGATCAGATTCTGGTTCAGTT
TTTATGGCAAGAAAAGTTTCGGCCGGGCGCCTGTAATCCCAGCACTTTGGGAGGCCGAGACGGGTGGATC
ACAAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAAAATACAAAA
ATTAGCTGGGCGAGGTGGCGGGCGCCTGTAGTCCCAGCTATACTGGAGGCTGAGGCAGGAGAATGGCTTG
AACCCAGGAGGCGGAGCTTGCAGTGAGTGGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGGGCGAG
ACTCCGTCTCAAAAAAAAAAAAAAAAAAAAAAAAAAAACTTTCTGGGTAGTTGGTGGTTATGTCTGTGTG
CATAGGCTGCAAATATCTGCTCGCTTCTGTGCTGTTCTGCGGACCACTGGATTCGGGTGTTACAAAGTTC
TCTGTCAGGTTTTCTCCTGATGCTTTTAGCGGACAGCCATGGCCACTGCCTTAATCTTTTTTATTTATTT
ATTTATTTATTTTTGAGATGGAGTCTTGCTCTGTCGCCCAGGTTGGAGTGCAGTGGTGTGATCTCGGCTC
ACTGCAACCTCTGCCTTCCAGGTTCAGGCGATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGATTACAGG
CGCATGCCACTATGCCCGGCTAATTTTTGTATTTTTTTGGTAGAGATGGGGTTTCACCATGTTGGTCAGG
CTGGTCTTAAACTCCTGACCTTGTGATCCACCTGCCTCGGCCTCCCAAAATGCTGGGATTACAGGCATCA
GGCATGAGCCAGCGCGCCTGGCCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGAGAGGGAGTCTGC
CTCTGTCACCAGGCTGGAGTGCAGTGGGCATGATCTCGGTTGACTGCAACCTCCACCCCTCAGGTTCAAG
TGATCCTCCTGCCTCAGCCTCCTTAGTCGCTGGAATTACAGGTGCACACTACCACACCCAGCTACTTTTT
GTATTTTTAGTAGAGACGGGGTTTCACCATGTTGGCCAGGATGGATTTCTTTTTTTTTAGAGAGATGGAG
TTTCACTCTTATTGCCCAGGCTGTAATACAATGGCATGAACTCGGCTCACTGCAACCTCTGCCTCCTAGA
TTCAAGTAATCCTCCTGCCTCAGCCTCCAGGGTAGCTGGGACTACAGGCATGCGCCACCATGCACAGCTA
ATTTTTATATTTTTAGTAGAGACGGGGTTTCACCATGTTGGCGAAGCTGGTCTTGAACTCCTGACATCAG
GTGATCCGCCTGCCTCAGCCTCGCAGAGTGCNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNCACCGCGCCAGCCTTTTTCTTTTTTTTTTTTTTTAGACAGAGTCTTGCTCTGTC
GCCCGGGCTGGAATGCAATGGTGCAACCTCTGCCCACTGCAACCTTCGCATTCCGAGTTCAAGTGGTTCT
CCTGTCTCAGCCTCCTGAGTAACTGGGACTATAGGCGCCTGCCATCATGCCCAGCTAATTTTATGTATTT
TTAGTAGAGATGGGGTTTCACCATATTGGCTAAGCTGGTCTTGAACTCCTCACCTTGTGACCCACCCGCC
TCAGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCACTGTGCCTGGCCCCAAGTTTATAAATTTTAAT
TTATAAAGCTCAATTTTATCTTTGATTCTGTAGCTTTGTTGTGTATTCTCTTTAAGGAATCTTTCCTCCG
AGAAAGGTATTCACCTATGTCTTCTAGAAGCTTAGTTGATGAATAGCTTCCACATTTAGTGATACCATTG
ATTTTGAGTTAATTGCCTGTTATGATGAGGGTAGGAGTTGAGGTTCATATGTCCAGCCAGCATCATTTGT
TGCTAGACCATCATCCCCTCTCCCTCACTGGACTGCAGGGGAGTGTGTTTTGTGTGTAAGGTGTGGATCT
GCTTCTGACCCTCTCCTATTCTGCTGATTATTGGACTTAGTGTCAGTACCTCACTCTTGATTTGATGTAG
CTTTTTTTTTTTTTTTTCTTTTTTGAGATGGAGTCGCACTCTGTCGCCCAGGCTGGAGAGTAGTGGTGTG
ATCTCGGCTTACTGCAAGCTCCGACTCCCGCGTTCACGCCATTCTCCTGCCTCAGCCTCCCAAGTAGCTG
GTACTACAGGCGCCCGCCACCACACCCGGCTCATTTTTTTGTATTTTTAGTAGAGATGGAGTTTCACTGT
GTTAGCCAGGATGGTCTTGATCTCCTGACCTCCTGATCCGCCCACCTTGGCCTCCCAAAATGCTGGGATT
CCAGGTGTGAGCTACTGCACCCATCCTGAATCTATTTTTATGAGAGACATTGGCCTTAAGTTCTCTTTCT
TATAATGTCCTTTGTTGTCAAGATGATGCTGACCTCATAAAATATGCTGGGAGAGTGTTTCCTCTGTTTT
ATTGCCTGAAGAGTTTGCGTAGGAGTAGAATCATTTCTACATTGGAAGAATTCACTAATTGATGTCTTCC
GGACCTGGAATTTTAGTTTTCGGAAAGTTTTTTTTTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTATGT
CGCCCAGGGGGGGGGGCAGTGGCCGGATCTCAGCTCACTGCAAGCTCCGCCTCCCGGGTTTTTACCCCAT
TCTCCTGCCTCAGCCTCCCGAGTAGCCGGGACTACAGGTGCCCACCACCTCCCCTGGCTAGTTTTTTGTA
TTTTTTAGTAAAAACAGAGTTTCACTGTGTTAGCCAGGATGGTCTCGAACTCCTGACCTCGTGATCCGCC
CGTCTCGGCCTCCCAAAGTGCTGGGATTACAGGCTTGAACCACCGCGCCCGGCCAGTTTTCGGAAAGTTT
TAAACTATGGATTAAACATTTTATTTATTTATTTTTTTNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNCAGCTACTCGGGAGGCTGAGGCCGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCTG
AGATCCGGCCACTGCACTCCAGCCTGGGTGACAGAGCGAGACTCCGTCTCAAAAAAAAAAAAAAAAAATA
CTTACAGGACTGCTGACATTTTAAATTTCCTCTTGTGTCAGTTTAGAAGGTTGTATTTATCAAGAATGTG
TTCAGTTCATCTAAATTTTCAAATGTGTTAGTATGGAATTTTTCATAATTATCCTCTATCTTTTTTTTTC
CTTTCCCCAAGACGAAATCTCGCTCTGTCACTCAGGCTGGAGTGCAGTGGCACGATCCCAGCTCACTGCA
ACCTCTGCCTTCCAGGTTCAAGCGATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGACTACAGGTGCCCA
GCTAATTTTTGTATTTTTAGTAGAGATGGGGTTTCACCACGTTGGCCAGTCTGGTCTCAAACTCCTGACC
CCAGGTGATCCACCCACTTTGGCCTCCCAAAGTGTTGGGATTACAGGCGTGAGCCACCATGCCCAGCCCA
GGGAGGTGACATCTTGAGGGGACACCTTCAGGGTGGATAGGTTCAGTCTCTGTCACCTGGGAAGCGCCTC
CTCTTTTACCACCACATTATCCGGGGTTAGCACATTGCAAACATGGAGGCCTCTTTCTGTCATTACCCAG
CCCTGGCCCTGGGAGTGGTGGGCTCGGGGCTTAGACCTGTCTGCCTGGTTTCCTGCAGAGCCCCCCTCCA
TGCGCCTGAAGGCCCGACCCGGCAACCCTGGCTTTTCCGTGCTTACCTGCAGCGCCTTCTCCTTCTACCC
TCCGGAACTGCAACTGCGGTTCCTGCGGAATGGGATGGCCGCTGGCACCGGACAGGGCGACTTCGGCCCC
AACAGTGACGGCTCCTTCCACGCCTCGTCGTCACTAACAGTCAAAAGTGGCGATGAGCACCACTACTGCT
GCATCGTGCAGCACGCGGGGCTGGCGCAGCCCCTCAGGGTGGAGCTGGGTGAGGCCCCGCCCGGTGGTGA
TGCTCCTGGTTTCCCGTTGCCTTGTCTCACTGCTGCGCCGGTCCTTCCTGAGTCTGACCTTCCTCCCCGC
TGCTGCCATCTCCTTGAATCTGACTGCCTTGTGCCTCGCGCCTTTCAGTGCCCCCAAAGCCTGATGCCTT
GTCCTTCCCAAGGCCGACTGCCTTCCGTCCTGCTGCTTCTGGCCTCACTGAGTCTGAAGAGCTGTTAACC
ACCATGGCCAGTCCTCCCTGAGTCTGACCGTCTTCCATCCTGCTGCTGCTGCGGCTGCAGGTCTTCCTGG
AATCTGACCATTCGTTGTCTGCTATGCCCGTCCTCACCAAGACTGACCACTTGCTGCCTTGCTACTGCTG
GGGCCCATGAGGCTGACTTCCCACTGCTCTGCCTGCCTCTCCCCGCTGCGCCGGGACAGCCCCACCCTGC
CGCTGCTGGTCCATTGCCAGTGTGACCACGGCGGCCGCTCGTGCTGTGGCTGGTTCTTACATCCAGCCTG
GGGGCACCCTGCCGAGATCGCCCGCCTGGCCTTGCCTCTGTCCATCAGACACTTGGTGCTGGGATCTCCA
AGGCTGGGAGGGACTGGGACCCCCCACTGCTGTGTCCTGACTGGGTGGGGGTGGACGGGCTGCTCCACAT
CTCACAGCGTTCTCTGGCTGCAGAAACTCCAGCCAAGTCCTCGGTGCTCGTGGTGGGAATCGTCATCGGT
GTCTTGCTACTCACGGCAGCGGCTGTAGGAGGAGCTCTGTTGTGGAGAAGGATGAGGAGTGGGCTGCCAG
GTGTGGGCAGCGGGAGGAAGAGCCTTGGAGAGAGGGACAGAGACCCCAAGAGAGGGGCACACAGACCTGG
GAGGAGAGACCTGGTGTGGGGACAGACCCAAAGAGAGGAGGACAGAGACCAGAGAGAAGTGGAGACAGAA
ACCCAGAGACGGGGGAACAGAGGCACAGAGAGAGGGGACAGAGGAAGGGGGAGACAGAGACCCCGAGGAG
GGAGGCAAAGATGTAGAAAGAGGGGGGATGGAAAATTGGGAGAAGGGGAGACAGGCCCAGAAGGAAGGGG
TTAGAGACTGAGGGAGTGTGTGTGAGACACACACAGAAATGGGGGATGCCAGTCAGACCCAGAGCACCTC
AGAGATTCTGATGACCTCCCCCTCTCTCTCCACAGCCCCTTGGATCTCCCTCCGTGGAGATGACACCGGG
TCCCTCCTGCCCACCCCGGGGGAGGCCCAGGATGCTGATTCGAAGGATATAAATGTGATCCCAGCCACTG
CCTGACCATCTGCCATTCCGACTGCTAAAAGCGAATGTAGTCAGGCCCCTTTCATGCTGTGAGACCTCCT
GGAACACTGGCATCTCTGAGCCTCCAGAAGGGGTCCTGGGCCCTGTTGTCCTCCCTCTGGAGCCCCGTCC
TGTGGTCTGCCTCAGTTTCCCCTCCTAATACATATGGCTCTTTTCCACCTCGATAATATAACACGAGTTT
GGGCCCGAATCAGTGTGTTCTCATCATTTTTCAGGCAGGGGAGGTAAGGGAATAAATCAGGGGACTGAAT
GGCCGCTGAGGCTCAGATCTCTCCTACAGGTAA</dna_sequence>
        <protein_sequence>>gi|383873191|ref|NP_001244449.1| Fc fragment of IgG, receptor, transporter, alpha precursor [Macaca mulatta]
MRVPRPQPWALGLLLFLLPGSLGAESHLSLLYHLTAVSSPAPGTPAFWVSGWLGPQQYLSYDSLRGQAEP
CGAWVWENQVSWYWEKETTDLRIKEKLFLEAFKALGGKGPYTLQGLLGCELSPDNTSVPTAKFALNGEEF
MNFDLKQGTWGGDWPEALAISQRWQQQDKAANKELTFLLFSCPHRLREHLERGRGNLEWKEPPSMRLKAR
PGNPGFSVLTCSAFSFYPPELQLRFLRNGMAAGTGQGDFGPNSDGSFHASSSLTVKSGDEHHYCCIVQHA
GLAQPLRVELETPAKSSVLVVGIVIGVLLLTAAAVGGALLWRRMRSGLPAPWISLRGDDTGSLLPTPGEA
QDADSKDINVIPATA</protein_sequence>
        <phi_function>Vaximmutor</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1193">
        <gene_name>IL4</gene_name>
        <strain>Macaca mulatta</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>574281</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>74136371</ncbi_protein_id>
        <gene_locus_tag>EGK_16838</gene_locus_tag>
        <gene_refseq>CM001258</gene_refseq>
        <protein_refseq>NP_001028076</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>9544</taxonomy_id>
        <chromosome>6</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>129082063</gene_start>
        <gene_end>129090398</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>interleukin 4</protein_name>
        <protein_pi>9.44</protein_pi>
        <protein_weight>17265.73</protein_weight>
        <protein_length>153</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|109157119:129082063-129090398 Macaca mulatta chromosome 6, Mmul_051212, whole genome shotgun sequence
AATGGGTCTCACCTCCCAACTGCTTCCCCCTCTGTTCTTCCTGCTAGCATGTGCCGGCAACTTTGCCCAC
GGACACAACTGCCATATCGCCTTACGGGAGATCATCGAAACTCTGAACAGCCTCACAGAGCAGAAGGTGA
GTACCTATCTGGCACCATCTCTCCAGATGTTCTGGTGATGCTGTCAGTATTTCTAGGCCATGAAAACGTT
AACAGTTGCTAGAGAAGTTGGAACTGGTGGTTGGTGGCAGCCCGGGGCACACAGCCAGGCTTCCCCTGTC
ACTCTTTTTTCTGAGGGTTTGTAGGAAGTTTCCTCAGTTGGAGGGAGTGAGAGATGCTCATCAAGGACTG
CTCTGTCCAGTTGGAGGTTAACTCTGTCTCTTGCTCTCTCATTTCTGCCTGGACCAAGACTCTGTGCACC
AAGTTGACCATAACGGACATCCTTGCTGCCTCCAAGGTAAGAAGCCGTCCCACGGTCTGTTTTAGCACAT
GGGGAGATCCATCCCCAAGTGTCTGAATAAGAAACTTGTCTAATGGAAAACAAGCGGGCCCAAATTAACT
CTAAGGTGTTAGATGTTTTCAAAGAACGAGAAGTCTGATTTTTACTCTTAAGTGTGTTTTGGTCTTTCTG
GTTTCACTTGATTTAGATGTGTAATAGAAAGCTTACATGCTATAGTCCTGACTCAGATCCTGGTCAAAGA
AAAGCCCTCTTGGGTTTTACTTAGCTTTGGCATAGTGCCTGGAACGTAGGAGGCACTCAATAAATGCCTG
TTGAATGGGAGAATTTTTCTGGCCCATACATTTCTGAAAAACCAAATACTCTCACAGAAACAGATATTGA
GATGACAGGTTGAGGGAGCTTTCATTTTGTCTAAGAGACTTCCTATGGCAACAGAAAAGGTATCACCAGA
GCCCCTCCTCTTCCACAGCCTGGCCACCTAACAGCCCTCTGGGTTCCAGGGCTGGCGGTCCAGGGCTCCT
CAGCTTGCTCTGGCGGGTCGAATTCCCGTCCAGCTCGGTCCGGAACCATCCTGCTGGGCAGCGTCCAGCA
CATCCCTGCTTCCGGTTGCCTGGGCACCTCGCCTCTCTGCCTCCTGTGCTGCCTCACCCCCACCCCTCTA
TCTGTAGTGGGAGGAGATAGATTTGACAGCTGATAGTGCATTTTCTCTGACAAACACATGACTACAGCCG
TATCAATAGTTTTGTGCATTTCAGTTCCTGTTTTCATGGAAACACACAGCTGAGAATGAAAGCCCCAAAG
CCTCAATTTCACAGTGGTCTCCTAACTACTGCTTTCCATGCGAACTAGGGGGATGATTTGGCCAGCAGTG
AAGCCCTGTGTGTTGGGCAGGGTCACGCCCTGGCACCCAGGCCATAGAACAGGGCCCATCCTGCTTCATG
AGGGAAACTGCTCTTCGGGCCTTTATCTGGACTATCTCATTCATTAAACGTTATCCCAGGAGTTCAATAC
AGGATGAGATTCCTGAAGGGTAAATCCACACTTTGTTTTTTTTTTCTTTTGAGATAGGGTCTTGCTCTGT
CACCCAGGCTAGAGTGCAGTGGTGCGATTTCAGCTCACAGCAGCCTCCACCTCCCAGGCTCAAGCTAACC
TCCCACCTCAGCCTCCCAAGTAACTGGGATGACAGGTCTGCGCCACCACGCCTGGCTAACTTTTGTATTT
TTGTTGTAAAGATGGGGTCTTGCCATTTCATTTTGCCCAGGCTTGTCTTGAACTTCTGAGCTCAAGCAAT
CCATCCACCTCGGCCTCCCAAAGTGCTGGGATTAGCCACTGCACCTGGACAACAGTTTGTGTGTGTGTGT
GTGTGTGTGTGTGTGTGTATACACAAAATTTCTAAGTCCTTCCAACCGAGATGGCTCCTACTAGAAGCCA
AGAGTCCACCGGGTTGAGCACTGGGTCTCTGGAGGCCTGTGGCACTGCTGAGAAGGCTCTAACAAAGCCA
AGGGAAGGGCCACCTCACTAGAAGTCAGGCCTGGAGGAAGGGTGAGGGTTGAGGGCCTGGAGGTGAGACT
GCCTATGGTTTTAGACCCCGCTCTGCCACTGACAGCTGTGTGGCTGGCCTTCGGCACATCTTCACACCTC
TCTGCACCTCAGTTTCCACGTGTGAAGATACGAAAGTGATTCTGAAGGTGATTGCAAGGTTGATTGGAAT
CCAGTTCTTGAGTTAGTGGAAAGGGTTATTGTGAGATGATATAACCCTGATTAAAAGCAAGGACACGTTG
CAGAGAAGCGATGATTCTAAGAAGGAGGTGCCCAGGTTGGAAAGGATCAAACCCTCCAGGATGCTGAGCC
TGGGGCTATCCATCTGGGCTGTTTCTGGAAGACCTCCAGGCGCAGGCGAGGACACCACTGCCCTCCCGTC
CTTAACTCCCCTCTTCACTCAGTCCTCACTCACCTCCCTCTCACACACACAGACATCTCCTAGAACAATC
CCCACTGCCTGCCTTTACTCTTACCTGTCTCATTCGCCTTCCCCGAACTTCATCCTCCTGGAGTTCTCAA
TCTCACTCTTCTACTCTTTTCTTCCCCTTGAAGATTCAGCACTGCTTACTTACATGTTAAGATATTTCAG
AACAGTGAAATGTTGCTATTTTCAAAAACCTACAAAGGTGGTATGCAGAGGAAAAGGTACTTCTTTGTGT
TCCCAAAGAAAACATCTTTCCAAAATCCAGCCTATTGATTTTATTTCTTCGGGGGGAACAAGAATTTTAG
TATCTCTAAGTTGGGTAGCATTCTACTCTTGGCAGTTGCTGGAAAGAAGGCACTGATCTAGGTCCTGGGC
TTCATAGGTAACACCTGTTGGGGTGTCTATGAAGTCAAGGCTGTCTGAGGAACAGCAAAGTGGGAAGAAG
CAAGCTGGCTGGTCGATGAAGGGTTTCTTGGGTGGACAAGTAGATGGAGCTATTTCCTACTTACCAAAGA
GAGCTAAAGTTCATAATTCTACAGAGAGTTCCATAATGAACCTCAAATATCTCTGTTTTTTGAAGGAGTT
TCTCATATAGAGCACTAGCTGACTACCCTGGGCAGGATGGGAGATAATGAATGCAGTGCCAGTCGGGCTG
GATTTGTATGGTCCTCAGTGAGGCTGGTCAAGAACCAAGTCAGAACTCTCACAGAGTCACTGCCACAGAA
GAAATCTCCTAAGTGGCTGTTTCCTGACATTCCCGGGAGGGACAGACCTCCTTCTCAGTCACTCCCTAAG
CAGTTCTGAACGGTGAGGTCAGCCAGGCTGTCAAAGTGCACTCCCTGAGCCACTGGCAGACACACTCAGC
AGCCGGAGCTAGACAGGCAGGTAGAAGGAGTCCAGGGTCACAGCAGGGATGGAGTGTCGCCCCCTCGCTG
CGATACCAGAGCAACTAAAACGTAAAGGCCGCACTAAAGCTGCCCTTAGGATGTATTCTTTTAAAGTTTT
TCCATTTAATGCAGACTCTTTTCAATTCTTATTTTATCCTTGTTTCCTTTAGAAAGTCCTTTGAAAAATA
TCTTTAGAGGATTTTTTCCTATACTATGTGGCCATATATGGGTCAAAATTAAGTTTAATTTCCAGGGTCC
AAGCCAGCATTTCAGAAAAATCTCACCAAGGTTTGTGGGAAAAGAAGCAAAGGCTTTTTGGCCTTCTTGA
AGCTCACTGTTCCCTCTGCAGCAGCATGCATGTCTGCCCACCTCCAGACACTCAGGTAGCATGTGCTGCC
CCCCACCAGCCCCTGTGTCCCCTCCACCTCGACTCGCCCACAAAGCACAGAGAGGTCTGTTTCTTGGCTC
CAAGAGCCCAAAAATACTGACACACTCTTGTATTTCCAACTAGAATCAGGAACCAGGAGTGACTCTCAGT
CAGTTCATTAAGTAAATGTCTTTCCAACCGCTCTGCCCATGGGATGTCACGCCCCACAGAGGAAAGGGGA
AGCTTCCGTAGCCTGGGATTCTGGTGCCTCAATCTGGGTCTAGATCTTCCTGAAAAAAAAACGTTAAAAT
ATGAACTGCATTCCTAGAATGTAGCCTATATAAATAAGAGATGAACACAAAGATTTATATAGTTTACTCA
CTGCCACTTATTTACAGAAAGAGAAAGCTGCTGTAAATAAGGCAAATTACAATTGTAAAGGGGCCTGACA
AATGACAGCACCACTATGCAATACGTTTCTATGCAGCTCTCAAACCCATGTTCTCAAATACCACCGAAGG
GCTTAGGAAATGCTTATAGTATATGCAAAGGGTAAAAAAGTTACAAAACAGTATCAACAGTTGATCCCTA
TTTTAAAAAGTGTTTTTTAAAGTGTGATGATATTTACCAAAATATTAACAGCAGTAGTTACCTCTGGCTG
ATGGGATGAGTGAATGTACTTTTGTTGAATATATAATTACCTTTATAGTAAATACACGTTACCTTGATCA
TCAGAAAAAAAAATGTAACCGTAAGAACTTGAAAGCTGCTTGGACAGTGCTGCTGATAGAAATCCCTGAG
GATCTTGTCACTGTTCTGATTCAGAGGGTCTGGGTGGGGCAGGGGTGGTCTGAGATTCTGTATTCTAAGA
AGCTCCCAGTGATGTCCATGATTCTGGTCATGGACCACACTTTTGAGTAGCAAGGGACCAGAGCATGTCG
GGGGAGAGGCTGGGGATAGCTTTATCTCAACTGGATAAAGGAACTAGGCTCAAGCTAAGAACCCTCTCCA
AGTTCTGCATCTTTGTTCTTCAGTGAAAAATGAGAGGACAGACCAGTTCAGACCGAGACAAAATCCCTCT
CCTGGGTTCCCAATGACTTGTCTCCCTGTGTGTCCATTCCCTTCTCTAAGGTTAAGGGCCCCAGGAAGAG
CCATGTGGCCAGACCCTCACAGTTGCCAGCATTTCAGGGAGATTCTCACTCTGCACCATTTGGGGCCAAA
AGGCCCCTTACAGAAACTCTGCCCAACGCTCAGCTCAATGGCACCTGCTCCCAGAGCCTCCCCTGATCTC
CCAGGACACCTTTCCCCAATCTGTACACTTATCTCTTGCTGCCTGGGGTAATGTCTTAGCTCCTCACTTG
GACCATGTGCTGCTCTCCTCTCCCATGGGGAGGACCAAACGGATAGTGCTGCCCAAAGCAGCAGAGTCCA
GGCCAAAGGATGTGCCCTCATTTATTCAACAGGCATGCAGGATTTCCAGGGAAAGCTGGATTTTAAAACC
TTTGGGAACGAGAGCAGAACCTGACTGAGAGCTCATGTGGGCACTGTCCATAGCAGAATAGCTCATGGGG
TATAGAGATACGGACGCGGAACGTGGGCTGTAGCGATAGATAGTCCTGCATTCTAGTCCCCACTGTGCCC
TTTCCTTGCGGGGTGGCTTTATTCAGGTACCCTTTCAGCAAAATCCTCCAAGAGAAAAGAAACTGGGGGG
TTCTGGGGAGAAGGCTGCTGCGTTTGCAATTGGGAGAGGTTGTTGACAGAGGTTTGTGTCTGTGGCAAGC
AGCCTTCCTTCAGTGGAATACTTGAAGACAGGTCTGTAGTTGAGCAAACTCACCTCCATTTGTCCCTCTG
GAAAGAAGAAATCAAGAGGAAAAAATCTCTTTCCCATCCTCCAAATGGAGCTGGCACATGGCTATCTATG
GCATTTGTCTTTCCAGAACACAACTGAGAAGGAAACCTTCTGCAGGGCTGCGACTGTGCTCCGGCAGTTC
TACAGCCACCATGAGAAGGACACTCGCTGCCTGGGTGCGACTGCACAGCAGTTTCACAGGCACAAGCAGC
TGATCCGATTCCTGAAACGGCTCGACAGGAACCTCTGGGGCCTGGCGGGCTTGGTAAGCTGCACTGTATT
CCTAGCAAGCTGGCAGCATGGCTCCTGGTGGACAGCAGCCTCACTTCTAAACACTCCTCCTTAGGAGCTG
CAGCACCCTTGGTCAACCCATTCATTCATTCACTCATTCACTAAGTATTTGTTGAAGTTCCGTAAGTGCT
GGGTGCGGTTCTAGGTGCTGAGGACGTGTCACTAAAGACACGCAGGCCAAGTCCCTGTTCTCGTGGGATG
TTCTAGTGGGAGAGTCAGAAAAACAAACATGTAAAATGATGCCCAGTAGTGATACGTGCTACAAAGAAAA
ACATAGGAATAAAGAATGTAAGGGTCATGGGGGAGGGGGCTGACTTAGGAGCTGGTGACATTATCTGAGC
AGATATTTGAATTAAGTGAGGGAGCAGGCCACATGACTAACTGGGGAGAGACCATTCCAGGCAGAAGGAG
GAGCTATGCAAAGGCCTTAGGATGGAAATGAACTTCCTGTATTTGAAGACCAGTAGGAAGGCCAGTGTGG
CTGGATCACAGTGAGTGAGGGGGAGTTTCTAGGACAGCAGATCACACAAGGCCTTGAGATTCCACCACGA
GTATGGCAGGGAACACCTGCAGAGCTCTGGGCAGGGCAAAGACTGTACGATCTGATTTACGTGATTTAAA
AGGGTCAGTCTGGCTACTGTGTGGTAAATAGGCTGAAAGGGGGAGGCATAGAAGCAAGATGGCCTGTTGG
GAGGCAGTAAACCAGGCTAGAGATGATGGTGGCATGGACAGGATGGGAACAGTGGATAGATTTGGGATAT
GACTAAAAATAAAACCAGAAAGATTTGCTGACAGATCAGTTGTAAGGGGTAAGATACAGGGGAGGAAAAG
ATGACCTCTTCGTTCCTGCCTAAACCCGTCTGGCGATGGTTGGTACCGTTTATAGAGCGATGGAAGACTG
GGGGCAAGGCAGGGCTGGAGGTTAAGCAGAAGATCAAGAGTTCAATTTTGTACGTTGTACATGTAAGGTG
GCTGTTGGACAGCCAAGTGAAGATGTTGAGAAGATGGTTAGAAGAGTCTGGAACTTAGAGGAGAGGTCAG
AACTTGCAGTACAAAAAGGAGAGTCCTTAGATAGATGCTATTGAAAGTCTGAATGACAGAAAGGGAGAGA
TCAAAGGACTGAGCCTGAGATCAACACATGGAGGTCAGGAGAGGAGGATCCAGTAAAGGCGCCTGAGACT
CCTCAGACCAGTGAGGCAGGAGAACACTGGAGAGTGGGCGGTATCCCAGGAGGCCAGTGAGGACACTCAC
GGAGGGAGGGTCGACTGTTTCAAATGTACTGAAAGGTCAGGTCAGGTAAGGACTGAGAAAGGCCCCTGGG
TTTGACTGATGGAGGTCATGGGTGAGGCTGATGTAAATGGAGAAGCAGGAAGGAAAGTCCAGCTGGAGTG
GGCTCACCGAGGATGGGGCGGTGAGAGAAGCCAAAGAAGGAACAGTGAGGGCAGAACACTCTTTGAAGGT
GTTTAGCTATAAGGCTGCAGAGAAACTGAACCATGGCTGCAGGGCGGTTATGGAGTGAGGGAAGCTCTTT
TAAGGTGGGGTGTATACCCAGCATGCTAATGCACCTGGGGGAACGGTCTGGTGGAGTAGGGAGAACTGAA
GAGAGGAGAAGGAGGAGGAATCATTAGAGGGCAGAAGTCCTTGTGGCCCAGAGTGGGTGTTATCTAATAT
CGAGTGGAGGAATTAATTGGCTTTAGAAGAGAACAAGGACATGTATCCCTTCTTTGGGCCTATCACCTTG
TAGACAATGGGATAGGTCATGGGATAGGAACTTGGCACAACACATGTTCTCTTTTAATTCTCTCCATTAT
CTTATGAAGCAGGCAAGTAGGCAAACAATTGTCCCGACTTTAAAAATAAACTGAAGCTTTTATAAATTAA
GTAGTACGTTCTCAGCAATACAATTAATAAATGGTAGAGCTGAGATTCAAACTGAAGCAGTGGCCTGGGG
GTAGCATCTGGAACCCTTCCCACCTTTAGGGCTGCTGTGCTGCAGTGCTGCTGTTTAATGACAGGAGGGC
CACATGACTGAATCTCTCTCAGCAGTCCAGGCAGCCATGCAGAAGGCCCAGTAGAGCACGGGCAGGTCTG
AGCCAGCACCTTCAAGTTCTACCCTCTGAGCAAGCACCTAGCTGTGACACACCTCTCCAGAGACTGCACT
CCCCGCCGCCCTGCCCACCGCAAAAGCAGATAGGTAATGGTATACAGTAACCATTTCTAGAAGTGTAAGT
AGTATGCACCCAAAACAGGCAACACCTGCTGGCCTAGTGATAGAGACGACTCCCAGTCAGGCTAGACTGG
AGGCCTTGGTTTGGTAAGTGTTCAGGTGGCAAGTACCAGAGTAGGCTTGATCAAGTAGACAGGCAGGCAA
GACAAATGCTTACCAATGCAAGCTAATTAAATGCTTCTTTTGTAGAACTCCTGTCCTGTGAAGGAAGCCA
GCCAGAGTACGTTGGAAGACTTCTTGGAAAGGCTAAAGACGATCATGAAAGAGAAATATTCAAAGTGTCG
GAGCTG</dna_sequence>
        <protein_sequence>>gi|74136371|ref|NP_001028076.1| interleukin-4 precursor [Macaca mulatta]
MGLTSQLLPPLFFLLACAGNFAHGHNCHIALREIIETLNSLTEQKTLCTKLTITDILAASKNTTEKETFC
RAATVLRQFYSHHEKDTRCLGATAQQFHRHKQLIRFLKRLDRNLWGLAGLNSCPVKEASQSTLEDFLERL
KTIMKEKYSKCRS</protein_sequence>
        <phi_function>Vaximmutor</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene707">
        <gene_name>Nef</gene_name>
        <strain>Human immunodeficiency virus 1</strain>
        <vo_id>VO_0011261</vo_id>
        <ncbi_gene_id>156110</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>28872818</ncbi_protein_id>
        <gene_locus_tag>HIV1gp9</gene_locus_tag>
        <gene_refseq>AF033819</gene_refseq>
        <protein_refseq>NP_057857</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>11676</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>8342</gene_start>
        <gene_end>8962</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>Nef</protein_name>
        <protein_pi>6.42</protein_pi>
        <protein_weight>22179.3</protein_weight>
        <protein_length>206</protein_length>
        <protein_note>This particular nucleotide sequence has a premature stop codon in place of a well-conserved tryptophan codon at position 8712-8714 that truncates the HIV1 Nef protein sequence to a 123 amino acids-long N-terminal portion (not shown).</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_001802.1:8342-8962 Human immunodeficiency virus 1, complete genome
GATGGGTGGCAAGTGGTCAAAAAGTAGTGTGATTGGATGGCCTACTGTAAGGGAAAGAATGAGACGAGCT
GAGCCAGCAGCAGATAGGGTGGGAGCAGCATCTCGAGACCTGGAAAAACATGGAGCAATCACAAGTAGCA
ATACAGCAGCTACCAATGCTGCTTGTGCCTGGCTAGAAGCACAAGAGGAGGAGGAGGTGGGTTTTCCAGT
CACACCTCAGGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAA
AAGGGGGGACTGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATATCCTTGATCTGTGGATCTACCACA
CACAAGGCTACTTCCCTGATTAGCAGAACTACACACCAGGGCCAGGGGTCAGATATCCACTGACCTTTGG
ATGGTGCTACAAGCTAGTACCAGTTGAGCCAGATAAGATAGAAGAGGCCAATAAAGGAGAGAACACCAGC
TTGTTACACCCTGTGAGCCTGCATGGGATGGATGACCCGGAGAGAGAAGTGTTAGAGTGGAGGTTTGACA
GCCGCCTAGCATTTCATCACGTGGCCCGAGAGCTGCATCCGGAGTACTTCAAGAACTGCTG

</dna_sequence>
        <protein_sequence>>NP_057857.2 Nef [Human immunodeficiency virus 1]
MGGKWSKSSVIGWPTVRERMRRAEPAADRVGAASRDLEKHGAITSSNTAATNAACAWLEAQEEEEVGFPV
TPQVPLRPMTYKAAVDLSHFLKEKGGLEGLIHSQRRQDILDLWIYHTQGYFPDWQNYTPGPGVRYPLTFG
WCYKLVPVEPDKIEEANKGENTSLLHPVSLHGMDDPEREVLEWRFDSRLAFHHVARELHPEYFKNC

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Study compared the handling of overlapping 24-mer peptides from HIV Nef either mixed or covalently linked in tandem in one protein.  With adjuvant, overlapping peptides were capable of protecting Balb/c mice against lethal viral challenge with 3 × 108 plaque forming units of vv-nef, whereas the intact protein was less protective [Ref1296:Zhang et al., 2009].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1718">
        <gene_name>nef</gene_name>
        <strain>Human immunodeficiency virus 2</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>1845210</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:249884</xrefs>
        <taxonomy_id>11709</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>nef protein</protein_name>
        <protein_pi>6.88</protein_pi>
        <protein_weight>28422.79</protein_weight>
        <protein_length>319</protein_length>
        <protein_note>similar to HIV2BEN, GenBank Accession Number M30502, and to HIV2D194, GenBank Accession Number J04542</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAB47785.1 nef protein [Human immunodeficiency virus 2]
MGASGSKKLSKQSQGLRERLLRARGGGYVRQCSASGGESSQSQGGSGREQKSPSCEGQQYRQGDYMNTPW
RTPAMEGQKESYKQQNMDDVDSDDNDQVGVSVTSRVPLRPMTYKLAVDMSHFIKEKGGLEGMFYSRDRHR
ILDLYLEKEEGVIPDWQNYTHGPGVRYPMCFGWLWKLVPVNMSQEAEDDETNCLMHPAQTSRYDDIHGET
LVWRFNSMLAYEYKAFTLYPEEFGHKSGLPEKEWKAKLKARGIPYSE

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1246">
        <gene_name>Nef SIV</gene_name>
        <strain>Simian immunodeficiency virus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>1490008</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>9627209</ncbi_protein_id>
        <gene_locus_tag>SIVgp7</gene_locus_tag>
        <gene_refseq>M66437</gene_refseq>
        <protein_refseq>NP_054373</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>11723</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>8599</gene_start>
        <gene_end>9270</gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>nef protein</protein_name>
        <protein_pi>6.4</protein_pi>
        <protein_weight>24504.09</protein_weight>
        <protein_length>223</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|9627204:8599-9270 Simian immunodeficiency virus, complete genome
TATGGGCTCCAGCAACTCCAAGAGGCAGCAACAGGGCTTGCTCAAGCTCTGGCGAGGGCTGCGAGGGAAG
CCTGGGGCAGACTGGGTGCTATTGTCCGATCCGCTTATCGGGCAGTCATCAACAGTCCAAGAAGAGTGCG
GCAAGGCCTTGAAAAAGTCCTGGGGTAAAGGTAAAATGACTCCAGACGGCCGCCGCCTGCAAGAAGGAGA
CACCTTTGATGAGTGGGATGATGATGAAGAAGAAGTAGGCTTCCCTGTGCAACCTCGAGTCCCCTTAAGA
CAGATGACCTATAAATTAGCAGTGGACTTTTCCCACTTTTTAAAATCAAAGGGGGGACTGGATGGGATAT
ATTACTCTGAAAGAAGAGAAAAGATCCTGAATTTGTATGCCTTGAACGAGTGGGGAATAATAGATGATTG
GCAAGCTTACTCACCAGGCCCGGGGATAAGGTACCCGAGAGTCTTTGGCTTCTGCTTTAAGCTAGTCCCA
GTGGACCTGCATGAGGAGGCACGCAACTGTGAGAGACACTGTCTGATGCATCCAGCACAGATGGGGGAAG
ATCCTGATGGAATAGATCATGGAGAAGTCTTGGTCTGGAAGTTTGACCCGAAGTTGGCGGTGGAGTACCG
CCCGGACATGTTTAAGGACATGCACGAACATGCAAAGCGCTA</dna_sequence>
        <protein_sequence>>gi|9627209|ref|NP_054373.1| nef protein [Simian immunodeficiency virus]
MGSSNSKRQQQGLLKLWRGLRGKPGADWVLLSDPLIGQSSTVQEECGKALKKSWGKGKMTPDGRRLQEGD
TFDEWDDDEEEVGFPVQPRVPLRQMTYKLAVDFSHFLKSKGGLDGIYYSERREKILNLYALNEWGIIDDW
QAYSPGPGIRYPRVFGFCFKLVPVDLHEEARNCERHCLMHPAQMGEDPDGIDHGEVLVWKFDPKLAVEYR
PDMFKDMHEHAKR</protein_sequence>
        <phi_function>Other</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1271">
        <gene_name>pol</gene_name>
        <strain>Human immunodeficiency virus 1</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>7021456</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:278505
CDD:133149
CDD:238823
CDD:278506
CDD:284283
CDD:284281
CDD:278503
CDD:259998
CDD:280240
CDD:279057</xrefs>
        <taxonomy_id>11676</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>pol</protein_name>
        <protein_pi>7.77</protein_pi>
        <protein_weight>90126.73</protein_weight>
        <protein_length>918</protein_length>
        <protein_note>long-term nonprogressor</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAF35355.1 pol, partial [Human immunodeficiency virus 1]
FFREDLAFPQGKAREFPSEQTRAISPARRELQVWGRDNNSLSEAGANRQGTVSFSFPQITLWQRPLVAIK
IGGQLKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYDQVAIEICGHKAIGTVLIGPTPVNI
IGRNLLTQIGCTLNFPISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENP
YNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFR
KYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEI
GQHRIKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLN
WASQIYAGIKVKQLCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGQG
QWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKVAIESIVIWGKTPKFKLPIQKETWEAWWTEY
WQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTDRGRQKVVPLTDTTNQ
KTELQAIHLALQDSGLEVNIVTDSQYALGIIQAQPDKSESELVSQIIEQLIKKEKVYLAWVPAHKGIGGN
EQVDKLVSAGIRKVLFLDGIDKAQEEHEKYHSNWRAMAGDFNLPPVVAKEIVACCDKCQLKGEAMHGQVD
CSPGIWQLDCTHLEGKVILVAVHVASGYIEAEVIPAETGQETAYFLLKLAGRWPVKTIHTDNGSNFTSNT
VKAACW

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1710">
        <gene_name>pol</gene_name>
        <strain>Simian-Human immunodeficiency virus strain SHIV-89.6</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>2828038</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:133149
CDD:295487
CDD:278506
CDD:238185
CDD:284283
CDD:284281
CDD:278503
CDD:259998
CDD:280240
CDD:279057
CDD:278951</xrefs>
        <taxonomy_id>57667</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>pol</protein_name>
        <protein_pi>7.9</protein_pi>
        <protein_weight>113326.45</protein_weight>
        <protein_length>1139</protein_length>
        <protein_note>Retropepsins, pepsin-like aspartate proteases; cd05482</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAB99959.1 pol, partial [Simian-Human immunodeficiency virus]
LELWERGTLCKAMQSPKKTGMLEMWKNGPCYGQMPRQTGGFFRPWSMGKEAPQFPHGSSASGADANCSPR
GPSCGSAKELHAVGQAAERKAERKQREALQGGDRGFAAPQFSLWRRPVVTAHIEGQPVEVLLDTGADDSI
VTGIELGPHYTPKIVGGIGGFINTKEYKNVEIEVLGKRIKGTIMTGDTPINIFGRNLLTALGMSLNFPIA
KVEPVKVALKPGKDGPKLKQWPLSKEKIVALREICEKMEKDGQLEEAPPTNPYNTPTFAIKKKDKNKWRM
LIDFRELNRVTQDFTEVQLGIPHPAGLAKRKRITVLDIGDAYFSIPLDEEFRQYTAFTLPSVNNAEPGKR
YIYKVLPQGWKGSPAIFQYTMRHVLEPFRKANPDVTLVQYMDDILIASDRTDLEHDRVVLQSKELLNSIG
FSTPEEKFQKDPPFQWMGYELWPTKWKLQKIELPQRETWTVNDIQKLVGVLNWAAQIYPGIKTKHLCRLI
RGKMTLTEEVQWTEMAEAEYEENKIILSQEQEGCYYQEGKPLEATVIKSQDNQWSYKIHQEDKILKVGKF
AKIKNTHTNGVRLLAHVIQKIGKEAIVIWGQVPKFHLPVEKDVWEQWWTDYWQVTWIPEWDFISTPPLVR
LVFNLVKDPIEGEETYYTDGSCNKQSKEGKAGYITDRGKDKVKVLEQTTNQQAELEAFLMALTDSGPKAN
IIVDSQYVMGIITGCPTESESRLVNQIIEEMIKKSEIYVAWVPAHKGIGGNQEIDHLVSQGIRQVLFLEK
IEPAQEEHDKYHSNVKELVFKFGLPRIVARQIVDTCDKCHQKGEAIHGQANSDLGTWQMDCTHLEGKIII
VAVHVASGFIEAEVIPQETGRQTALFLLKLAGRWPITHLHTDNGANFASQEVKMVAWWAGIEHTFGVPYN
PQSQGVVEAMNHHLKNQIDRIREQANSVETIVLMAVHCMNFKRRGGIGDMTPAERLINMITTEQEIQFQQ
SKNSKFKNFRVYYREGRDQLWKGPGELLWKGEGAVILKVGTDIKVVPRRKAKIIKDYGGGKEVDSSSHME
DTGEAREVA

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1245">
        <gene_name>Pol SIV</gene_name>
        <strain>Simian immunodeficiency virus SIV-mnd 2</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>956107</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>27311168</ncbi_protein_id>
        <gene_locus_tag>Siv2gp2</gene_locus_tag>
        <gene_refseq>AF367411</gene_refseq>
        <protein_refseq>NP_758887</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>159122</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>2049</gene_start>
        <gene_end>5081</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>pol protein</protein_name>
        <protein_pi>7.91</protein_pi>
        <protein_weight>106929.88</protein_weight>
        <protein_length>1010</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|27311166:2049-5081 Simian immunodeficiency virus SIV-mnd 2, complete genome
ATTTTTTAGGGAATACCCCCTGGGGCAGTGGCAAACCCAGGAACTTCCCGGCGATGCCATTGACCCCAAC
GGCCCCTCCAATGCCAGGGATGGAAGACCCAGCAGAGAGAATGCTGTTAGATTACATGAAGAAAGGGCAA
CAGCAGAAAGCGGAAAGCAAACAGGAAAAGAAAGAGAGGGGTCCATACGAGGCAGCTTACAACTCCCTCA
GTTCTCTCTTTGGAACAGACCAACTACAGTAGTAGAGATAGAAGGGCAAAAAGTGGAGGCCTTACTGGAC
ACAGGAGCTGATGATACAGTAATCAAAGATCTAGATTTAAAAGGTAATTGGAAACCACAGATTATTGGAG
GAATTGGAGGATCAATCAATGTAAAACAGTTTTTCAATTGTAAAGTAACAATAGCAGGCAAAACTACACA
CGCTTCAGTCCTAGTGGGCCCCACACCTGTAAATATTGTAGGTAGAAATGTGCTGAAGAAATTAGGATGT
ACACTAAATTTTCCAGTTAGTAAAGTAGAAACAGTAAAGGTAACACTAAAACCAGGAACTGACGGACCTA
AAATAAAACAATGGCCATTGTCTAAGGAAAAGATTTTAGCCTTACAAGAAATATGTAGTCAAATGGAGAA
GGAAGGCCAGATCTCTAAGATAGGTCCAGAAAATCCTTACAACACACCGGTGTTTTGCATCAAAAAGAAA
GATGGAACCAGCTGGAGAAAATTGGTAGATTTTAGACAGTTAAACAAAGTAACTCAGGACTTCTTTGAGG
TGCAGTTGGGAATCCCACACCCTGGAGGTCTCAAACAATGTGAGCAAATTACAGTACTGGACATAGGGGA
TGCCTATTTCTCATGTCCTTTGGATGAGGACTTTAGAAAGTACACTGCATTCACCATTCCATCGGTGAAT
AATCAGGGCCCAGGAATCAGGTACCAGTATAATGTCCTACCACAGGGATGGAAGGGCTCCCCAGCCATTT
TCCAGGCAACAGCAGATAAAATCTTACAGCCCTTCAGAGAGAGACATCCAGATGTAGTGATCTATCAATA
TATGGATGATCTCTTTGTTGGGAGTGATAGAGTTGCCCCAGAACACAGCAGAATGATTCAAGAGTTAAGA
GACCACCTCTTGTTTTGGGGGCTCGAGACCCCAGACAAGAAGTTTCAAAAGGAACCACCCTTTGAGTGGA
TGGGATACATACTGCACCCTAAGAAATGGACAGTGCAGAAAGTACAGCTTCCAGAGAAAGAAGAATGGAC
AGTAAATGACATCCAAAAGTTGGTAGGGAAACTTAATTGGGCAAGTCAGATTTATTCCGGAATTAAAACA
AAAGAGCTCTGTAGACTAATTAGAGGGGCAAAACCCCTAGATGAAAAAGTAGAATGGACTAGAGAAGCAG
AATTAGAATATGAAGAAAACAAACTCATAGTGCAGGAGGAAGTGCATGGAGTATACTATCAACCAGAGAA
GCCTTTAATGGCAAAGGTTCAAAAATTGACACAAGGGCAATGGAGTTACCAAATAGAGCAGGAGGATAAT
AAGCCGCTGAAGGTAGGGAAATATGCCAGAACAAAGAATGCTCATACAAATGAGCTTAGAGTGCTTGCAG
GACTAGTACAGAAGATTGCAAAAGAAGCTTTAGTGATCTGGGGAAAACTCCCTAAGTTTTATCTGCCAAT
AGAAAGAGAAGTCTGGGACCAGTGGTGGCCAGAATATTGGCAAGCCACATGGATTCCCGAATGGGAATTT
GTATCCACTCCACACCTTATCGGGTTGTGGTATAACCTGTTGAGAGAACCTGTGCCAGGAGAAGATGTGT
ATTATGTGGATGGAGCAGCTAACAGAAACTCCAAAGAAGGGAAAGCAGGATATGTAACAGCTAGAAATAA
ATCCAGAGTAATAGCCCTAGAGAATACCACAAACCAAAAAGCAGAATTGGAGGCAATAAAAATGGCATTA
CAAGACTCAGGACCAAAAGTAAATATAGTGACAGATTCACAGTATGCTATGGGTATCCTATCGGCAGCAC
CCGACCAATCAGACAACCCCATAGTAAGAGAAATTATAGAACTCATGATCCACAAGGAAGCAGTATACCT
AGCTTGGGTACCAGCACACAAAGGCATAGGAGGGAATGAGCAAGTAGATAAACTAGTGAGCAGAGGAGTA
AGGCAAGTACTGTTTTTAGAAGGCATAGATAAAGCACAAGAAGAGCATGATAAATATCACAATAATTGGA
GGGCATTAGCACAAGACTTCTGTATACCAAACATAGTGGCAAAAGAAATAGTAGCCCAGTGTCCAAAGTG
TCAAACAAAAGGAGAGCCAATACATGGCCAGGTAGATACATCCCCAGGAACCTGGCAAATGGACTGCACA
CATATGGAAGGAAAAGTAATCATAGCAGCAGTCCATGTAGCAAGTAGGTATCTAGAAGCAGAAGTAATAC
CCACAGAAACAGGAAAAGAAACAGCACACTTCCTGTTAAAATTAGCAGGTAGATGGCCAGTAAAACATCT
ACACACAGATAATGGCCCTAATTTCACCAGTGAAAAAGTAGCCACAGTCTGTTGGTGGGCTCAAATAGAG
CACACTACAGGAATTCCCTACAATCCTCAGAGTCAAGGAGTAATAGAGGCAAAAAACCATCATCTCAAAC
AAATCATAGGGCAAGTTAGAGACCAAGCAGAGAAACTAGAAACAGCAGTTCAAATGGCAGTATTAATTCA
CAATTTTAAAAGAAAAGGGGGGATAGGGGAATACAGTCCAGGAGAAAGAATAGTAGACATTATAGCAACA
GACCTCCTAACAACTAAATTACAACACAATATTCAAAAAATTCAAAATTTTCGGGTTTATTACAGAGAAG
GAAGGGACCAACAGTGGAAAGGACCAGCAGAACTCATTTGGAAAGGAGAAGGAGCGGTGGTAATCAAAGA
GGGGACAGACTTGAAGGTAGTACCAAGGAGAAAAGCAAAAATCATCAGAGATTATGGAAAAACAGTGGAT
AGTGATCCCAACGTGGAAGCTTG</dna_sequence>
        <protein_sequence>>gi|27311168|ref|NP_758887.1| pol protein [Simian immunodeficiency virus SIV-mnd 2]
FFREYPLGQWQTQELPGDAIDPNGPSNARDGRPSRENAVRLHEERATAESGKQTGKEREGSIRGSLQLPQ
FSLWNRPTTVVEIEGQKVEALLDTGADDTVIKDLDLKGNWKPQIIGGIGGSINVKQFFNCKVTIAGKTTH
ASVLVGPTPVNIVGRNVLKKLGCTLNFPVSKVETVKVTLKPGTDGPKIKQWPLSKEKILALQEICSQMEK
EGQISKIGPENPYNTPVFCIKKKDGTSWRKLVDFRQLNKVTQDFFEVQLGIPHPGGLKQCEQITVLDIGD
AYFSCPLDEDFRKYTAFTIPSVNNQGPGIRYQYNVLPQGWKGSPAIFQATADKILQPFRERHPDVVIYQY
MDDLFVGSDRVAPEHSRMIQELRDHLLFWGLETPDKKFQKEPPFEWMGYILHPKKWTVQKVQLPEKEEWT
VNDIQKLVGKLNWASQIYSGIKTKELCRLIRGAKPLDEKVEWTREAELEYEENKLIVQEEVHGVYYQPEK
PLMAKVQKLTQGQWSYQIEQEDNKPLKVGKYARTKNAHTNELRVLAGLVQKIAKEALVIWGKLPKFYLPI
EREVWDQWWPEYWQATWIPEWEFVSTPHLIGLWYNLLREPVPGEDVYYVDGAANRNSKEGKAGYVTARNK
SRVIALENTTNQKAELEAIKMALQDSGPKVNIVTDSQYAMGILSAAPDQSDNPIVREIIELMIHKEAVYL
AWVPAHKGIGGNEQVDKLVSRGVRQVLFLEGIDKAQEEHDKYHNNWRALAQDFCIPNIVAKEIVAQCPKC
QTKGEPIHGQVDTSPGTWQMDCTHMEGKVIIAAVHVASRYLEAEVIPTETGKETAHFLLKLAGRWPVKHL
HTDNGPNFTSEKVATVCWWAQIEHTTGIPYNPQSQGVIEAKNHHLKQIIGQVRDQAEKLETAVQMAVLIH
NFKRKGGIGEYSPGERIVDIIATDLLTTKLQHNIQKIQNFRVYYREGRDQQWKGPAELIWKGEGAVVIKE
GTDLKVVPRRKAKIIRDYGKTVDSDPNVEA</protein_sequence>
        <phi_function>Other</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1713">
        <gene_name>rev</gene_name>
        <strain>Simian-Human immunodeficiency virus strain SHIV-89.6</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>2828043</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:278833</xrefs>
        <taxonomy_id>57667</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>rev</protein_name>
        <protein_pi>9.94</protein_pi>
        <protein_weight>12952.65</protein_weight>
        <protein_length>173</protein_length>
        <protein_note>REV protein (anti-repression trans-activator protein); pfam00424</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAB99964.1 rev [Simian-Human immunodeficiency virus]
MAGRSGDSDEELIRTVRLIKLLYQSNPPPSLEGTRQARRNRRRRWRERQRQIRSISERILGTYLGRSAEP
VPLQLPPLERLTLDCNEDCGTSGTQGVGSPQILVESPTVLESGTKE

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1263">
        <gene_name>rev from HIV 1</gene_name>
        <strain>Human immunodeficiency virus 1</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>155908</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>9629359</ncbi_protein_id>
        <gene_locus_tag>HIV1gp6</gene_locus_tag>
        <gene_refseq>AF033819</gene_refseq>
        <protein_refseq>NP_057854</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>11676</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>5515</gene_start>
        <gene_end>8198</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>Rev</protein_name>
        <protein_pi>9.36</protein_pi>
        <protein_weight>12578.23</protein_weight>
        <protein_length>116</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_001802.1:5515-8198 Human immunodeficiency virus 1, complete genome
TATGGCAGGAAGAAGCGGAGACAGCGACGAAGAGCTCATCAGAACAGTCAGACTCATCAAGCTTCTCTAT
CAAAGCAGTAAGTAGTACATGTAATGCAACCTATACCAATAGTAGCAATAGTAGCATTAGTAGTAGCAAT
AATAATAGCAATAGTTGTGTGGTCCATAGTAATCATAGAATATAGGAAAATATTAAGACAAAGAAAAATA
GACAGGTTAATTGATAGACTAATAGAAAGAGCAGAAGACAGTGGCAATGAGAGTGAAGGAGAAATATCAG
CACTTGTGGAGATGGGGGTGGAGATGGGGCACCATGCTCCTTGGGATGTTGATGATCTGTAGTGCTACAG
AAAAATTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAAGGAAGCAACCACCACTCTATTTTGTGC
ATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACACATGCCTGTGTACCCACAGAC
CCCAACCCACAAGAAGTAGTATTGGTAAATGTGACAGAAAATTTTAACATGTGGAAAAATGACATGGTAG
AACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAGCCATGTGTAAAATTAACCCCACT
CTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACCAATAGTAGTAGCGGGAGAATGATA
ATGGAGAAAGGAGAGATAAAAAACTGCTCTTTCAATATCAGCACAAGCATAAGAGGTAAGGTGCAGAAAG
AATATGCATTTTTTTATAAACTTGATATAATACCAATAGATAATGATACTACCAGCTATAAGTTGACAAG
TTGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCCTTTGAGCCAATTCCCATACATTATTGT
GCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACGTTCAATGGAACAGGACCATGTACAAATG
TCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTATCAACTCAACTGCTGTTAAATGGCAGTCT
AGCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCACGGACAATGCTAAAACCATAATAGTACAGCTG
AACACATCTGTAGAAATTAATTGTACAAGACCCAACAACAATACAAGAAAAAGAATCCGTATCCAGAGAG
GACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGAAATATGAGACAAGCACATTGTAACATTAGTAG
AGCAAAATGGAATAACACTTTAAAACAGATAGCTAGCAAATTAAGAGAACAATTTGGAAATAATAAAACA
ATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAAATTGTAACGCACAGTTTTAATTGTGGAGGGGAAT
TTTTCTACTGTAATTCAACACAACTGTTTAATAGTACTTGGTTTAATAGTACTTGGAGTACTGAAGGGTC
AAATAACACTGAAGGAAGTGACACAATCACCCTCCCATGCAGAATAAAACAAATTATAAACATGTGGCAG
AAAGTAGGAAAAGCAATGTATGCCCCTCCCATCAGTGGACAAATTAGATGTTCATCAAATATTACAGGGC
TGCTATTAACAAGAGATGGTGGTAATAGCAACAATGAGTCCGAGATCTTCAGACCTGGAGGAGGAGATAT
GAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCC
ACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGT
TCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCCTCAATGACGCTGACGGTACAGGCCAGACAATTATT
GTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTC
ACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGC
TCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAG
TAATAAATCTCTGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAATTAC
ACAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAGAATTATTGG
AATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGCTGTGGTATATAAAATTATT
CATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTTTTGCTGTACTTTCTATAGTGAATAGAGTT
AGGCAGGGATATTCACCATTATCGTTTCAGACCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAG
GAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCCATTCGATTAGTGAACGGATCCTTGGCACT
TATCTGGGACGATCTGCGGAGCCTGTGCCTCTTCAGCTACCACCGCTTGAGAGACTTACTCTTGATTGTA
ACGAGGATTGTGGAACTTCTGGGACGCAGGGGGTGGGAAGCCCTCAAATATTGGTGGAATCTCCTACAGT
ATTGGAGTCAGGAACTAAAGAATA

</dna_sequence>
        <protein_sequence>>NP_057854.1 Rev [Human immunodeficiency virus 1]
MAGRSGDSDEELIRTVRLIKLLYQSNPPPNPEGTRQARRNRRRRWRERQRQIHSISERILGTYLGRSAEP
VPLQLPPLERLTLDCNEDCGTSGTQGVGSPQILVESPTVLESGTKE

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1262">
        <gene_name>rev MN isolate</gene_name>
        <strain>Human immunodeficiency virus 1 MN</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>3511264</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:189539</xrefs>
        <taxonomy_id>11676</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>rev protein</protein_name>
        <protein_pi></protein_pi>
        <protein_weight></protein_weight>
        <protein_length>116</protein_length>
        <protein_note>neutralization phenotype variant molecular clone</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>gi|3511264|gb|AAC33786.1| rev protein [Human immunodeficiency virus 1]
MAGRNGDSDEELLKTVRLIKFLHQSNPPPSSEGTRQARRNRRRRWRERQRHIRSISAWILSNYLGRPAEP
VPPQLPPLERLTLDCSEDCGTSGTQGVGSPQILVESPTVLESGTKE</protein_sequence>
        <phi_function>Other</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene711">
        <gene_name>Tat</gene_name>
        <strain>Human immunodeficiency virus 1</strain>
        <vo_id>VO_0011262</vo_id>
        <ncbi_gene_id>155871</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>9629358</ncbi_protein_id>
        <gene_locus_tag>HIV1gp5</gene_locus_tag>
        <gene_refseq>AF033819</gene_refseq>
        <protein_refseq>NP_057853</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>11676</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>5376</gene_start>
        <gene_end>7969</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>Tat</protein_name>
        <protein_pi>10.43</protein_pi>
        <protein_weight>9638.3</protein_weight>
        <protein_length>86</protein_length>
        <protein_note>the length of Tat varies depending on virus strain or clade</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_001802.1:5376-7969 Human immunodeficiency virus 1, complete genome
AATGGAGCCAGTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGTCAGCCTAAAACTGCTTGTACC
AATTGCTATTGTAAAAAGTGTTGCTTTCATTGCCAAGTTTGTTTCATAACAAAAGCCTTAGGCATCTCCT
ATGGCAGGAAGAAGCGGAGACAGCGACGAAGAGCTCATCAGAACAGTCAGACTCATCAAGCTTCTCTATC
AAAGCAGTAAGTAGTACATGTAATGCAACCTATACCAATAGTAGCAATAGTAGCATTAGTAGTAGCAATA
ATAATAGCAATAGTTGTGTGGTCCATAGTAATCATAGAATATAGGAAAATATTAAGACAAAGAAAAATAG
ACAGGTTAATTGATAGACTAATAGAAAGAGCAGAAGACAGTGGCAATGAGAGTGAAGGAGAAATATCAGC
ACTTGTGGAGATGGGGGTGGAGATGGGGCACCATGCTCCTTGGGATGTTGATGATCTGTAGTGCTACAGA
AAAATTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAAGGAAGCAACCACCACTCTATTTTGTGCA
TCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACACATGCCTGTGTACCCACAGACC
CCAACCCACAAGAAGTAGTATTGGTAAATGTGACAGAAAATTTTAACATGTGGAAAAATGACATGGTAGA
ACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAGCCATGTGTAAAATTAACCCCACTC
TGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACCAATAGTAGTAGCGGGAGAATGATAA
TGGAGAAAGGAGAGATAAAAAACTGCTCTTTCAATATCAGCACAAGCATAAGAGGTAAGGTGCAGAAAGA
ATATGCATTTTTTTATAAACTTGATATAATACCAATAGATAATGATACTACCAGCTATAAGTTGACAAGT
TGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCCTTTGAGCCAATTCCCATACATTATTGTG
CCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACGTTCAATGGAACAGGACCATGTACAAATGT
CAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTATCAACTCAACTGCTGTTAAATGGCAGTCTA
GCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCACGGACAATGCTAAAACCATAATAGTACAGCTGA
ACACATCTGTAGAAATTAATTGTACAAGACCCAACAACAATACAAGAAAAAGAATCCGTATCCAGAGAGG
ACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGAAATATGAGACAAGCACATTGTAACATTAGTAGA
GCAAAATGGAATAACACTTTAAAACAGATAGCTAGCAAATTAAGAGAACAATTTGGAAATAATAAAACAA
TAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAAATTGTAACGCACAGTTTTAATTGTGGAGGGGAATT
TTTCTACTGTAATTCAACACAACTGTTTAATAGTACTTGGTTTAATAGTACTTGGAGTACTGAAGGGTCA
AATAACACTGAAGGAAGTGACACAATCACCCTCCCATGCAGAATAAAACAAATTATAAACATGTGGCAGA
AAGTAGGAAAAGCAATGTATGCCCCTCCCATCAGTGGACAAATTAGATGTTCATCAAATATTACAGGGCT
GCTATTAACAAGAGATGGTGGTAATAGCAACAATGAGTCCGAGATCTTCAGACCTGGAGGAGGAGATATG
AGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCCA
CCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTT
CTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCCTCAATGACGCTGACGGTACAGGCCAGACAATTATTG
TCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCA
CAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCT
CCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGT
AATAAATCTCTGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAATTACA
CAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAGAATTATTGGA
ATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGCTGTGGTATATAAAATTATTC
ATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTTTTGCTGTACTTTCTATAGTGAATAGAGTTA
GGCAGGGATATTCACCATTATCGTTTCAGACCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGG
AATA

</dna_sequence>
        <protein_sequence>>NP_057853.1 Tat [Human immunodeficiency virus 1]
MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRRAHQNSQTHQASLS
KQPTSQPRGDPTGPKE

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>HIV-1 DNA plasmids expressing Env, Gag and Tat, either alone or combined with the corresponding protein immunogens formulated in the MF59 adjuvant, resulted in protection against an experimental HIV-1 infection in C57Bl/6 mice [Ref1301:Bråve et al., 2007].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1712">
        <gene_name>tat</gene_name>
        <strain>Simian-Human immunodeficiency virus strain SHIV-89.6</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>2828042</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:278940</xrefs>
        <taxonomy_id>57667</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>tat</protein_name>
        <protein_pi>10.4</protein_pi>
        <protein_weight>11598.34</protein_weight>
        <protein_length>158</protein_length>
        <protein_note>Transactivating regulatory protein (Tat); pfam00539</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAB99963.1 tat [Simian-Human immunodeficiency virus]
MEPVDPRLEPWKHPGSKPKTACTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRRAHQNSQTHQASLS
KQPSSQPRGDPTGPKEQKKKVERETETDPVH

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1719">
        <gene_name>tat</gene_name>
        <strain>Human immunodeficiency virus 2</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>1845211</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:278940</xrefs>
        <taxonomy_id>11709</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>tat protein</protein_name>
        <protein_pi>9.61</protein_pi>
        <protein_weight>14481.48</protein_weight>
        <protein_length>190</protein_length>
        <protein_note>similar to HIV2BEN, GenBank Accession Number M30502, and to HIV2D194, GenBank Accession Number J04542</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAB47786.1 tat protein [Human immunodeficiency virus 2]
METPLKAPESSLKSYNEPSPCTSEWEVAAQELAKQGEELLAQLHRPLEACTNPCYCKKCSFHCQLCFLKK
GLGIWYVRKGGRRRTPKRTKTHPPSTPDKSISIQTGDSRPTKKQKETPETPVATTSGLGR

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1714">
        <gene_name>vif</gene_name>
        <strain>Simian-Human immunodeficiency virus strain SHIV-89.6</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>2828039</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:278957</xrefs>
        <taxonomy_id>57667</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>vif</protein_name>
        <protein_pi>10.5</protein_pi>
        <protein_weight>24244.15</protein_weight>
        <protein_length>273</protein_length>
        <protein_note>Retroviral Vif (Viral infectivity) protein; pfam00559</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAB99960.1 vif [Simian-Human immunodeficiency virus]
MEEEKRWIAVPTWRIPERLERWHSLIKYLKYKTKDLQKVCYVPHFKVGWAWWTCSRVIFPLQEGSHLEVQ
GYWHLTPEKGWLSTYAVRITWYSKNFWTDVTPNYADILLHSTYFPCFTAGEVRRAIRGEQLLSCCRFPRA
HKYQVPSLQYLALKVVSDVRSQGENPTWKQWRRDNRRGLRMAKQNSRGDKQRGGKPPTKGANFPGLAKVL
GILA

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1715">
        <gene_name>vpr</gene_name>
        <strain>Simian-Human immunodeficiency virus strain SHIV-89.6</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>2828041</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:278923</xrefs>
        <taxonomy_id>57667</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>vpr</protein_name>
        <protein_pi>5.91</protein_pi>
        <protein_weight>11514.23</protein_weight>
        <protein_length>158</protein_length>
        <protein_note>VPR/VPX protein; pfam00522</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAB99962.1 vpr [Simian-Human immunodeficiency virus]
MEERPPENEGPQREPWDEWVVEVLEELKEEALKHFDPRLLTALGNHIYNRHGDTLEGAGELIRILQRALF
MHFRGGCIHSRIGQPGGGNPLSAIPPSRSML

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1258">
        <gene_name>vpu</gene_name>
        <strain>Human immunodeficiency virus 1</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>155945</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>9629366</ncbi_protein_id>
        <gene_locus_tag>HIV1gp7</gene_locus_tag>
        <gene_refseq>AF033819</gene_refseq>
        <protein_refseq>NP_057855</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>11676</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>5607</gene_start>
        <gene_end>5855</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>Vpu</protein_name>
        <protein_pi>4.43</protein_pi>
        <protein_weight>8250.01</protein_weight>
        <protein_length>82</protein_length>
        <protein_note>Vpu and gp160 are translated from different reading frames of the same bicistronic mRNA</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|9629357:5607-5855 Human immunodeficiency virus 1, complete genome
AATGCAACCTATACCAATAGTAGCAATAGTAGCATTAGTAGTAGCAATAATAATAGCAATAGTTGTGTGG
TCCATAGTAATCATAGAATATAGGAAAATATTAAGACAAAGAAAAATAGACAGGTTAATTGATAGACTAA
TAGAAAGAGCAGAAGACAGTGGCAATGAGAGTGAAGGAGAAATATCAGCACTTGTGGAGATGGGGGTGGA
GATGGGGCACCATGCTCCTTGGGATGTTGATGATCTGTA</dna_sequence>
        <protein_sequence>>gi|9629366|ref|NP_057855.1| Vpu [Human immunodeficiency virus 1]
MQPIPIVAIVALVVAIIIAIVVWSIVIIEYRKILRQRKIDRLIDRLIERAEDSGNESEGEISALVEMGVE
MGHHAPWDVDDL</protein_sequence>
        <phi_function>Other</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1716">
        <gene_name>vpu</gene_name>
        <strain>Simian-Human immunodeficiency virus strain SHIV-89.6</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>2828044</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:109608</xrefs>
        <taxonomy_id>57667</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>vpu</protein_name>
        <protein_pi>4.6</protein_pi>
        <protein_weight>8647.38</protein_weight>
        <protein_length>138</protein_length>
        <protein_note>Vpu protein; pfam00558</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAB99965.1 vpu [Simian-Human immunodeficiency virus]
MQPIQIAIVALVVAIIIAIVVWSIVIIEYRKILRQRKIDRLIDRLIERAEDSGNESEGEISALVEMGVEM
GHHAPWDVDDL

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<reference reference_id="reference2196">
		<reference_name>Aggarwal et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Aggarwal P, Kumar S, Vajpayee M, Seth P</authors>
		<title>Adjuvant action of murine IL-2/Ig plasmid after intramuscular immunization with Indian HIV-1 subtype C recombinant env.gp 120 construct</title>
		<year>2005</year>
		<volume>18</volume>
		<issue>4</issue>
		<pages>649-656</pages>
		<journal_book_name>Viral immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2794">
		<reference_name>Ami et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ami Y, Izumi Y, Matsuo K, Someya K, Kanekiyo M, Horibata S, Yoshino N, Sakai K, Shinohara K, Matsumoto S, Yamada T, Yamazaki S, Yamamoto N, Honda M</authors>
		<title>Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity</title>
		<year>2005</year>
		<volume>79</volume>
		<issue>20</issue>
		<pages>12871-12879</pages>
		<journal_book_name>Journal of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2188">
		<reference_name>Ara et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ara Y, Saito T, Takagi T, Hagiwara E, Miyagi Y, Sugiyama M, Kawamoto S, Ishii N, Yoshida T, Hanashi D, Koshino T, Okada H, Okuda K</authors>
		<title>Zymosan enhances the immune response to DNA vaccine for human immunodeficiency virus type-1 through the activation of complement system</title>
		<year>2001</year>
		<volume>103</volume>
		<issue>1</issue>
		<pages>98-9105</pages>
		<journal_book_name>Immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference320">
		<reference_name>Ayyavoo et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ayyavoo V, Muthumani K, Kudchodkar S, Zhang D, Ramanathan P, Dayes NS, Kim JJ, Sin JI, Montaner LJ, Weiner DB</authors>
		<title>HIV-1 viral protein R compromises cellular immune function in vivo</title>
		<year>2002 Jan</year>
		<volume>14</volume>
		<issue>1</issue>
		<pages>13-22</pages>
		<journal_book_name>International immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2211">
		<reference_name>Bagley et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bagley KC, Shata MT, Onyabe DY, DeVico AL, Fouts TR, Lewis GK, Hone DM</authors>
		<title>Immunogenicity of DNA vaccines that direct the coincident expression of the 120 kDa glycoprotein of human immunodeficiency virus and the catalytic domain of cholera toxin</title>
		<year>2003</year>
		<volume>21</volume>
		<issue>23</issue>
		<pages>3335-3341</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2195">
		<reference_name>Barouch et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Barouch DH, Klasse PJ, Dufour J, Veazey RS, Moore JP</authors>
		<title>Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission</title>
		<year>2012</year>
		<volume>109</volume>
		<issue>22</issue>
		<pages>8694-8698</pages>
		<journal_book_name>Proceedings of the National Academy of Sciences of the United States of America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2062">
		<reference_name>Barrett et al., 1989</reference_name>
		<reference_type>journal</reference_type>
		<authors>Barrett N, Mitterer A, Mundt W, Eibl J, Eibl M, Gallo RC, Moss B, Dorner F</authors>
		<title>Large-scale production and purification of a vaccinia recombinant-derived HIV-1 gp160 and analysis of its immunogenicity</title>
		<year>1989</year>
		<volume>5</volume>
		<issue>2</issue>
		<pages>159-171</pages>
		<journal_book_name>AIDS research and human retroviruses</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3291">
		<reference_name>Benson et al., 1998</reference_name>
		<reference_type>journal</reference_type>
		<authors>Benson J, Chougnet C, Robert-Guroff M, Montefiori D, Markham P, Shearer G, Gallo RC, Cranage M, Paoletti E, Limbach K, Venzon D, Tartaglia J, Franchini G</authors>
		<title>Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure</title>
		<year>1998</year>
		<volume>72</volume>
		<issue>5</issue>
		<pages>4170-4182</pages>
		<journal_book_name>Journal of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference707">
		<reference_name>Bielinska et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bielinska AU, Janczak KW, Landers JJ, Markovitz DM, Montefiori DC, Baker JR Jr</authors>
		<title>Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates</title>
		<year>2008</year>
		<volume>24</volume>
		<issue>2</issue>
		<pages>271-281</pages>
		<journal_book_name>AIDS research and human retroviruses</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1890">
		<reference_name>Bomford et al., 1992</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bomford R, Stapleton M, Winsor S, McKnight A, Andronova T</authors>
		<title>The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants</title>
		<year>1992</year>
		<volume>8</volume>
		<issue>10</issue>
		<pages>1765-1771</pages>
		<journal_book_name>AIDS research and human retroviruses</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2237">
		<reference_name>Bower et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bower JF, Yang X, Sodroski J, Ross TM</authors>
		<title>Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d</title>
		<year>2004</year>
		<volume>78</volume>
		<issue>9</issue>
		<pages>4710-4719</pages>
		<journal_book_name>Journal of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2214">
		<reference_name>Boyer et al., 1997</reference_name>
		<reference_type>journal</reference_type>
		<authors>Boyer JD, Ugen KE, Wang B, Agadjanyan M, Gilbert L, Bagarazzi ML, Chattergoon M, Frost P, Javadian A, Williams WV, Refaeli Y, Ciccarelli RB, McCallus D, Coney L, Weiner DB</authors>
		<title>Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination</title>
		<year>1997</year>
		<volume>3</volume>
		<issue>5</issue>
		<pages>526-532</pages>
		<journal_book_name>Nature medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1301">
		<reference_name>Bråve et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bråve A, Hinkula J, Cafaro A, Eriksson LE, Srivastava IK, Magnani M, Ensoli B, Barnett SW, Wahren B, Rollman E</authors>
		<title>Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge</title>
		<year>2007</year>
		<volume>25</volume>
		<issue>39-40</issue>
		<pages>6882-6890</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2231">
		<reference_name>BrÃ¥ve et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>BrÃ¥ve A, Ljungberg K, Boberg A, Rollman E, Isaguliants M, Lundgren B, Blomberg P, Hinkula J, Wahren B</authors>
		<title>Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery</title>
		<year>2005</year>
		<volume>12</volume>
		<issue>6</issue>
		<pages>1197-1205</pages>
		<journal_book_name>Molecular therapy : the journal of the American Society of Gene Therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3082">
		<reference_name>Breton et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Breton M, Zhao C, Ouellette M, Tremblay MJ, Papadopoulou B</authors>
		<title>A recombinant non-pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection</title>
		<year>2007</year>
		<volume>88</volume>
		<issue>Pt 1</issue>
		<pages>217-225</pages>
		<journal_book_name>The Journal of general virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference225">
		<reference_name>Buchbinder et al., 1994</reference_name>
		<reference_type>journal</reference_type>
		<authors>Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD</authors>
		<title>Long-term HIV-1 infection without immunologic progression</title>
		<year>1994 Aug</year>
		<volume>8</volume>
		<issue>8</issue>
		<pages>1123-8</pages>
		<journal_book_name>AIDS (London, England)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2216">
		<reference_name>Calarota et al., 1998</reference_name>
		<reference_type>journal</reference_type>
		<authors>Calarota S, Bratt G, Nordlund S, Hinkula J, Leandersson AC, SandstrÃ¶m E, Wahren B</authors>
		<title>Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients</title>
		<year>1998</year>
		<volume>351</volume>
		<issue>9112</issue>
		<pages>1320-1325</pages>
		<journal_book_name>Lancet</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2207">
		<reference_name>Calarota et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Calarota SA, Dai A, Trocio JN, Weiner DB, Lori F, Lisziewicz J</authors>
		<title>IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine</title>
		<year>2008</year>
		<volume>26</volume>
		<issue>40</issue>
		<pages>5188-5195</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference588">
		<reference_name>Caley et al., 1999</reference_name>
		<reference_type>journal</reference_type>
		<authors>Caley IJ, Betts MR, Davis NL, Swanstrom R, Frelinger JA, Johnston RE</authors>
		<title>Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy</title>
		<year>1999 Aug 6</year>
		<volume>17</volume>
		<issue>23-24</issue>
		<pages>3124-35</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2239">
		<reference_name>Caputo et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Caputo A, Gavioli R, Altavilla G, Brocca-Cofano E, Boarini C, Betti M, Castaldello A, Lorenzini F, Micheletti F, Cafaro A, Sparnacci K, Laus M, Tondelli L, Ensoli B</authors>
		<title>Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat</title>
		<year>2003</year>
		<volume>21</volume>
		<issue>11-12</issue>
		<pages>1103-1111</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2225">
		<reference_name>Casimiro et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, Tang A, Chen M, Huang L, Harris V, Freed DC, Wilson KA, Dubey S, Zhu DM, Nawrocki D, Mach H, Troutman R, Isopi L, Williams D, Hurni W, Xu Z, Smith JG, Wang S, Liu X, Guan L, Long R, Trigona W, Heidecker GJ, Perry HC, Persaud N, Toner TJ, Su Q, Liang X, Youil R, Chastain M, Bett AJ, Volkin DB, Emini EA, Shiver JW</authors>
		<title>Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene</title>
		<year>2003</year>
		<volume>77</volume>
		<issue>11</issue>
		<pages>6305-6313</pages>
		<journal_book_name>Journal of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference236">
		<reference_name>Chan et al., 1997</reference_name>
		<reference_type>journal</reference_type>
		<authors>Chan DC, Fass D, Berger JM, Kim PS</authors>
		<title>Core structure of gp41 from the HIV envelope glycoprotein</title>
		<year>1997 Apr 18</year>
		<volume>89</volume>
		<issue>2</issue>
		<pages>263-73</pages>
		<journal_book_name>Cell</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference313">
		<reference_name>Chen et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Chen X, Rock MT, Hammonds J, Tartaglia J, Shintani A, Currier J, Slike B, Crowe JE Jr, Marovich M, Spearman P</authors>
		<title>Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses</title>
		<year>2005 May</year>
		<volume>79</volume>
		<issue>9</issue>
		<pages>5537-47</pages>
		<journal_book_name>Journal of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2240">
		<reference_name>Chin'ombe et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Chin'ombe N, Bourn WR, Williamson AL, Shephard EG</authors>
		<title>Oral vaccination with a recombinant Salmonella vaccine vector provokes systemic HIV-1 subtype C Gag-specific CD4+ Th1 and Th2 cell immune responses in mice</title>
		<year>2009</year>
		<volume>6</volume>
		<issue></issue>
		<pages>87</pages>
		<journal_book_name>Virology journal</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference237">
		<reference_name>Coakley et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Coakley E, Petropoulos CJ, Whitcomb JM</authors>
		<title>Assessing chemokine co-receptor usage in HIV</title>
		<year>2005 Feb</year>
		<volume>18</volume>
		<issue>1</issue>
		<pages>9-15</pages>
		<journal_book_name>Current opinion in infectious diseases</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference223">
		<reference_name>Coffin et al., 1986</reference_name>
		<reference_type>journal</reference_type>
		<authors>Coffin J, Haase A, Levy JA, Montagnier L, Oroszlan S, Teich N, Temin H, Toyoshima K, Varmus H, Vogt P</authors>
		<title>What to call the AIDS virus?</title>
		<year>1986 May 1-7</year>
		<volume>321</volume>
		<issue>6065</issue>
		<pages>10</pages>
		<journal_book_name>Nature</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2187">
		<reference_name>Cristillo et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Cristillo AD, Ferrari MG, Hudacik L, Lewis B, Galmin L, Bowen B, Thompson D, Petrovsky N, Markham P, Pal R</authors>
		<title>Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations</title>
		<year>2011</year>
		<volume>92</volume>
		<issue>Pt 1</issue>
		<pages>128-140</pages>
		<journal_book_name>The Journal of general virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2227">
		<reference_name>Dale et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Dale CJ, De Rose R, Stratov I, Chea S, Montefiori DC, Thomson S, Ramshaw IA, Coupar BE, Boyle DB, Law M, Kent SJ</authors>
		<title>Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus</title>
		<year>2004</year>
		<volume>78</volume>
		<issue>24</issue>
		<pages>13819-13828</pages>
		<journal_book_name>Journal of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference324">
		<reference_name>Davis et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Davis NL, West A, Reap E, MacDonald G, Collier M, Dryga S, Maughan M, Connell M, Walker C, McGrath K, Cecil C, Ping LH, Frelinger J, Olmsted R, Keith P, Swanstrom R, Williamson C, Johnson P, Montefiori D, Johnston RE</authors>
		<title>Alphavirus replicon particles as candidate HIV vaccines</title>
		<year>2002 Apr-May</year>
		<volume>53</volume>
		<issue>4-5</issue>
		<pages>209-11</pages>
		<journal_book_name>IUBMB life</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference238">
		<reference_name>Deng et al., 1996</reference_name>
		<reference_type>journal</reference_type>
		<authors>Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR</authors>
		<title>Identification of a major co-receptor for primary isolates of HIV-1</title>
		<year>1996 Jun 20</year>
		<volume>381</volume>
		<issue>6584</issue>
		<pages>661-6</pages>
		<journal_book_name>Nature</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2238">
		<reference_name>Denis-Mize et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Denis-Mize KS, Dupuis M, MacKichan ML, Singh M, Doe B, O'Hagan D, Ulmer JB, Donnelly JJ, McDonald DM, Ott G</authors>
		<title>Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells</title>
		<year>2000</year>
		<volume>7</volume>
		<issue>24</issue>
		<pages>2105-2112</pages>
		<journal_book_name>Gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2191">
		<reference_name>Duerr et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, Del Rio C, Casapia M, Santiago S, Gilbert P, Corey L, Robertson MN</authors>
		<title>Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study)</title>
		<year>2012</year>
		<volume>206</volume>
		<issue>2</issue>
		<pages>258-266</pages>
		<journal_book_name>The Journal of infectious diseases</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference314">
		<reference_name>Durier et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Durier C, Launay O, Meiffredy V, Saidi Y, Salmon D, Levy Y, Guillet JG, Pialoux G, Aboulker JP</authors>
		<title>Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults</title>
		<year>2006 Apr 24</year>
		<volume>20</volume>
		<issue>7</issue>
		<pages>1039-49</pages>
		<journal_book_name>AIDS (London, England)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2193">
		<reference_name>Flatz et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Flatz L, Cheng C, Wang L, Foulds KE, Ko SY, Kong WP, Roychoudhuri R, Shi W, Bao S, Todd JP, Asmal M, Shen L, Donaldson M, Schmidt SD, Gall JG, Pinschewer DD, Letvin NL, Rao S, Mascola JR, Roederer M, Nabel GJ</authors>
		<title>Gene-Based Vaccination with a Mismatched Envelope Protects against Simian Immunodeficiency Virus Infection in Nonhuman Primates</title>
		<year>2012</year>
		<volume>86</volume>
		<issue>15</issue>
		<pages>7760-7770</pages>
		<journal_book_name>Journal of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3209">
		<reference_name>Franco et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Franco D, Li W, Qing F, Stoyanov CT, Moran T, Rice CM, Ho DD</authors>
		<title>Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development</title>
		<year>2010</year>
		<volume>28</volume>
		<issue>35</issue>
		<pages>5676-5685</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3243">
		<reference_name>Gu et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Gu R, Shampang A, Nashar T, Patil M, Fuller DH, Ramsingh AI</authors>
		<title>Oral immunization with a live coxsackievirus/HIV recombinant induces gag p24-specific T cell responses</title>
		<year>2010</year>
		<volume>5</volume>
		<issue>9</issue>
		<pages></pages>
		<journal_book_name>PloS one</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2223">
		<reference_name>Gudmundsdotter et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, Moss B, Robb M, Cox J, Michael N, Marovich M, Biberfeld G, SandstrÃ¶m E, Wahren B</authors>
		<title>Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity</title>
		<year>2009</year>
		<volume>27</volume>
		<issue>33</issue>
		<pages>4468-4474</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2443">
		<reference_name>Hammer et al., 2009</reference_name>
		<reference_type>website</reference_type>
		<authors>Scott Hammer, Magdalena Sobieszczyk, Michael Yin</authors>
		<title>Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men</title>
		<year>2009</year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>http://www.clinicaltrials.gov/ct2/show/NCT00865566?term=Ad5+DNA&amp;rank=3</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2217">
		<reference_name>Hanke et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hanke T, McMichael AJ, Samuel RV, Powell LA, McLoughlin L, Crome SJ, Edlin A</authors>
		<title>Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya</title>
		<year>2002</year>
		<volume>21</volume>
		<issue>1-2</issue>
		<pages>108-114</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1889">
		<reference_name>Harris et al., 1996</reference_name>
		<reference_type>journal</reference_type>
		<authors>Harris SJ, Woodrow SA, Gearing AJ, Adams SE, Kingsman AJ, Layton GT</authors>
		<title>The effects of adjuvants on CTL induction by V3:Ty-virus-like particles (V3-VLPs) in mice</title>
		<year>1996</year>
		<volume>14</volume>
		<issue>10</issue>
		<pages>971-976</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2224">
		<reference_name>Harro et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Harro CD, Robertson MN, Lally MA, O'Neill LD, Edupuganti S, Goepfert PA, Mulligan MJ, Priddy FH, Dubey SA, Kierstead LS, Sun X, Casimiro DR, DiNubile MJ, Shiver JW, Leavitt RY, Mehrotra DV</authors>
		<title>Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults</title>
		<year>2009</year>
		<volume>25</volume>
		<issue>1</issue>
		<pages>103-114</pages>
		<journal_book_name>AIDS research and human retroviruses</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2184">
		<reference_name>Hawkins et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hawkins WG, Trcka J, Segal N, Blachere NE, Gold JS, Moroi Y, Bowne WB, Lewis JJ, Wolchok JD, Houghton AN</authors>
		<title>The role of lipopolysaccharide in T-cell responses following DNA vaccination</title>
		<year>2003</year>
		<volume>21</volume>
		<issue>13-14</issue>
		<pages>1548-1553</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2229">
		<reference_name>Hejdeman et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hejdeman B, BostrÃ¶m AC, Matsuda R, Calarota S, Lenkei R, Fredriksson EL, SandstrÃ¶m E, Bratt G, Wahren B</authors>
		<title>DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy</title>
		<year>2004</year>
		<volume>20</volume>
		<issue>8</issue>
		<pages>860-870</pages>
		<journal_book_name>AIDS research and human retroviruses</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2204">
		<reference_name>Hirao et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hirao LA, Wu L, Khan AS, Hokey DA, Yan J, Dai A, Betts MR, Draghia-Akli R, Weiner DB</authors>
		<title>Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques</title>
		<year>2008</year>
		<volume>26</volume>
		<issue>25</issue>
		<pages>3112-3120</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2194">
		<reference_name>Johnson et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Johnson MJ, Petrovas C, Yamamoto T, Lindsay RW, LorÃ© K, Gall JG, Gostick E, Lefebvre F, Cameron MJ, Price DA, Haddad E, Sekaly RP, Seder RA, Koup RA</authors>
		<title>Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity</title>
		<year>2012</year>
		<volume>188</volume>
		<issue>12</issue>
		<pages>6109-6118</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2182">
		<reference_name>Kaneko et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kaneko H, Bednarek I, Wierzbicki A, Kiszka I, Dmochowski M, Wasik TJ, Kaneko Y, Kozbor D</authors>
		<title>Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein</title>
		<year>2000</year>
		<volume>267</volume>
		<issue>1</issue>
		<pages>8-16</pages>
		<journal_book_name>Virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2218">
		<reference_name>Kang et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kang KK, Choi SM, Choi JH, Lee DS, Kim CY, Ahn BO, Kim BM, Kim WB</authors>
		<title>Safety evaluation of GX-12, a new HIV therapeutic vaccine: investigation of integration into the host genome and expression in the reproductive organs</title>
		<year>2003</year>
		<volume>46</volume>
		<issue>5</issue>
		<pages>270-276</pages>
		<journal_book_name>Intervirology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference318">
		<reference_name>Kent et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kent S, De Rose R, Rollman E</authors>
		<title>Drug evaluation: DNA/MVA prime-boost HIV vaccine</title>
		<year>2007 Feb</year>
		<volume>8</volume>
		<issue>2</issue>
		<pages>159-67</pages>
		<journal_book_name>Current opinion in investigational drugs (London, England : 2000)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2197">
		<reference_name>Kim et al., 1998</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kim JJ, Trivedi NN, Nottingham LK, Morrison L, Tsai A, Hu Y, Mahalingam S, Dang K, Ahn L, Doyle NK, Wilson DM, Chattergoon MA, Chalian AA, Boyer JD, Agadjanyan MG, Weiner DB</authors>
		<title>Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens</title>
		<year>1998</year>
		<volume>28</volume>
		<issue>3</issue>
		<pages>1089-1103</pages>
		<journal_book_name>European journal of immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2198">
		<reference_name>Kim et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kim JJ, Yang JS, VanCott TC, Lee DJ, Manson KH, Wyand MS, Boyer JD, Ugen KE, Weiner DB</authors>
		<title>Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants</title>
		<year>2000</year>
		<volume>74</volume>
		<issue>7</issue>
		<pages>3427-3429</pages>
		<journal_book_name>Journal of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2199">
		<reference_name>Kim et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kim JJ, Yang JS, Manson KH, Weiner DB</authors>
		<title>Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-gamma, or IL-4 gene adjuvants</title>
		<year>2001</year>
		<volume>19</volume>
		<issue>17-19</issue>
		<pages>2496-2505</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference239">
		<reference_name>Knight et al., 1990</reference_name>
		<reference_type>journal</reference_type>
		<authors>Knight SC, Macatonia SE, Patterson S</authors>
		<title>HIV I infection of dendritic cells</title>
		<year>1990</year>
		<volume>6</volume>
		<issue>2-3</issue>
		<pages>163-75</pages>
		<journal_book_name>International reviews of immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2208">
		<reference_name>Kutzler et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kutzler MA, Robinson TM, Chattergoon MA, Choo DK, Choo AY, Choe PY, Ramanathan MP, Parkinson R, Kudchodkar S, Tamura Y, Sidhu M, Roopchand V, Kim JJ, Pavlakis GN, Felber BK, Waldmann TA, Boyer JD, Weiner DB</authors>
		<title>Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help</title>
		<year>2005</year>
		<volume>175</volume>
		<issue>1</issue>
		<pages>112-123</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3317">
		<reference_name>Kwa et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kwa S, Lai L, Gangadhara S, Siddiqui M, Pillai VB, Labranche C, Yu T, Moss B, Montefiori DC, Robinson HL, Kozlowski PA, Amara RR</authors>
		<title>CD40L-adjuvanted DNA/MVA SIV239 vaccine enhances SIV-specific humoral and cellular immunity, and improves protection against a heterologous SIVE660 mucosal challenge</title>
		<year>2014</year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name>Journal of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2185">
		<reference_name>Leclerc et al., 1997</reference_name>
		<reference_type>journal</reference_type>
		<authors>Leclerc C, DÃ©riaud E, Rojas M, Whalen RG</authors>
		<title>The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA</title>
		<year>1997</year>
		<volume>179</volume>
		<issue>2</issue>
		<pages>97-9106</pages>
		<journal_book_name>Cellular immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2235">
		<reference_name>Lekutis et al., 1997</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lekutis C, Shiver JW, Liu MA, Letvin NL</authors>
		<title>HIV-1 env DNA vaccine administered to rhesus monkeys elicits MHC class II-restricted CD4+ T helper cells that secrete IFN-gamma and TNF-alpha</title>
		<year>1997</year>
		<volume>158</volume>
		<issue>9</issue>
		<pages>4471-4477</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2203">
		<reference_name>Lena et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lena P, Villinger F, Giavedoni L, Miller CJ, Rhodes G, Luciw P</authors>
		<title>Co-immunization of rhesus macaques with plasmid vectors expressing IFN-gamma, GM-CSF, and SIV antigens enhances anti-viral humoral immunity but does not affect viremia after challenge with highly pathogenic virus</title>
		<year>2002</year>
		<volume>20 Suppl 4</volume>
		<issue></issue>
		<pages>A69-79</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2206">
		<reference_name>Li et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Li W, Li S, Hu Y, Tang B, Cui L, He W</authors>
		<title>Efficient augmentation of a long-lasting immune responses in HIV-1 gag DNA vaccination by IL-15 plasmid boosting</title>
		<year>2008</year>
		<volume>26</volume>
		<issue>26</issue>
		<pages>3282-3290</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference587">
		<reference_name>Liu et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Liu YZ, Zhou L, Wang Q, Ye SQ, Li HX, Zeng Y</authors>
		<title>[Immune response induced by HIV DNA vaccine combined with recombinant adeno-associated virus]</title>
		<year>2004 Sep</year>
		<volume>18</volume>
		<issue>3</issue>
		<pages>251-4</pages>
		<journal_book_name>Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference323">
		<reference_name>Liu et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Liu J, Wyatt LS, Amara RR, Moss B, Robinson HL</authors>
		<title>Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccine</title>
		<year>2006 Apr 12</year>
		<volume>24</volume>
		<issue>16</issue>
		<pages>3332-9</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2023">
		<reference_name>Locher et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Locher CP, Witt SA, Ashlock BM, Polacino P, Hu SL, Shiboski S, Schmidt AM, Agy MB, Anderson DM, Staprans SI, zur Megede J, Levy JA</authors>
		<title>Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection</title>
		<year>2004</year>
		<volume>22</volume>
		<issue>17-18</issue>
		<pages>2261-2272</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference316">
		<reference_name>Lu et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lu Y, Friedman R, Kushner N, Doling A, Thomas L, Touzjian N, Starnbach M, Lieberman J</authors>
		<title>Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity</title>
		<year>2000 Jul 5</year>
		<volume>97</volume>
		<issue>14</issue>
		<pages>8027-32</pages>
		<journal_book_name>Proceedings of the National Academy of Sciences of the United States of America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2215">
		<reference_name>MacGregor et al., 1998</reference_name>
		<reference_type>journal</reference_type>
		<authors>MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, Chattergoon MA, Baine Y, Higgins TJ, Ciccarelli RB, Coney LR, Ginsberg RS, Weiner DB</authors>
		<title>First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response</title>
		<year>1998</year>
		<volume>178</volume>
		<issue>1</issue>
		<pages>92-9100</pages>
		<journal_book_name>The Journal of infectious diseases</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2228">
		<reference_name>MacGregor et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>MacGregor RR, Boyer JD, Ugen KE, Tebas P, Higgins TJ, Baine Y, Ciccarelli RB, Ginsberg RS, Weiner DB</authors>
		<title>Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips"</title>
		<year>2005</year>
		<volume>23</volume>
		<issue>17-18</issue>
		<pages>2066-2073</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference319">
		<reference_name>Malm et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Malm M, Rollman E, Ustav M, Hinkula J, Krohn K, Wahren B, Blazevic V</authors>
		<title>Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH</title>
		<year>2005</year>
		<volume>18</volume>
		<issue>4</issue>
		<pages>678-88</pages>
		<journal_book_name>Viral immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2230">
		<reference_name>Mascola et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Mascola JR, Sambor A, Beaudry K, Santra S, Welcher B, Louder MK, Vancott TC, Huang Y, Chakrabarti BK, Kong WP, Yang ZY, Xu L, Montefiori DC, Nabel GJ, Letvin NL</authors>
		<title>Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins</title>
		<year>2005</year>
		<volume>79</volume>
		<issue>2</issue>
		<pages>771-779</pages>
		<journal_book_name>Journal of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2226">
		<reference_name>McElrath et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR</authors>
		<title>HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis</title>
		<year>2008</year>
		<volume>372</volume>
		<issue>9653</issue>
		<pages>1894-1905</pages>
		<journal_book_name>Lancet</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference315">
		<reference_name>McEvers et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>McEvers K, Elrefaei M, Norris P, Deeks S, Martin J, Lu Y, Cao H</authors>
		<title>Modified anthrax fusion proteins deliver HIV antigens through MHC Class I and II pathways</title>
		<year>2005 Jul 14</year>
		<volume>23</volume>
		<issue>32</issue>
		<pages>4128-35</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2186">
		<reference_name>Moore et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Moore AC, Kong WP, Chakrabarti BK, Nabel GJ</authors>
		<title>Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice</title>
		<year>2002</year>
		<volume>76</volume>
		<issue>1</issue>
		<pages>243-250</pages>
		<journal_book_name>Journal of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2183">
		<reference_name>O'Hagan et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>O'Hagan D, Singh M, Ugozzoli M, Wild C, Barnett S, Chen M, Schaefer M, Doe B, Otten GR, Ulmer JB</authors>
		<title>Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines</title>
		<year>2001</year>
		<volume>75</volume>
		<issue>19</issue>
		<pages>9037-9043</pages>
		<journal_book_name>Journal of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1916">
		<reference_name>Otero et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Otero M, Calarota SA, Felber B, Laddy D, Pavlakis G, Boyer JD, Weiner DB</authors>
		<title>Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model</title>
		<year>2004</year>
		<volume>22</volume>
		<issue>13-14</issue>
		<pages>1782-1790</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference321">
		<reference_name>Otten et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Otten GR, Schaefer M, Doe B, Liu H, Srivastava I, Megede J, Kazzaz J, Lian Y, Singh M, Ugozzoli M, Montefiori D, Lewis M, Driver DA, Dubensky T, Polo JM, Donnelly J, O'Hagan DT, Barnett S, Ulmer JB</authors>
		<title>Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins</title>
		<year>2005 Jul</year>
		<volume>79</volume>
		<issue>13</issue>
		<pages>8189-200</pages>
		<journal_book_name>Journal of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2035">
		<reference_name>Ozpolat et al., 1998</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ozpolat B, Rao XM, Powell MF, Lachman LB</authors>
		<title>Immunoliposomes containing antibodies to costimulatory molecules as adjuvants for HIV subunit vaccines</title>
		<year>1998</year>
		<volume>14</volume>
		<issue>5</issue>
		<pages>409-417</pages>
		<journal_book_name>AIDS research and human retroviruses</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2786">
		<reference_name>Pal et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Pal R, Wang S, Kalyanaraman VS, Nair BC, Whitney S, Keen T, Hocker L, Hudacik L, Rose N, Cristillo A, Mboudjeka I, Shen S, Wu-Chou TH, Montefiori D, Mascola J, Lu S, Markham P</authors>
		<title>Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate</title>
		<year>2005</year>
		<volume>34</volume>
		<issue>5-6</issue>
		<pages>226-236</pages>
		<journal_book_name>Journal of medical primatology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2784">
		<reference_name>Pal et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Pal R, Kalyanaraman VS, Nair BC, Whitney S, Keen T, Hocker L, Hudacik L, Rose N, Mboudjeka I, Shen S, Wu-Chou TH, Montefiori D, Mascola J, Markham P, Lu S</authors>
		<title>Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype</title>
		<year>2006</year>
		<volume>348</volume>
		<issue>2</issue>
		<pages>341-353</pages>
		<journal_book_name>Virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference224">
		<reference_name>Palella et al., 1998</reference_name>
		<reference_type>journal</reference_type>
		<authors>Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD</authors>
		<title>Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators</title>
		<year>1998 Mar 26</year>
		<volume>338</volume>
		<issue>13</issue>
		<pages>853-60</pages>
		<journal_book_name>The New England journal of medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2442">
		<reference_name>Parker, 2007</reference_name>
		<reference_type>website</reference_type>
		<authors>Scott Parker</authors>
		<title>Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults</title>
		<year>2007</year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>http://clinicaltrials.gov/ct2/show/NCT00528489</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3288">
		<reference_name>Patterson et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Patterson LJ, Peng B, Abimiku AG, Aldrich K, Murty L, Markham PD, Kalyanaraman VS, Alvord WG, Tartaglia J, Franchini G, Robert-Guroff M</authors>
		<title>Cross-protection in NYVAC-HIV-1-immunized/HIV-2-challenged but not in NYVAC-HIV-2-immunized/SHIV-challenged rhesus macaques</title>
		<year>2000</year>
		<volume>14</volume>
		<issue>16</issue>
		<pages>2445-2455</pages>
		<journal_book_name>AIDS (London, England)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3095">
		<reference_name>Pegu et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Pegu P, Vaccari M, Gordon S, Keele BF, Doster M, Guan Y, Ferrari G, Pal R, Ferrari MG, Whitney S, Hudacik L, Billings E, Rao M, Montefiori D, Tomaras G, Alam SM, Fenizia C, Lifson JD, Stablein D, Tartaglia J, Michael N, Kim J, Venzon D, Franchini G</authors>
		<title>Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial</title>
		<year>2013</year>
		<volume>87</volume>
		<issue>3</issue>
		<pages>1708-1719</pages>
		<journal_book_name>Journal of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2232">
		<reference_name>Peters et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, Schmidt C, Gilmour J, Bogoshi M, Omosa-Manyonyi G, Dally L, Klavinskis L, Farah B, Tarragona T, Bart PA, Robinson A, Pieterse C, Stevens W, Thomas R, Barin B, McMichael AJ, McIntyre JA, Pantaleo G, Hanke T, Bwayo J</authors>
		<title>Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity</title>
		<year>2007</year>
		<volume>25</volume>
		<issue>11</issue>
		<pages>2120-2127</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2234">
		<reference_name>Qiu et al., 1999</reference_name>
		<reference_type>journal</reference_type>
		<authors>Qiu JT, Song R, Dettenhofer M, Tian C, August T, Felber BK, Pavlakis GN, Yu XF</authors>
		<title>Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses</title>
		<year>1999</year>
		<volume>73</volume>
		<issue>11</issue>
		<pages>9145-9152</pages>
		<journal_book_name>Journal of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2192">
		<reference_name>Rerks-Ngarm et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH</authors>
		<title>Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand</title>
		<year>2009</year>
		<volume>361</volume>
		<issue>23</issue>
		<pages>2209-2220</pages>
		<journal_book_name>The New England journal of medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2190">
		<reference_name>Reynolds et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Reynolds MR, Weiler AM, Piaskowski SM, Piatak M Jr, Robertson HT, Allison DB, Bett AJ, Casimiro DR, Shiver JW, Wilson NA, Lifson JD, Koff WC, Watkins DI</authors>
		<title>A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge</title>
		<year>2012</year>
		<volume>30</volume>
		<issue>30</issue>
		<pages>4465-4475</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2205">
		<reference_name>Robinson et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Robinson HL, Montefiori DC, Villinger F, Robinson JE, Sharma S, Wyatt LS, Earl PL, McClure HM, Moss B, Amara RR</authors>
		<title>Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine</title>
		<year>2006</year>
		<volume>352</volume>
		<issue>2</issue>
		<pages>285-294</pages>
		<journal_book_name>Virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference322">
		<reference_name>Santra et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Santra S, Barouch DH, Korioth-Schmitz B, Lord CI, Krivulka GR, Yu F, Beddall MH, Gorgone DA, Lifton MA, Miura A, Philippon V, Manson K, Markham PD, Parrish J, Kuroda MJ, Schmitz JE, Gelman RS, Shiver JW, Montefiori DC, Panicali D, Letvin NL</authors>
		<title>Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses</title>
		<year>2004 Jul 27</year>
		<volume>101</volume>
		<issue>30</issue>
		<pages>11088-93</pages>
		<journal_book_name>Proceedings of the National Academy of Sciences of the United States of America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2219">
		<reference_name>Sheets et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Sheets RL, Stein J, Manetz TS, Duffy C, Nason M, Andrews C, Kong WP, Nabel GJ, Gomez PL</authors>
		<title>Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts</title>
		<year>2006</year>
		<volume>91</volume>
		<issue>2</issue>
		<pages>610-619</pages>
		<journal_book_name>Toxicological sciences : an official journal of the Society of Toxicology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference263">
		<reference_name>Shiver et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ, Youil R, Kaslow DC, Emini EA</authors>
		<title>Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity</title>
		<year>2002 Jan 17</year>
		<volume>415</volume>
		<issue>6869</issue>
		<pages>331-5</pages>
		<journal_book_name>Nature</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2210">
		<reference_name>Sizemore et al., 1995</reference_name>
		<reference_type>journal</reference_type>
		<authors>Sizemore DR, Branstrom AA, Sadoff JC</authors>
		<title>Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization</title>
		<year>1995</year>
		<volume>270</volume>
		<issue>5234</issue>
		<pages>299-302</pages>
		<journal_book_name>Science (New York, N.Y.)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2020">
		<reference_name>Song et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Song R, Liu S, Adams RJ, Leong KW</authors>
		<title>Enhancing efficacy of HIV gag DNA vaccine by local delivery of GM-CSF in murine and macaque models</title>
		<year>2006</year>
		<volume>26</volume>
		<issue>6</issue>
		<pages>380-389</pages>
		<journal_book_name>Journal of interferon &amp; cytokine research : the official journal of the International Society for Interferon and Cytokine Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1897">
		<reference_name>Stieneker et al., 1991</reference_name>
		<reference_type>journal</reference_type>
		<authors>Stieneker F, Kreuter J, Löwer J</authors>
		<title>High antibody titres in mice with polymethylmethacrylate nanoparticles as adjuvant for HIV vaccines</title>
		<year>1991</year>
		<volume>5</volume>
		<issue>4</issue>
		<pages>431-435</pages>
		<journal_book_name>AIDS (London, England)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3276">
		<reference_name>Sun et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Sun C, Chen Z, Tang X, Zhang Y, Feng L, Du Y, Xiao L, Liu L, Zhu W, Chen L, Zhang L</authors>
		<title>Mucosal priming with a replicating-vaccinia virus-based vaccine elicits protective immunity to simian immunodeficiency virus challenge in rhesus monkeys</title>
		<year>2013</year>
		<volume>87</volume>
		<issue>10</issue>
		<pages>5669-5677</pages>
		<journal_book_name>Journal of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference265">
		<reference_name>Takehisa et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Takehisa J, Harada Y, Ndembi N, Mboudjeka I, Taniguchi Y, Ngansop C, Kuate S, Zekeng L, Ibuki K, Shimada T, Bikandou B, Yamaguchi-Kabata Y, Miura T, Ikeda M, Ichimura H, Kaptue L, Hayami M</authors>
		<title>Natural infection of wild-born mandrills (Mandrillus sphinx) with two different types of simian immunodeficiency virus</title>
		<year>2001 Aug 10</year>
		<volume>17</volume>
		<issue>12</issue>
		<pages>1143-54</pages>
		<journal_book_name>AIDS research and human retroviruses</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference312">
		<reference_name>Tatalick et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Tatalick LM, Gerard CJ, Takeya R, Price DN, Thorne BA, Wyatt LM, Anklesaria P</authors>
		<title>Safety characterization of HeLa-based cell substrates used in the manufacture of a recombinant adeno-associated virus-HIV vaccine</title>
		<year>2005 Apr 8</year>
		<volume>23</volume>
		<issue>20</issue>
		<pages>2628-38</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2212">
		<reference_name>Vecino et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Vecino WH, Morin PM, Agha R, Jacobs WR Jr, Fennelly GJ</authors>
		<title>Mucosal DNA vaccination with highly attenuated Shigella is superior to attenuated Salmonella and comparable to intramuscular DNA vaccination for T cells against HIV</title>
		<year>2002</year>
		<volume>82</volume>
		<issue>3</issue>
		<pages>197-204</pages>
		<journal_book_name>Immunology letters</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2236">
		<reference_name>Vinner et al., 1999</reference_name>
		<reference_type>journal</reference_type>
		<authors>Vinner L, Nielsen HV, Bryder K, Corbet S, Nielsen C, Fomsgaard A</authors>
		<title>Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons</title>
		<year>1999</year>
		<volume>17</volume>
		<issue>17</issue>
		<pages>2166-2175</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3249">
		<reference_name>Walther-Jallow et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Walther-Jallow L, Nilsson C, Söderlund J, ten Haaft P, Mäkitalo B, Biberfeld P, Böttiger P, Heeney J, Biberfeld G, Thorstensson R</authors>
		<title>Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaccinated cynomolgus monkeys</title>
		<year>2001</year>
		<volume>82</volume>
		<issue>Pt 7</issue>
		<pages>1601-1612</pages>
		<journal_book_name>The Journal of general virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2115">
		<reference_name>Wang et al., 1993</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wang B, Ugen KE, Srikantan V, Agadjanyan MG, Dang K, Refaeli Y, Sato AI, Boyer J, Williams WV, Weiner DB</authors>
		<title>Gene inoculation generates immune responses against human immunodeficiency virus type 1</title>
		<year>1993</year>
		<volume>90</volume>
		<issue>9</issue>
		<pages>4156-4160</pages>
		<journal_book_name>Proceedings of the National Academy of Sciences of the United States of America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2213">
		<reference_name>Wang et al., 1993</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wang B, Boyer J, Srikantan V, Coney L, Carrano R, Phan C, Merva M, Dang K, Agadjanan M, Gilbert L</authors>
		<title>DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and nonhuman primates</title>
		<year>1993</year>
		<volume>12</volume>
		<issue>9</issue>
		<pages>799-805</pages>
		<journal_book_name>DNA and cell biology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2222">
		<reference_name>Wang et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wang S, Farfan-Arribas DJ, Shen S, Chou TH, Hirsch A, He F, Lu S</authors>
		<title>Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine</title>
		<year>2006</year>
		<volume>24</volume>
		<issue>21</issue>
		<pages>4531-4540</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2233">
		<reference_name>Weber et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Weber R, Bossart W, Cone R, Luethy R, Moelling K</authors>
		<title>Phase I clinical trial with HIV-1 gp160 plasmid vaccine in HIV-1-infected asymptomatic subjects</title>
		<year>2001</year>
		<volume>20</volume>
		<issue>11</issue>
		<pages>800-803</pages>
		<journal_book_name>European journal of clinical microbiology &amp; infectious diseases : official publication of the European Society of Clinical Microbiology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference317">
		<reference_name>Xin et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Xin KQ, Jounai N, Someya K, Honma K, Mizuguchi H, Naganawa S, Kitamura K, Hayakawa T, Saha S, Takeshita F, Okuda K, Honda M, Klinman DM, Okuda K</authors>
		<title>Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV</title>
		<year>2005 Dec</year>
		<volume>12</volume>
		<issue>24</issue>
		<pages>1769-77</pages>
		<journal_book_name>Gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2041">
		<reference_name>Yoshino et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Yoshino N, Lü FX, Fujihashi K, Hagiwara Y, Kataoka K, Lu D, Hirst L, Honda M, van Ginkel FW, Takeda Y, Miller CJ, Kiyono H, McGhee JR</authors>
		<title>A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates</title>
		<year>2004</year>
		<volume>173</volume>
		<issue>11</issue>
		<pages>6850-6857</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1296">
		<reference_name>Zhang et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Zhang H, Hong H, Li D, Ma S, Di Y, Stoten A, Haig N, Di Gleria K, Yu Z, Xu XN, McMichael A, Jiang S</authors>
		<title>Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4+ T cells</title>
		<year>2009</year>
		<volume>284</volume>
		<issue>14</issue>
		<pages>9184-9191</pages>
		<journal_book_name>The Journal of biological chemistry</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
</VIOLIN>


